2017 ANNUAL REPORT
ONE MSK ONE FOCUS
This image, from the lab of Michel Sadelain, shows human T cells that have been stimulated to grow. Using the genome-editing tool CRISPR, scientists insert a specific gene into a very precise location within the cells that makes them more effective at killing leukemia cells. 2 MEMORIAL SLOAN KETTERING CANCER CENTER OUR SINGUL AR FOCUS ON CANCER DRIVES ALL OF OUR EFFORTS.
ONE MSK
THE INSIDE STORY A SNAPSHOT OF 2017 AT MSK ONE FOCUS
CAR T CELL THERAPY A GROUNDBREAKING TREATMENT PIONEERED BY MSK RESEARCHERS PASSED A SIGNIFICANT MILESTONE. SEE PAGE 8.
2 MEMORIAL SLOAN KETTERING CANCER CENTER OUR SINGUL AR FOCUS ON CANCER DRIVES ALL OF OUR EFFORTS.
ONE MSK
THE CANCER GENOME MSK RESEARCHERS MINED CANCER’S DNA TO FIND OUT WHAT MAKES THE DISEASE TICK — AND TO DESIGN STRATEGIES TO DEFEAT IT. SEE PAGE 18. 2017 ANNUAL REPORT 3 ONE FOCUS
This image, from the lab of Michel Sadelain, shows human T cells thatMSK-IMPACT have been stimulated to grow. Using the genome-editing tool CRISPR, scientists insert a specific gene into a very precise locationGENETIC within SEQUENCING the cells that TOLD makes PEOPLE them THE more STORY effective OF THEIR at CANCER AND GAVE killingSCIENTISTS leukemia DETAILS cells. TO PERSONALIZE TREATMENT. SEE PAGE 26. 4 MEMORIAL SLOAN KETTERING CANCER CENTER OUR SINGUL AR FOCUS ON CANCER DRIVES ALL OF OUR EFFORTS.
ONE MSK
CLINICAL TRIALS DRUGS DEVELOPED AND TESTED AT MSK LED TO A NUMBER OF FIRSTS, INCLUDING THE FIRST TREATMENT TO REHABILITATE CANCER CELLS AND THE FIRST TREATMENT FOR A RARE BLOOD DISORDER. SEE PAGE 34. 2017 ANNUAL REPORT 5 ONE FOCUS
This image, from the lab of Michel Sadelain, shows human T cells thatBASIC have been stimulated SCIENCE to grow. Using the genome-editing tool CRISPR, scientists insert a specific gene into a very precise locationSCIENTISTS within INthe THE cells SLOAN that makes KETTERING them moreINSTITUTE effective MADE at FUNDAMENTAL DISCOVERIES killingABOUT leukemia THE STRUCTURE cells. OF PROTEINS, A MUTATION CAUSING A RARE CANCER, AND THE TRIGGERS DRIVING CANCER’S SPREAD. SEE PAGE 44. 6 MEMORIAL SLOAN KETTERING CANCER CENTER OUR SINGUL AR FOCUS ON CANCER DRIVES ALL OF OUR EFFORTS.
ONE MSK
PATIENT CARE A HOMELIKE NEW RESIDENCE, ADVANCED TREATMENTS, AND NOVEL TECHNOLOGIES GAVE PATIENTS COMFORT AND EASED THEIR HEALING. SEE PAGE 54. 2017 ANNUAL REPORT 7 ONE FOCUS
This image, from the lab of Michel Sadelain, shows human T cells thatSEE have WHAT been stimulated A TEAM to grow. OF REMARKABLEUsing the genome-editing PEOPLE WITH tool CRISPR, scientists insert a specific gene into a very precise locationAN UNMATCHED within the cells that DEDICATION makes them more TO effective CHANGING at CANCER killingCAN leukemia DO IN cells. JUST ONE YEAR. 8 MEMORIAL SLOAN KETTERING CANCER CENTER OUR SINGUL AR FOCUS ON CANCER DRIVES ALL OF OUR EFFORTS.
ONE MSK
2017 ANNUAL REPORT 1 CONTENTS
THE CLINIMACS SYSTEM IS USED TO PURIFY T CELLS FROM PATIENTS. ONCE PURIFIED, THE CELLS CAN BE MODIFIED WITH THE CHIMERIC ANTIGEN RECEPTOR GENE TO BECOME CAR T CELLS. 04 MESSAGE FROM THE CHAIRMAN AND THE PRESIDENT
08 34 FOCUS ON FOCUS ON CAR T CELL THERAPY CLINICAL TRIALS
18 44 FOCUS ON FOCUS ON THE CANCER GENOME BASIC SCIENCE
26 54 FOCUS ON FOCUS ON MSK-IMPACT PATIENT CARE
72 STATISTICAL PROFILE 77 LEADERSHIP
74 FINANCIAL SUMMARY 79 DONORS TO MEMORIAL SLOAN KETTERING 76 BOARDS OF OVERSEERS AND MANAGERS 96 THE SOCIETY OF MEMORIAL SLOAN KETTERING
2017 ANNUAL REPORT 3 Craig B. Thompson MESSAGE FROM THE CHAIRMAN President and AND THE PRESIDENT Chief Executive Officer
Douglas A. Warner III Chair, Boards of Overseers Memorial Sloan Kettering’s singular and Managers focus on cancer — as true today as it was more than 130 years ago — sets our organization apart in New York City, the nation, and the world. The impact of our collective efforts can be seen in the dedicated workforce of more than 17,000 people, in scientific research that fundamentally changes the understanding of biology, and in clinical innovation that delivers new treatments and better care to thousands of people every year. Woven together, these threads form “One MSK.”
4 MEMORIAL SLOAN KETTERING CANCER CENTER ONE MSK
Our commitment to basic research is both substantial and sustained, and resulted in discoveries that once again yielded accolades in 2017. The Nature Index ranked the work of our research faculty, and specifically the scientists at the Sloan Kettering Institute, as number one among cancer research organizations.”
Our commitment to basic research is both substantial of cancer centers to provide this therapy to patients, and sustained, and resulted in discoveries that once again thanks to the unparalleled expertise of our doctors and yielded accolades in 2017. The Nature Index ranked the nurses. You can learn more starting on page 8. work of our research faculty, and specifically the scientists In 2017, the FDA reaffirmed MSK’s leadership in at the Sloan Kettering Institute, as number one among targeting molecular defects in cancer by authorizing cancer research organizations. In just two examples, Nikola MSK-IMPACT™, the first genetic-sequencing test of its Pavletich and Haijuan Yang mapped the structure of mTOR, a kind to receive the designation. This test scans tumors crucial growth regulator in cancer, in work enabled by a new for mutations in more than 460 genes linked to cancer. cryo-electron microscope installed in 2017. And Scott Lowe, Developed by physician-scientist Michael Berger and elected to the National Academy of Sciences in 2017, and others in the Marie-Josée and Henry R. Kravis Center colleagues used the gene-editing tool CRISPR to demonstrate for Molecular Oncology, MSK-IMPACT has analyzed the how a specific genetic mutation causes a rare liver cancer tumors of more than 20,000 MSK patients with advanced in children and young adults. More about the work of the cancer. Its use has generated actionable information that Pavletich and Lowe labs — as well as of other basic scientists has allowed many of those people to receive more targeted — can be found later in this report. treatment. (For more on MSK-IMPACT, see page 26.) Our researchers and clinicians have pioneered and MSK’s clinical trials program continues to transform continue to advance one of the most significant therapeutic research breakthroughs into lifesaving treatments that developments in recent years: the engineered immune often become the new standard of care. In 2017, nearly cells called CAR T cells. The therapy became commercially a third of MSK patients were enrolled in more than 800 available in 2017 when the US Food and Drug Administration clinical trials. As you’ll read on page 34, MSK faculty approved it for certain types of leukemia and lymphoma. distinguished themselves with FDA approvals of several Physician-scientist Michel Sadelain, along with researchers therapies that are the first of their kind, including a drug Renier Brentjens and Isabelle Rivière, were the first to devise that rehabilitates cancer cells rather than killing them and a this type of “living drug,” which employs a patient’s own targeted therapy developed simultaneously in children immune cells to find and fight cancer. MSK is one of a handful and adults.
2017 ANNUAL REPORT 5 Kathryn Martin José Baselga Joan Massagué James D. Robinson III Chief Operating Physician-in-Chief and Director, Sloan Honorary Chair, Officer Chief Medical Officer, Kettering Institute Boards of Overseers Memorial Hospital and Managers
MSK further strengthened its expertise in clinical common cancers as well as shaping a mutual research innovations in 2017 by recruiting Luis Diaz as Head of the agenda to advance the next generation of cellular treatments, Division of Solid Tumor Oncology in the Department of including CAR T cell therapy. The Miami Cancer Institute at Medicine. While at Johns Hopkins Medicine, Dr. Diaz was the Baptist Health South Florida became the latest member of principal investigator of a key clinical trial of pembrolizumab the MSK Cancer Alliance, which continues to flourish. And (Keytruda®), the first drug approved by the FDA to target we created a unique relationship with Norwalk Hospital in a specific genetic mutation in tumors. This work built on Connecticut: MSK Physicians at Norwalk Hospital, which groundbreaking research by MSK’s Jedd Wolchok and has MSK doctors providing on-site care to patients at a non- Timothy Chan. (See page 21 for more.) MSK facility outside of New York State for the first time. Of course, our leadership in developing targeted therapies Our commitment to new models of patient care was also comes with the responsibility of addressing the challenges shown in bold relief against the skyline of Manhattan, with the of these treatments. In 2017, MSK researchers strove to David H. Koch Center for Cancer Care hitting its “topping- improve these new approaches on several fronts, from reducing off” point on 74th Street. When it opens in 2019, this 23-floor, toxicities to testing whether they can be made more precise. state-of-the-art facility will define the future of cancer care, A major challenge for some of the most promising cancer focusing on outpatient procedures, innovative treatments treatments is that currently only a small percentage of people such as immunotherapy, and early-stage clinical trials. have access to genetic testing and clinical trials. Diversity in This same forward-thinking vision is found in the participation is also crucial to the success of clinical trials recently opened Center for Laboratory Medicine building and has been a continued goal. To address this, MSK has in Manhattan, an environmentally friendly lab that has sought to extend availability by establishing relationships brought important efficiencies to the processing of 5,000 with medical facilities that share our dedication to high- patient samples and 24,000 clinical lab tests every day. quality research and patient care. Within ten years, projections are that nearly 80 percent In 2017, our partnership with Hackensack Meridian of MSK’s patients will never spend a day in the hospital. Health in New Jersey made important progress, completing This fact drove the remarkable growth and success of our shared guidelines for patient care in several of the most outpatient centers in the regional care network. In its first
6 MEMORIAL SLOAN KETTERING CANCER CENTER Of course, our leadership in developing targeted therapies comes with the responsibility of addressing the challenges of these treatments. In 2017, MSK researchers strove to improve these new approaches on several fronts, from reducing toxicities to testing whether they can be made more precise.”
year of operation, MSK Monmouth saw patient volumes that Tabar’s election to the National Academy of Medicine and her were years ahead of schedule, with positive reviews from appointment as Chair of MSK’s Department of Neurosurgery, patients about both the facility and its exceptional team. MSK after the retirement of Philip Gutin. Other highlights include Bergen is on track to open in 2018, and MSK Nassau in 2019. the election of Maria Jasin, Scott Keeney, and Christopher This increased demand for MSK’s superior clinical care Lima to the American Academy of Arts and Sciences, along across the region combined with sustained philanthropic with Marie-Josée Kravis, a member of MSK’s Board. Sasha support resulted in exceptional financial performance. Rudensky won the Crafoord Prize; Lorenz Studer was Prudent management of MSK resources played a significant given the Ogawa-Yamanaka Stem Cell Prize; and Andrea role because 2017 marked the end of royalty payments for a Schietinger received a New Innovator Award from the major clinical discovery made in the laboratory of Malcolm National Institutes of Health. Moore. This loss required careful planning throughout the Ultimately, though, these individual honors are a past several years to ensure the continued vitality of our testament to the fact that we all share the same passion, research program. conviction, and drive to conquer cancer. The profound energy Charitable gifts to MSK reached new levels in 2017, thanks and seriousness of purpose that all of our staff pour into to the leadership of Anne McSweeney, Special Advisor to improving the understanding, prevention, and treatment of the President, and Richard Naum, Senior Vice President for cancer make us truly One MSK. Development. During the past 15 years, they have helped ensure MSK’s ability to invest in promising areas of research and patient care. The Campaign for MSK, which they directed and which recently ended, surpassed its lifetime goal of $3.5 billion by $700 million. We wish them well in retirement. And Cycle for Survival continues to generate millions for research into rare cancers. Craig B. Thompson Douglas A. Warner III This past year also saw MSK faculty receive numerous President and Chair, Boards of Overseers individual awards and honors. Of particular note is Viviane Chief Executive Officer and Managers
2017 ANNUAL REPORT 7 FOCUS ON CAR T CELL THERAPY
In 2017, the US Food and Drug Administration approved the first-ever cancer therapy using genetically modified versions of a person’s own immune cells. MSK scientists pioneered this approach, called chimeric antigen receptor (CAR) T cell therapy, and continue to lead the way in making it safer and more effective. It takes many people to bring CAR T cells, like the one shown in the photo at left, to life. Xiuyan Wang manufactures these cells for use in patients on MSK clinical trials. ONE FOCUS CAR AND DRIVERS
10 MEMORIAL SLOAN KETTERING CANCER CENTER ONE FOCUS ONE MSK
CREATING “LIVING DRUGS” Against one wall of Xiuyan Wang’s office is a floor-to-ceiling bookcase stuffed I remember one of the patients with thick colored folders. Each one very vividly. He was an ALL represents a patient treated at MSK with an experimental immune treatment patient. The primary investigator called CAR T cell therapy. from the clinical trial came to us The folders are color coded: orange and said, ‘The family wants to for chronic lymphocytic leukemia, black meet the people who are making for non-Hodgkin lymphoma, blue for the magic cells.’ So we met with acute lymphoblastic leukemia (ALL), red for ovarian cancer. There are about them. The son was very happy 300 binders in total. to see us. He said it helped his “You see the shelf is kind of bulging father to feel like we would treat already,” Dr. Wang says, pointing. his cells with the utmost care. As Assistant Director of the Cell ” Therapy and Cell Engineering Facility, –XIUYAN WANG Dr. Wang is responsible for manufacturing CAR T cells, a type of “living drug,” for infusion into patients on clinical trials. A CAR is a designer protein that scientists genetically engineer into a person’s own immune cells, turning them into souped-up cancer fighters. Dr. Wang is part of a large orchestra of players who collaborate to bring these living therapies to life. But you might say she’s the maestro, since she’s the one making these sensitive, powerful cells. The process is delicate. Immune cells called T cells are removed from a patient’s blood, the CAR gene is delivered to the cells, and then they’re grown in incubators until they multiply into the billions. The cells are then infused back into the patient, in the hope that these genetically modified versions will find and destroy the cancer. Left: Xiuyan Wang and senior research specialist “I remember one of the patients very Jolanta Stefanski in the lab where they manufacture CAR T cells for use in patients vividly,” Dr. Wang says. “He was an ALL on MSK clinical trials. Below: Each of the patient. The primary investigator from colorful folders carefully organized in the clinical trial came to us and said, ‘The Dr. Wang’s office represents a life — an MSK family wants to meet the people who are patient who’s received CAR T therapy. making the magic cells.’ So we met with them. The son was very happy to see us. He said it helped his father to feel like we would treat his cells with the utmost care. We actually treat every patient’s cells with the utmost care.” Dr. Wang is well aware that the cells that pass through her hands can represent someone’s best and last treatment option. For many people, the best that CAR therapy offers is a significantly longer life, and sometimes, an outright cure.
continued
2017 ANNUAL REPORT 11 ONE FOCUS
A TRANSFORMATIVE THERAPY disease, those in the low-disease category GLEN’S STORY MSK investigators have played a lived significantly longer and experienced The scientists also sought the answer pioneering role both in developing the fewer life-threatening side effects. to another conundrum. Many patients technology of CAR T cells and in showing “This is the longest follow-up study on CAR T therapy receive bone marrow that it is an effective treatment for people of people with ALL treated with CAR transplants (BMTs) afterward as a with different types of cancer. They built therapy,” says Jae Park, a medical preventive measure to keep the cancer the first effective CAR T cells in 2002 oncologist and principal investigator of from returning. But if people received and began treating patients with them the adult ALL clinical trial. “It confirms CAR T cell therapy earlier, before a relapse, in 2007. A trial of CAR T cells in adults the power of CAR T cells as an effective and had better outcomes, might they be with ALL opened at MSK in 2010. MSK cancer therapy in adults with ALL.” able to forgo a BMT altogether? investigators published the results of that Ultimately, he says, these findings Like many people who come to MSK, trial in early 2018 in the New England show that it may make sense for people Glen Blum had already been treated at Journal of Medicine (NEJM). to receive CAR T cell therapy as a first another hospital for a cancer that was These findings showed conclusively treatment, rather than after other options proving stubbornly hard to beat. what anecdotal reports had already have failed. His journey began several years documented: Some people with terminal “This study represents the ago, when lingering back pain led to a cancer could be cured with genetically culmination of 20 years of research at blood test, a biopsy, and eventually a engineered T cells made to detect and kill MSK,” says Michel Sadelain, Director diagnosis of ALL. This aggressive cancer, their cancer cells. The study also helped of the Center for Cell Engineering and which grows in the bone marrow, had to identify the factors influencing who a pioneer of CAR therapy. “These data already damaged several of his vertebrae. had the best results from the treatment, strongly support the use of this CAR Mr. Blum received conventional including that people with less disease therapy for adults with relapsed ALL treatment with both chemotherapy and benefited the most. Compared with and predict better outcomes when used radiation, which helped for a while. But patients who had a greater amount of earlier in the course of the disease.” as is often the case with ALL, the cancer came roaring back. And when it did, it was resistant to further treatment with the usual drugs.
THE CAR T PIT CREW This study represents the culmination of 20 years of research at MSK. These data strongly support the use of this CAR Center for Cell Engineering (CCE) therapy for adults with relapsed ALL and predict better DIRECTOR: Michel Sadelain outcomes when used earlier in the course of the disease.” This multidisciplinary center is composed of – MICHEL SADELAIN basic scientists, translational researchers, and clinicians with an interest in developing cell therapies. CCE scientists help design and test new cell therapies, including better and safer CARs.
Cell Therapy and Cell Engineering Facility Michel Sadelain and colleagues were the first to show that CAR T cells could kill cancer cells. The roots DIRECTOR: Isabelle Rivière of CAR T therapy stretch back nearly to the beginning of Dr. Sadelain’s career as an immunologist. This clinically certified, state-of-the-art manufacturing facility is where CAR T cells are made for use in MSK clinical trials.
Cellular Therapeutics Center DIRECTOR: Renier Brentjens This group of clinician-scientists takes the lead in caring for the patients treated with CAR T cells as part of clinical trials at MSK. The clinical data obtained from these trials are an important part of improving CAR T treatments.
Bone Marrow Transplant Service DIRECTOR: Sergio Giralt Members of this service are responsible for caring for patients treated with FDA-approved CAR T therapies. The doctors and nurses on this team are skilled at dealing with immune-related complications.
12 MEMORIAL SLOAN KETTERING CANCER CENTER ONE FOCUS ONE MSK
That’s when Mr. Blum’s doctor immune system, people are vulnerable recommended that he enroll in a clinical to infections while the new bone marrow trial of CAR T cell therapy at MSK. The grows. There is also the risk that immune goal of this treatment would be to shrink cells from the donor marrow will start to The way they explained it to his cancer to a point where he would be attack the body’s healthy cells. me is that the treatment would eligible for a potentially lifesaving bone The NEJM study suggests that getting marrow transplant. a BMT after CAR therapy does not make get my own immune cells to “The way they explained it to me is an important difference in how well see the cancer cells as foreign that the treatment would get my own people do in the long term. This result is and eliminate them. Then the immune cells to see the cancer cells as preliminary, however, and needs to be bone marrow transplant was a foreign and eliminate them,” says confirmed with further research. secondary step so that I wouldn’t Mr. Blum, who is now 32 and lives in East According to Dr. Park, at this time the grow more cancer cells. Harlem in New York City. “Then the bone decision to recommend a BMT or not ” marrow transplant was a secondary step becomes a question of weighing different –GLEN BLUM so that I wouldn’t grow more cancer cells.” factors, including the number of previous Historically, a BMT is often the treatments, the characteristics of the last, best hope for a cure for a person disease, the risks of the transplant, with leukemia once initial therapy has the risk of relapse, and the age of the patient. failed. But the procedure is not without “These are the practical conversations significant risks. To receive new bone we’re having with patients every day,” marrow, people must first have their he says. “And while we have not answered existing bone marrow destroyed with the question definitively, this study raises Glen Blum, a CAR T cell therapy patient who high-dose chemotherapy or radiation. the possibility that — at least for some visits MSK regularly for follow-up appointments, plays pool in MSK’s Charles Hallac Patient Because the bone marrow is what patients — CAR therapy could be an Recreation Center. The center was redone in 2017 produces blood cells, including the end point.” and now includes tables for arts and crafts, a white blood cells that make up the coffee and beverage bar, shelves of board games, continued and ample lounge space.
2017 ANNUAL REPORT 13 ONE FOCUS
HOW TO ENGINEER A CAR The process of building a safe genetically engineered T cell was neither easy nor These are the practical conversations we’re having straightforward. It took the expertise with patients every day. And while we have not of numerous investigators working over a period of decades. Leading the answered the question definitively, this study raises manufacturing effort at MSK was Isabelle the possibility that — at least for some patients — Rivière, an immunologist who trained in CAR therapy could be an end point. ” France and the United States and is now Director of the Cell Therapy and –JAE PARK Cell Engineering Facility. Dr. Rivière, who has been at MSK since 1998, was the first to design a standard operating procedure for the manufacturing of CAR T cells. Or rather, procedures — there are currently 250. “I can honestly say I don’t think we knew what we were getting into,” she says. “We were really establishing the field as we went.” After many years of effort, exploring many different variables, she succeeded in developing a protocol that works. It involves a precise series of steps that include capturing T cells with magnetized beads and growing them in baglike incubators rolling on an oscillating tray. The engineered T cells target a marker on B cell leukemias called CD19. When the therapy was used in people with B cell ALL, the researchers knew they were onto something special. “The most dramatic result was when we took the bone marrow of these patients a couple of weeks postinfusion, and the disease had completely vanished,” she says. “That was really the eureka moment. We had to convince ourselves that this was real.”
The most dramatic result was when we took the bone marrow of these patients a couple of weeks postinfusion, and the disease had completely vanished. That was really the eureka moment. We had to convince ourselves that this was real.” – ISABELLE RIVIÈRE
Top: Jae Park (right) is a principal investigator of CAR T clinical trials at MSK. Above: Isabelle Rivière (left), with Jinrong Qu, senior research assistant, leads CAR T manufacturing at MSK.
14 MEMORIAL SLOAN KETTERING CANCER CENTER ONE FOCUS ONE MSK
FIRST CARS HIT THE ROAD Two CAR T cell therapies were approved by the FDA in 2017. One, made by the company Novartis, is for children and young adults with ALL. Another, made by Kite Pharma (now owned by Gilead Sciences), is for adults with non- Hodgkin lymphoma. Pediatric oncologist Kevin Curran, a member of the Pediatric Bone Marrow Transplant Service who leads MSK’s CAR T cell efforts in children and young adults, calls the treatment “revolutionary” and says it opens a whole new avenue of options for patients. “It gives them hope,” he adds. These approvals are “only the beginning,” Dr. Curran says. “Just like a new model of an automobile comes out each year, there are going to be new models of CAR T cells that come out too. We think some of the ones we’ve built and are testing at MSK have the potential to be even better.” MSK is one of only a handful of cancer centers that have the experience and expertise necessary to administer CAR T cell therapies safely to patients. “Our primary job is making sure that each person gets the very best care — whether that’s CAR T cell therapy or another approach,” says Sergio Giralt, Chief of the Adult Bone Marrow Transplant Service. “It’s a great privilege to be among such an incredible group Kevin Curran leads MSK’s CAR T efforts in children with blood cancers. of professionals, who all do their utmost each day to return our patients to a life free of cancer.”
continued
Our primary job is making sure that each person gets the very best care — whether that’s CAR T cell therapy or another approach. It’s a great privilege to be among such an incredible group of professionals, who all do their utmost each day to return our patients to a life free of cancer.” –SERGIO GIRALT
Sergio Giralt oversees the care of patients receiving FDA-approved CAR T cell therapies at MSK.
2017 ANNUAL REPORT 15 ONE FOCUS
GROUP EFFORT clinical trial. They work alongside people who received this powerful Senior clinical research supervisor Yvette doctors, nurses, and lab monitors to experimental therapy. Bernal has been a crucial player in MSK’s collect data. They also liaise with MSK’s “It was an exciting but also an CAR T program from the beginning. In Institutional Review Board, which intimidating time,” Ms. Halton says. fact, her career path has closely mirrored oversees all clinical trials, and the FDA, “We did not know what to expect after the development of the therapy itself. to ensure the highest level of adherence infusing the CAR T cells.” She joined MSK as a physician office to the study protocol and to keep things She credits Dr. Park, in particular, assistant in the Division of Hematologic running smoothly. for developing effective clinical measures Oncology in 2004. Then, about a decade The RSAs “really are the backbone to deal with the sometimes severe side ago, she became among the first on the of the service,” Ms. Bernal says. “They effects of CAR therapy. “We called him in CAR T crew when she began working with monitor the patients from the moment the middle of the night. Together, we physician-scientist Renier Brentjens as they walk through the door of MSK to the learned what worked, what didn’t — and he established the Cellular Therapeutics moment they are deemed cancer free.” then we tweaked it for the next patient,” Center, the group that treats people Nurse practitioner Elizabeth Halton Ms. Halton says. receiving investigational CAR T therapies is also an integral longtime member Looking back over the decade-plus at MSK. She started as a research study of the group, and of MSK. She spent it took to get where the treatment is assistant (RSA) and is now a supervisor more than a decade working with the today, Ms. Halton is quietly optimistic. for the RSAs on the team. Leukemia Service before coming to the “Originally, most of these patients had Ms. Bernal stresses the collaborative CAR T program. Like Ms. Bernal, she run out of treatment options. Now, nature of the work, as well as the entire joined Dr. Brentjens when the first CAR with CAR T cells, we have something team’s dedication to their common goal. T trials began at MSK in 2007, and she to offer them. And while it doesn’t The RSAs serve as liaisons between was instrumental in getting the CAR T work for everyone, I’m hopeful that, the different clinical, academic, and program up and running. She and the with improvements in the technology, regulatory groups involved. They are other advanced practice nurses from the more people will eventually benefit and certified in human subjects protection, Leukemia Service on the 12th floor experience longer disease-free periods which is an important part of every of Memorial Hospital first cared for and hopefully cures.”
Every clinical trial must follow a careful plan, called a protocol, that describes exactly what will happen during the study. Research study assistants (RSAs), including those on the CAR T team, help monitor and record data. Yvette Bernal oversees and trains these RSAs.
16 MEMORIAL SLOAN KETTERING CANCER CENTER ONE FOCUS ONE MSK
Originally, most of these patients had run out of treatment options. Now, with CAR T cells, we have something to offer them. ... I’m hopeful that, with improvements in the technology, more people will eventually benefit and experience longer disease-free periods and hopefully cures.” – ELIZABETH HALTON
GOING THE LAST MILE As for Mr. Blum, though his results have been good, his experience with bone marrow transplantation after CAR T cell therapy demonstrates why doctors are eager to get to a point at which they can safely avoid it. About a month after the transplant, he got an infection that led to a severe case of pneumonia. “I was in the ICU, and honestly, it was a really scary time,” Mr. Blum says. “The doctors told my mother not to leave the hospital. They were worried I might not make it.” But thanks to CAR T cell therapy, he’s just beginning a new life. It’s been nearly two years since Mr. Blum had his BMT. He’s since gotten married, and he and his wife, Ashley, took a trip to Jamaica to celebrate. He says he always felt very well cared for at MSK. “That hospital is a piece of heaven,” Mr. Blum says. “Everyone there has a heart three times the size of normal.” Top: Elizabeth Halton has been part of the CAR T program from the very beginning. Above: Renier Brentjens, who helped pioneer CAR T therapy, is Director of the Cellular Therapeutics Center, the group of doctors, nurses, and staff who care for patients treated with CAR T cells as part of clinical trials at MSK.
2017 ANNUAL REPORT 17 FOCUS ON THE CANCER GENOME
Thanks to the unwavering focus of Memorial Sloan Kettering researchers, the human genome continues to disclose vital secrets about the origins of cancer. These details are changing how cancer is treated, for patients both today and in the future. One main focus of precision oncology is to quickly translate discoveries made in the lab into treatment approaches that can benefit people with cancer. ONE FOCUS
In 2017, MSK investigators made major discoveries about the kinds of mutations that lead to runaway cell growth, including important insights into DNA repair, and the genetic factors that determine the effectiveness of treatments.
Timothy Chan studies how the immune system recognizes and responds to cancer- specific mutations.
Q: What gave you the idea to look at HLA genes and immunotherapy response?
A: We have known for a while that HLA genes play a role in response to infections. Certain HLA profiles are associated with better outcomes in people with HIV, hepatitis B, and malaria. The INTERVIEW WITH Q: How was this study different human body is constantly under assault from others that have looked at from pathogens, and HLAs are how we TIMOTHY CHAN responses to immunotherapy? recognize and eliminate them. Director, Immunogenomics and We found that people who had more Precision Oncology Platform A: It was large, including more than variation in their HLA genes responded 1,500 people with many different types much better to immunotherapy compared For some people with cancer, of cancer. This suggests that what we with those who had less. No one had checkpoint inhibitors have found applies broadly. And we looked not ever looked at HLA genes in people been a game changer. These only at genetic changes inside the tumor undergoing immunotherapy, so this immunotherapy drugs work by tissue but also at certain genes that make was a new finding. taking the brakes off the immune up people’s normal DNA. Specifically, we system, enabling it to attack looked at human leukocyte antigen (HLA) cancer. They have been shown to genes, which are critical for regulating shrink even very advanced cancers the immune system. to undetectable levels. For most The HLA system is used to match people, though, these drugs have recipients and donors for stem cell and been disappointing. Researchers We found that people who bone marrow transplants. HLA genes had more variation in their are trying to figure out why. guide immune cells called T cells to HLA genes responded much recognize what is the body’s own and One of those studying this what is not. For transplants, we want better to immunotherapy issue is MSK physician-scientist the donor’s HLA system to be similar compared with those who Timothy Chan. In December 2017, enough to the recipient’s that donated had less. No one had ever Dr. Chan and colleagues published T cells will not attack the recipient’s looked at HLA genes in people in Science the largest-ever genetic tissues. In the case of cancer, we want undergoing immunotherapy, analysis of people being treated to boost the T cells’ ability to destroy so this was a new finding. with checkpoint inhibitors. They tumor cells. HLA proteins determine ” found that certain genes people what T cells can see. – TIMOTHY CHAN are born with may play a critical role.
20 MEMORIAL SLOAN KETTERING CANCER CENTER ONE FOCUS ONE MSK
Q: Did this result surprise you?
A: Not completely. Several years ago our Luis Diaz is looking for better ways to diagnose cancer at its very earliest stage, while it is still group at MSK and investigators elsewhere relatively easy to treat. began looking at the effects of the tumor genome on immunotherapy response. We found that tumors with a greater number of mutations were more recognizable to the immune system. Our latest findings represent the other side of the same coin: Just as tumors with a greater number of genetic changes are more recognizable to immune cells, having more-diverse HLA genes means that the immune system has a greater ability to recognize what doesn’t belong inside the body. Both are important for maximizing the ability of the immune system to see and destroy cancer cells.
Q: Will this finding change how people with cancer are treated?
A: I think it will have a strong effect very soon. There is a rush to develop genetic tests to measure how many mutations are present in tumors as a way to predict response to immunotherapy. Our group was responsible for starting this revolution. Now we have shown that the other side of the equation — a patient’s normal inherited DNA — is critical as well. We now know that people with less diversity in their HLA genes as well INTERVIEW WITH Q: How did you discover that as a low number of mutations in their immunotherapy drugs may work tumors are much less likely to respond LUIS DIAZ better for cancers with a high to checkpoint inhibitor drugs, especially Head of the Division of Solid number of mutations? when those drugs are given alone. Tumor Oncology So we may want to treat them with a A: Pembrolizumab is a checkpoint In May 2017, the US Food and combination of different immunotherapy inhibitor, which helps the immune Drug Administration approved drugs, or try other treatments instead. system fight cancer. From the early the immunotherapy drug clinical trials in 2012, it was clear that Q: What are the next steps for pembrolizumab (Keytruda®) these drugs worked very well for certain this research? for cancers that share a certain cancers. What became obvious was that genetic abnormality. This marked the tumors that often responded well to A: the first approval for a cancer drug Our findings will need to be validated these drugs, including melanoma and that attacks tumors no matter in prospective studies, although because lung cancer, tended to have a lot of where they develop. Up to this we included such a large and diverse genetic mutations. point, drugs have been approved number of people, we think we’ve set We noticed that with other types of to treat cancers based on where the bar pretty high. cancer, including colon cancer, which they grow in the body. We can’t do anything about the doesn’t have a lot of mutations, the drugs HLA genes that people are born were rarely effective. Then one of my with. But we think that learning more Luis Diaz led the pivotal clinical colleagues at Johns Hopkins told me about immune system recognition trial that resulted in this approval about a person with colon cancer who was can help with the development of new while he was at Johns Hopkins taking another checkpoint inhibitor drug, cancer treatments. University School of Medicine. nivolumab [Opdivo®], and had responded He joined MSK as Head of the very well. We looked more closely at Division of Solid Tumor Oncology the tumor and found that it had a high in the Department of Medicine in number of mutations. We immediately April 2017, prior to the approval. suspected that the increase was the reason this person had responded to the drug.
continued
2017 ANNUAL REPORT 21 ONE FOCUS
MMR mutations are relatively rare, though that small proportion translates to tens of thousands of people with cancer in the United States every year and half a million worldwide. Our findings suggest that all people with advanced cancer should have their tumors screened for MMR deficiencies.” – LUIS DIAZ
Q: We normally think of mutations Q: How did the pembrolizumab in cancer as a bad thing. In this study come about? case, why is it better to have more of them? A: Based on the discovery with nivolumab, we began a study looking at A: Gene mutations can lead to the whether pembrolizumab, which is similar, production of foreign substances called would work in people whose tumors had neoantigens. Neoantigens are an alien MMR deficiencies. We included people presence in the body that flags the tumor with a dozen different types of cancer. as something that doesn’t belong. This In 2015, we reported that MMR- draws an immune response. The more deficient tumors were more likely to mutations you have, the more your respond to pembrolizumab than those chances increase that the immune system without the deficiency, regardless of where spots the tumor because there is a much the tumor was located. The FDA approval greater possibility that it manufactures was based on the data from that study. a neoantigen. INTERVIEW WITH Q: How could this new approval Q: Why do some tumors have more change the way cancer is treated? ALEX KENTSIS mutations than others? Cancer biologist and pediatric oncologist A: MMR mutations are relatively rare, A: Melanoma and lung cancer often have though that small proportion translates In May 2017, a study led by MSK a lot of mutations because they are caused to tens of thousands of people with cancer cancer biologist and pediatric by exposure to environmental hazards — in the United States every year and half a oncologist Alex Kentsis found that specifically UV light and tobacco smoke. million worldwide. Our findings suggest many childhood cancers have a The person whose colon cancer had so that all people with advanced cancer surprising cause. A gene called many mutations had a genetic defect should have their tumors screened for PGBD5 becomes abnormally called DNA mismatch repair [MMR] MMR deficiencies. activated and snips out DNA deficiency. MMR-deficient cells have lots segments, flipping them or moving of mutations — 1,700 on average compared Q: What are your plans in your them to a different location in with 70 in a typical cancer cell. That’s new role at MSK? the genome. The shuffling can because the mismatch repair pathway is drastically alter normal gene a major way that cells fix DNA mistakes A: I’m involved in leading MSK’s new function and trigger cancer. that happen during replication, which Precision Interception and Prevention cells do each time they divide. initiative. It’s focused not only on This discovery helps solve a baffling catching cancer very early but also on puzzle: why some children with eventually preventing it from developing no inherited gene defects develop in the first place. MSK is bringing together tumors at a young age — especially experts in many different areas to build ones with complicated genomic this program. What we are doing is so rearrangements. The finding also farahead of what any other cancer center provides insight into what causes is doing. many cancers that affect children and young adults. Further research led by Dr. Kentsis suggests a strategy for turning this genomic havoc against itself.
22 MEMORIAL SLOAN KETTERING CANCER CENTER ONE FOCUS ONE MSK
We looked at human rhabdoid tumors, which are aggressive solid tumors that can affect children and young adults, and found evidence of DNA rearrangements associated with high activity of a gene called PGBD5. That really piqued our interest.” –ALEX KENTSIS
In his lab, Alex Kentsis is studying the role of certain proteins in difficult-to-treat childhood cancers.
Q: What about children’s can rearrange DNA segments known as have major functions in biology that we’re cancers made you look into transposons — so-called jumping genes. just starting to appreciate. this potential cause? This phenomenon was first uncovered in the 1940s and ’50s by Barbara McClintock Q: How could this insight lead to A: Cancer is primarily a disease of aging. in Nobel Prize–winning work using corn. better therapies? Over time, genetic mutations pile up, due These types of DNA rearrangements to either copying mistakes as cells replace explain how corn can produce many A: When PGBD5 scrambles other genes, themselves or ongoing exposure to colors of kernels on a single ear — the it creates breaks in the DNA that must environmental factors. We were puzzled transposons alter the expression of continuously be fixed in order for the cell by why tumors develop in younger people, pigment-controlling genes. But we to survive. The cells become especially who presumably haven’t had enough time didn’t suspect that transposons can also dependent on DNA repair and signaling for large numbers of random mutations function in human diseases like cancer. pathways that sustain it. In November to accumulate. We looked at human 2017, we published results showing that rhabdoid tumors, which are aggressive Q: What are the implications of blocking DNA damage signaling causes solid tumors that can affect children and the finding? tumor cells to become so overwhelmed young adults, and found evidence of by DNA damage that they self-destruct. DNA rearrangements associated with A: This is a major advance in There are many drugs that interfere high activity of a gene called PGBD5. understanding pediatric cancers in with DNA damage signaling already That really piqued our interest. particular and human cancers in in clinical trials. One of them — olaparib general. It’s an unexpected mechanism [Lynparza®], a PARP inhibitor — was Q: What is unusual about that raises the possibility that recently approved by the US Food and overactive PGBD5 compared genome rearrangements can operate Drug Administration to treat specific with most genetic mutations? in human tissues. It also explains a subtypes of breast cancer with error- longstanding conundrum about how prone DNA repair. [See page 24 for more.] A: It’s a case where the overactive gene pediatric tumors develop and provides Understanding how PGBD5 works has itself is causing mutations in other genes. a new understanding of human cancers immediate therapeutic implications for Recently, my colleagues and I found that result from this process. And it a wide range of cancers. We hope to start that the protein made by PGBD5 can underscores yet again that the human testing these treatments soon. act as a transposase, meaning that it genome has unexpected features that
2017 ANNUAL REPORT 23 ONE FOCUS
INTERVIEW WITH Q: What are PARP inhibitors and Cancers that respond to PARP how do they work? inhibitors are associated with mutations MARK ROBSON in the genes BRCA1 and BRCA2. BRCA Chief, Breast Medicine Service A: PARP inhibitors block poly ADP-ribose mutations prevent cells from repairing polymerases, or PARPs for short. They the damage caused by these drugs. In the summer of 2017, MSK medical are enzymes that help repair breaks in Besides their association with breast oncologist and clinical geneticist DNA. If DNA cannot be repaired, cells — and ovarian cancers, BRCA mutations Mark Robson reported results whether normal or cancerous — cannot have been linked to many cases of from the first multicenter phase III divide and will die. An emerging strategy advanced prostate cancer, as well as clinical trial of the drug olaparib in cancer therapy has been to block the pancreatic cancer, in recent studies. (Lynparza®) for breast cancer that repair role of PARPs. Normal cells can Clinical trials currently under way at has spread to other parts of the overcome having this method of repair MSK and other centers are looking at body. Based on that work, the US blocked, but cancer cells from people expanding PARP drugs to these other Food and Drug Administration with inherited BRCA1 or BRCA2 cancers associated with BRCA. approved the drug in January 2018 mutations cannot. for people with breast cancer who Q: Based on your findings, who have inherited mutations in the Q: Besides breast cancer, what should get BRCA testing? BRCA1 or BRCA2 genes and who other cancers can be treated have been previously treated with with PARP inhibitors? A: Now that olaparib is an approved chemotherapy. The BRCA genes therapy, I would recommend that anyone have been linked to an increased A: Olaparib was previously approved for with advanced breast cancer who might risk of breast and ovarian cancers treating certain types of ovarian cancer. benefit from this treatment get the BRCA for more than two decades. There are two other PARP inhibitors test. It can help guide their treatment Olaparib was the first drug in the approved for these ovarian cancers as well. and may allow them to avoid getting class called PARP inhibitors to chemotherapy for longer. be approved for breast cancer.
24 MEMORIAL SLOAN KETTERING CANCER CENTER ONE FOCUS ONE MSK
Mark Robson, with medical resident Daniel Klufas, helps people incorporate findings about their genetic risks for cancer into their treatment plan. For people who haven’t yet been diagnosed but are at an increased risk, the goal is to prevent cancer’s development or limit its impact if it occurs.
People with earlier-stage breast cancer a family history that would prompt them as well as other forms of cancer that have to get tested. But there are also possible been associated with BRCA mutations risks if people aren’t prepared to learn may also want to consider getting tested, that they have a mutation. It’s an incredibly exciting if their personal or family history suggests and interesting time to they might be carrying a mutation. That Q: You have been studying BRCA is best determined through consultation for a long time. Is there anything be involved in this field. with a genetic counselor. Knowing that’s surprised you about recent The ways that we are that people have a mutation can help developments? using genetic information them plan ways to reduce their risk now are how we always for developing another cancer. It also A: It’s an incredibly exciting and dreamed we would be might tell them if there is a clinical trial interesting time to be involved in this able to. available that might help them. field. The ways that we are using genetic ” And because these are inherited genes, information now are how we always – MARK ROBSON close relatives of people who are known dreamed we would be able to. So I would to have BRCA mutations should strongly not say that I’m surprised, even though consider talking to a genetic counselor I couldn’t have predicted exactly what and getting tested. we’d be doing today. It’s important to Some have suggested that because note that we have reached the place BRCA mutations are more common in we’re at in this field through investments people of Ashkenazi Jewish descent, this in fundamental research. It’s been whole group should be tested. There is a privilege to help turn promise certainly the potential to benefit, since into reality. many people with mutations don’t have
2017 ANNUAL REPORT 25 FOCUS ON MSK–IMPACT
Knowing more about the changes that drive tumors helps open the door for precision oncology, in which a person is matched with a treatment that targets the specific weaknesses in the cancer. MSK’s genetic-sequencing test, which provides those details, marked two major advances in 2017. Genetic counselors like Meg Sheehan meet with patients and families to explain the inherited risks for cancer that are passed down through generations. ONE FOCUS A SWEEPING IMPACT
28 MEMORIAL SLOAN KETTERING CANCER CENTER ONE FOCUS ONE MSK
GUIDING TREATMENT WITH DATA Not all genetic mutations cause cancer. But some do, and thanks to rapid advances in technology, scientists have amassed a wealth of information about which genetic mistakes are most likely to lead to the disease. The most pressing challenge has been testing people for cancer-causing mutations — and handling the data produced as a result. MSK-IMPACT™, a genetic-sequencing test, is MSK’s answer to this issue. Doctors can use it to probe a tumor for mutations and other genetic changes in 468 genes that are seen in both common and rare cancers. Currently, all MSK patients with advanced solid tumors have their cancer tested by MSK-IMPACT, which has been in use as a clinical test approved by the New York State Department of Health since 2014. The test hit two major milestones in 2017: authorization from the US Food and Drug Administration as a tumor-profiling test, the first test of its kind to receive this designation; and the publication of data from the first 10,000 people whose tumors were sequenced.
continued
These landmark achievements are the result of a major collaborative effort. In addition to guiding treatment choices, this test is producing valuable insights about how cancer grows and resists treatment.” – MICHAEL BERGER
Far left: Marc Ladanyi (right), with molecular geneticist Liying Zhang (left) and pathologist Diana Mandelker, played a key role in the authorization of MSK-IMPACT. Left, top: The Biomek FXp machine uses unique bar-code sequences to tag patients’ DNA, which will be sequenced using molecular testing like MSK-IMPACT. Left, bottom: Michael Berger, with computational biologist Helen Won, helped lead the development of MSK-IMPACT.
2017 ANNUAL REPORT 29 ONE FOCUS
“These landmark achievements are LOOKING FOR CANCER DRIVERS patient-identifying information from the the result of a major collaborative effort,” Although MSK-IMPACT was developed records, then pools the information for says geneticist Michael Berger, who led largely to aid in diagnosis and to guide analysis, allowing researchers across the the development of the test and is an treatment, investigators knew from the nation to study the data. The resource Associate Director of the Marie-Josée beginning that the information they enables them to discover new links and Henry R. Kravis Center for Molecular were collecting could be instrumental for between cancer-related genetic mutations Oncology (CMO). “In addition to guiding research. Everyone who has had a tumor and patient outcomes. treatment choices, this test is producing sequenced by MSK-IMPACT — more than In January 2017, Project GENIE valuable insights about how cancer grows 24,000 people to date — has had their announced the release of its first batch and resists treatment.” genetic data linked to clinical records of data: genomic-sequencing information “MSK-IMPACT has allowed us to showing how they fared after treatment. on tumors from nearly 19,000 people establish an entirely new paradigm for “This is a huge data set,” Dr. Berger with cancer, linked to information about cancer care,” says Marc Ladanyi, Chief says. “It’s extremely valuable to labs that their clinical care. These data, now up of the Molecular Diagnostics Service. are studying specific genes and biological to 38,000 people, will help researchers Dr. Ladanyi’s team, including molecular pathways that are important in cancer. figure out which mutations are drivers pathologist Maria Arcila, was responsible They can focus their research on the most (changes that actually induce cells to for the clinical validation of the test and frequently observed mutations, rather grow out of control) and which are now oversees its performance as well as than having to guess which mutations passengers. Knowing the difference the analysis and interpretation of the may be the most important.” is crucial to developing effective test results. “In this new paradigm, it Beyond using those priceless data in cancer drugs. is critical not only to identify the exact MSK’s own labs, it’s equally important to “Many of the mutations linked to type of cancer someone has and how far share them with other organizations to cancer are rare, making it difficult for it has spread but also to determine the move cancer research forward as quickly one institution to collect enough data to mutations that drive cancer cells as possible. One of these efforts is AACR make statistically significant connections to divide,” Dr. Ladanyi adds. Project GENIE, initiated by the American between a particular mutation and its MSK-IMPACT makes it possible Association for Cancer Research and role in causing cancer,” Dr. Sawyers says. for precision oncology to take place. spearheaded by Charles Sawyers, Chair of “There is a great value in joining together Also called personalized medicine, this MSK’s Human Oncology and Pathogenesis and pooling the insights that we’re approach is based on the idea that the Program. This multicenter effort strips gaining from sequencing patient tumors.” genetic alterations that drive cancer cells to grow can be targeted with specific drugs. The test has also allowed investigators to undertake basket studies. While traditional clinical trials focus on a particular cancer type, basket studies concentrate on a specific mutation found in the tumor, regardless of where the cancer originated in the body. This type of testing is already changing how people are treated. In May 2017, MSK investigators published the aforementioned study in Nature Medicine, showing that nearly 37 percent of the first 10,000 people who had their tumors sequenced using the MSK-IMPACT test had at least one actionable mutation, which means drugs were available that precisely targeted the mutation. According to the study, about 11 percent of the people with actionable mutations participated in clinical trials involving molecularly targeted therapies as a direct result of MSK-IMPACT. Still others received immunotherapy based on their results. “The breadth and depth of MSK- IMPACT has allowed us to detect important genomic alterations that would have been missed by other approaches,” says David Solit, Director of the CMO, Above: Maria Arcila, Director of the Diagnostic Molecular Pathology Laboratory, helps oversee the use of MSK-IMPACT. which financially supports the bulk of Right: Charles Sawyers, with research fellow Elizabeth Adams, MSK-IMPACT testing. is part of an international collaboration among research institutions that shares data from genetic sequencing.
30 MEMORIAL SLOAN KETTERING CANCER CENTER ONE FOCUS ONE MSK
Ahmet Zehir has participated in a number of studies relating to MSK-IMPACT and how it’s being used. It was a tremendous effort to develop MSK-IMPACT, orchestrated by many people with diverse backgrounds.” –AHMET ZEHIR
FAR-REACHING VALIDATION to some medical devices and laboratory- Before MSK-IMPACT, next-generation developed tests, is to set up the test as sequencing technology had been used a model and establish standards for the mainly in the context of research studies. development and validation of similar The pathologists, technologists, and tests in the future. bioinformaticians on the development This validation could lead to team worked painstakingly to create broader insurance coverage for genomic- and enhance methods for collecting and sequencing panels in cancer — a huge issue analyzing clinical samples, which present if these tests are to be widely accessible. a much greater challenge. Moving such a “People making reimbursement complex research test into the diagnostic decisions for Medicare and private laboratory setting was a major advance. insurance companies are realizing that “It was a tremendous effort to develop this kind of sequencing is a bargain MSK-IMPACT, orchestrated by many because patients can receive all the people with diverse backgrounds,” information they need to get the right says Ahmet Zehir, Director of Clinical treatment from a single test,” says Bioinformatics. David Klimstra, Chair of the Department The FDA recognized this innovation of Pathology. “We’re optimistic that as when it authorized MSK-IMPACT as a the positive impact of genetic sequencing tumor-profiling test in November 2017. A becomes more apparent, we’ll be able to benefit of this designation, which is given use the test to benefit more people.”
continued
There is a great value in joining together and pooling the insights that we’re gaining from sequencing patient tumors.” – CHARLES SAWYERS
2017 ANNUAL REPORT 31 ONE FOCUS
BRANCHING OUT TO THE FAMILY TREE While the MSK-IMPACT test was established primarily to screen for mutations in tumor cells, it also offers the opportunity to better understand the contribution of inherited cancer-related genes among people with cancer and their families. For Mitchell Katz, 64, findings from MSK-IMPACT helped researchers understand why he responded so well to a new immunotherapy drug and, more importantly, may have saved the lives of several of his close family members. Mr. Katz was first diagnosed with urothelial cancer in one of his kidneys in 2011 and had MSK-IMPACT testing in 2015. Although his family history did not suggest it, his test results showed he had a condition called Lynch syndrome. Also known as hereditary nonpolyposis colorectal cancer, Lynch syndrome is associated with a genetic predisposition to a number of different cancer types. It’s most commonly linked to colon and rectal cancers, but it’s also known to increase the risk of developing uterine, urothelial, and ovarian cancers, as well as other gastrointestinal cancers, such as tumors in the stomach, small intestine, and pancreas. His doctors made this diagnosis are also offered the opportunity to because, in addition to flagging undergo genetic testing and counseling. cancer-causing mutations in tumors, After Mr. Katz learned he had MSK-IMPACT provides extensive Lynch syndrome in 2015, he met with information about a patient’s normal MSK genetic counselor Meg Sheehan, DNA. Clinical geneticists use this who explained the risks to him and information to uncover which genetic recommended that other family members changes were inherited by a person at get tested. “I was very surprised to find birth and increase the risk of developing out I had this mutation because I didn’t cancer and which developed over time have a strong family history of cancer,” within the cancer cell. Cancer-causing he says. “Once I knew, it was important genes that are inherited are likely to to me that my family have testing too, be shared by brothers, sisters, and just in case they had the same condition.” children, as well as parents. Ultimately, his daughters, Stacy, MSK’s specialists are uniquely Top: Mitchell Katz and his doctor Gopa Iyer. 34, and Shana, 29, were found to carry Above: Mr. Katz (right) and his brother, Elliot, experienced in interpreting these the same mutation, as well as his older were both found to have Lynch syndrome. clues. People who harbor these genetic brother, Elliot, 66. All four of them, alterations can undergo genetic including Mr. Katz, who is still at counseling and learn about what these risk of developing additional cancers, drug atezolizumab (Tecentriq®) when findings mean. Their family members began undergoing regular colonoscopy he found out that his urothelial cancer screenings to check for the presence of had an excess number of mutations due colorectal cancer, an action they never to his underlying Lynch syndrome. It would have known to take otherwise. turned out that people with mutations in In February 2018, Elliot Katz was Lynch syndrome–associated genes were found to have an early-stage colorectal among those in the trial whose cancers Once I knew, it was important cancer, thanks to a colonoscopy. In responded best to the immunotherapy. to me that my family have April 2018, MSK surgeon José Guillem Mr. Katz continues to see MSK medical performed surgery to remove the tumor oncologist Gopa Iyer for his treatment testing too, just in case they and a portion of his colon. and has had no evidence of disease in had the same condition.” Mitchell Katz was already enrolled the nearly four years since he started – MITCHELL KATZ in a clinical trial for the immunotherapy receiving the drug.
32 MEMORIAL SLOAN KETTERING CANCER CENTER ONE FOCUS ONE MSK
FAMILY MATTERS For a long time, experts thought that only 5 to 10 percent of cancers were triggered in part by a hereditary component. But By learning about the presence of inherited mutations, we as a result of MSK-IMPACT, they’re can set the stage for providing genetic counseling to families. realizing that the inherited risk may be substantially higher for some people, That in turn can lead to better screening and prevention. No particularly those with advanced cancer. other institution is doing tests that compare tumor and normal They’re also finding that inherited factors tissues and family notification to the same degree as MSK.” may play a role in a much greater variety – KENNETH OFFIT of cancer types. “At the time a person is diagnosed with advanced cancer, we have a vital opportunity to conduct comprehensive genetic testing,” says Kenneth Offit, Chief of the Clinical Genetics Service and head of the Robert and Kate Niehaus Center for Inherited Cancer Genomics. The Niehaus Center, working closely with molecular pathologists Diana Mandelker and Liying Zhang, aims to use hereditary genomic data to develop new approaches for cancer prevention, early detection, and treatment for families with these inherited risks. “By learning about the presence of inherited mutations, we can set the stage for providing genetic counseling to families. That in turn can lead to better screening and prevention,” says Dr. Offit. “No other institution is doing tests that compare tumor and normal tissues and family notification to the same degree as MSK.” A study published in September 2017 in the Journal of the American Medical Association (JAMA) and led by Dr. Offit’s team found that 17.5 percent of those with advanced cancer had inherited cancer- causing mutations, and half of those people would not have been screened for those mutations based on their personal or family history alone. Like Mr. Katz, the other people in the JAMA study who were found to have inherited mutations in cancer- causing genes were invited to participate in counseling, along with their families. Family members then had the opportunity to undergo genetic testing as well. Going forward, MSK hopes to expand tumor sequencing to even more people. “This new technology has enabled our doctors to extend the promise of precision medicine to many people, including those with common or rare tumor types,” Dr. Klimstra says.
Top: In addition to consulting with adult patients and their families, Meg Sheehan also works with families of children who have cancer. Above: Kenneth Offit (left) and genetic counselor Yelena Kemel have found that inherited cancer mutations are more common than expected in people who have advanced cancer.
2017 ANNUAL REPORT 33 FOCUS ON CLINICAL TRIALS
Clinical trials are the engine of new cancer treatments. Without them — and without all the people who participate in them, despite having no guarantee of success — progress in understanding and treating cancer would grind to a halt. Memorial Sloan Kettering’s clinical trials program is among the largest in the world, with investigators from all disciplines and departments studying potential cures for hundreds of cancer types. At any given time, MSK offers hundreds of clinical trials for a variety of cancers, from the most common to the most rare. ONE FOCUS THE CURE CONVERSATION
36 MEMORIAL SLOAN KETTERING CANCER CENTER ONE FOCUS ONE MSK
In 2017, clinical trials at MSK resulted in a number of firsts: the first cancer therapy developed simultaneously in children and adults; the first drug to rehabilitate cancer cells rather than kill them; the first treatment for a rare and deadly blood disorder. The year also saw progress for a treatment that helps children survive a nerve tissue cancer that spreads to the brain, a disease that used to be a death sentence.
When it comes to advancing cancer care, clinical research is the rocket fuel for better treatments, more accurate diagnoses, and ultimately cures.” –JOSÉ BASELGA
Clockwise from left: David Hyman, Lauren Kaplanis, Alexander Drilon, Kim Kramer, Nai-Kong Cheung, and Eytan Stein.
2017 ANNUAL REPORT 37 ONE FOCUS
DRUG: omburtamab DRUG: larotrectinib TARGET: neuroblastoma, a TARGET: TRK fusions rare nerve-tissue cancer that Larotrectinib is a targeted often spreads to the brain and is cancer therapy that inhibits most common in young children a protein called TRK fusion Dr. Cheung created and tested that fuels growth in multiple omburtamab in clinical trials. cancer types. This drug was When linked to a radioactive developed simultaneously element and injected into the in children and adults and spinal fluid, it delivers precision resulted in dramatic cancer liquid radiation to strike cancer shrinkage for some patients, cells dead. In 2017, the US regardless of age or cancer Food and Drug Administration type. Dr. Drilon led MSK’s granted the drug a Breakthrough phase II adult/adolescent Therapy Designation for clinical trial of larotrectinib NAI-KONG CHEUNG neuroblastoma that has spread ALEXANDER DRILON as part of a multicenter to the brain. The designation is study. In 2017, the drug’s Pediatric oncologist; Medical oncologist; given when early clinical data manufacturer, Loxo Oncology, Head, Neuroblastoma Clinical Director, Early Drug indicate a drug demonstrates submitted a new drug Program Development Service substantial improvement over application to the FDA. existing therapies.
DRUG: vemurafenib (Zelboraf®) SERVICE: Early Drug TARGET: malignant Development histiocytosis, a rare blood Ms. Kaplanis has been a nurse disorder also known as at MSK for more than seven Erdheim-Chester disease years. She has participated Vemurafenib is the first targeted in multiple clinical trials, therapy that was approved including the study of based on a basket trial, a type larotrectinib with Drs. Drilon of clinical trial pioneered at and Hyman. She specializes MSK by Dr. Hyman, MSK in caring for MSK’s child and Physician-in-Chief José Baselga, young adult patients. and others that focuses on the genetic mutations fueling disease instead of where in the body tumors develop. The DAVID HYMAN FDA approved it for treating LAUREN KAPLANIS melanoma in 2011. In 2017, Medical oncologist; vemurafenib became the first Clinical research nurse Chief, Early Drug drug approved by the FDA to Development Service treat malignant histiocytosis.
DRUG: omburtamab DRUG: enasidenib (Idhifa®) TARGET: neuroblastoma, TARGET: acute myeloid a rare nerve-tissue cancer that leukemia (AML) often spreads to the brain and is Enasidenib is the first drug to most common in young children be approved that rehabilitates Dr. Kramer headed the clinical cancer cells rather than killing trial involving 105 children them. The drug reverses a that led the FDA to give stalled state of development omburtamab a Breakthrough for the cells, allowing them to Therapy Designation in 2017. mature normally. Dr. Stein led MSK treats more people with MSK’s phase I/II clinical trials neuroblastoma than any of the drug. MSK President other institution in the world. and CEO Craig Thompson Dr. Kramer is also researching and physician-scientists new treatments to eliminate Ross Levine and Omar Abdel- KIM KRAMER microscopic tumor cells in the EYTAN STEIN Wahab conducted much of the central nervous system. preclinical research upon which Pediatric oncologist Hematologic oncologist the therapy is based. In 2017, the FDA approved the drug for treating AML that has stopped responding to other therapies.
38 MEMORIAL SLOAN KETTERING CANCER CENTER ONE FOCUS ONE MSK
The researchers who spearheaded EYTAN STEIN these advances sat down to talk My experience is a little bit like Alex’s. I worked as a research fellow with enasidenib. The first patient about their efforts, what keeps them I gave the drug to went into a complete remission going when treatments don’t go as and the cancer disappeared. The depressing part planned, and what they appreciate came afterward, when many of the patients we gave the drug to started relapsing. What kept me going about doing this work at MSK. was figuring out how to prevent that relapse and to understand what combinations we needed to use to get those people in remission.
DAVID HYMAN We were running a study of vemurafenib that targeted a specific cancer mutation, but I had no way to identify the people with that mutation. Then MSK’s Information Systems group set up a way that once a person was identified through genetic testing, I would get a message. So I got an email the first day that system went live, and I opened up the email really excited. But the pathology report said the patient had this condition called Erdheim-Chester disease. I was immediately disappointed because I didn’t even know what that was. I Googled it, and even after that I wasn’t sure it was a cancer. It turned out that the company funding the trial was willing to treat the patient, so we went on to treat her and 30 others with the same disease. The drug is now approved in these patients — the first drug approved for people with this condition, ever. I’m a medical oncologist for gynecologic cancers. But all of a sudden my entire clinic was full of these patients with Erdheim-Chester disease and not ovarian cancer. There were days I would go from one room to another to another to treat people with this incredibly rare disease, which most doctors probably never see a single case of. That was the embodiment of “something is definitely working here.” It was such an exciting experience.
KIM KRAMER I’m really moved by the strides we’ve made in treating neuroblastoma. It used to be a death NAI-KONG CHEUNG sentence. But now we have kids who have survived for decades, grown into adults, and gone on to have I bet you often get asked, “Why did you go into their own kids. And the FDA giving a Breakthrough oncology?” But I have a different question: What Therapy Designation to omburtamab gives us keeps you in oncology? How do you sustain yourself even more cause for hope. This fall will be the 20th in a field that we know is sometimes depressing? anniversary of our first celebration for survivors of ALEXANDER DRILON neuroblastoma. It’s been a real privilege to see these kids who had previously been given fatal diagnoses Well, to me, things actually seem less depressing grow up and visit us to celebrate. than they were before. We’re finding new targets for treatment and developing new medicines. We’re continued seeing palpable differences in how much longer people survive and an increase in their quality of life. That keeps me going. We’ve seen Lazarus responses where patients whose tumors have a specific mutation come in horribly sick and turn around very quickly if you give them the right targeted therapy for their cancer. You can really make a huge difference in how they feel.
2017 ANNUAL REPORT 39 ONE FOCUS
THE CHALLENGES OF FAILURE
NAI-KONG CHEUNG But what about when we don’t get results for patients? What if we hit a roadblock? I always admire the nurses who are at the bedside taking care of the sickest patients. It’s really hard for me to imagine how nurses can keep going.
LAUREN KAPLANIS Thank you. I appreciate the acknowledgement. As an oncology certified nurse, I’m at MSK because the work is as rewarding as it is challenging. When you’re involved in a clinical trial, you become such a part of each patient’s life, from the day you first screen them to seeing them weekly to the time when they are clinically responding and getting back to their normal everyday lives — traveling, family, hobbies. The weight of the sadness that you see EYTAN STEIN is overcome by the good that you see, and by how I’m really moved by the altruism of some patients patients are really grateful for the time that you when clinical trials don’t turn out as we hope. I’ve spend with them and the relationships that you had patients say to me, “Can’t I just stay on the drug — form over time. It’s really incredible. even though it’s not working — a little bit longer ALEXANDER DRILON because maybe you’ll learn something more from me being on this drug?” That kind of trust, that they’re With these therapies we’re developing, sometimes willing not only to help research but also to help other it’s actually more heartbreaking when you have human beings, is really dramatic and very impactful. something that can work really well and you know a person has done so great for a prolonged period ALEXANDER DRILON of time. But then suddenly the cancer learns how I think that’s an important point. I’ve also had to outsmart the pill. And you realize that you don’t patients have a really good response to therapy who have anything left for that person. It’s back to tell me, “Doc, thank you so much. I wouldn’t be here square one. today if you didn’t have this therapy on this trial.” But we make it a point to tell them, “No. Thank you, because without your experience and without your contribution, we wouldn’t have been able to establish this data and get this drug approved for other patients.” I think it’s important to feed that back to them, that they’re part of this process.
40 MEMORIAL SLOAN KETTERING CANCER CENTER ONE FOCUS ONE MSK
NEW TREATMENTS FOR CHILDREN AND YOUNG PEOPLE
NAI-KONG CHEUNG I think pediatric oncology faces a lot of challenges. First, in young patients it’s often difficult to give anything that is really toxic. They may have to live with the consequences for a long time. The second thing is that there are very few pediatric patients. So that means the pharmaceutical industry doesn’t pay as much attention. They’re not going to make as much money developing drugs for pediatric patients. That’s the way it is. Numbers count. This is the problem those of us in pediatric oncology have faced for decades. How do you get anything done, make a drug, prove that it works, and after all that have someone make it? Because a therapy can be great and help children on clinical trials at MSK, ALEXANDER DRILON but it cannot be used anywhere else. That’s why it’s We’re trying to address that issue in the development so important when treatments like omburtamab of therapies that target cancer-fueling gene reach important milestones in approval from the mutations regardless of where tumors occur in the Food and Drug Administration, so they can body. That’s the idea with this new drug that David, hopefully help more kids. Lauren, and I have worked on called larotrectinib, a KIM KRAMER TRK inhibitor. It’s for cancers that have a particular gene change called a TRK fusion. It was recognized There are some organizations that are trying to that a really important group of people with this gene make drug accessibility equal for adults, young change was adolescents. So we ran a phase II trial. adults, and children. There’s the RACE for Children Early in the development of the program, the cutoff Act [Research to Accelerate Cures and Equity] was lowered for the adult trial to age 12 to make it an that was just passed earlier in 2018, which will adult and adolescent trial. We’re doing this with more mandate that drugs in development are accessible for clinical trials now. pediatric patients as well. So hopefully the increased continued awareness at that level will improve things.
MSK PEDIATRICS
MORE THAN 100 MORE THAN 100 years of expert pediatric clinical trials available hematology-oncology care TEAM OF MORE MORE THAN 90% THAN 400 of hematology-oncology doctors, nurses, and treatments are performed on other specialists an outpatient basis TWO UNIQUE 850 MORE THAN 150 antibody treatments and NEW PATIENTS patients in treatment cellular therapies developed ANNUALLY each day at MSK and patented for national trials MORE THAN 99% survival rate at MSK for patients with retinoblastoma
2017 ANNUAL REPORT 41 ONE FOCUS
DAVID HYMAN WHAT SETS MSK APART What it really comes down to is not protecting kids from research but protecting them through research. DAVID HYMAN That’s not a line I invented, but I think it’s true. When I started working here, I realized that everyone I think what is a unique opportunity at MSK is that at MSK, no matter what role they play, knows they’re you have this enormous program that’s treating as at an institution dedicated to treating people with many kids, if not more, than anybody else. And it’s cancer. They could work at any other hospital. But embedded within this hospital that has a lot of adult from answering the telephone to pushing a stretcher research. A big opportunity, like Alex said, is bringing or infusing a medicine, they know they’re going to down the age limit on our studies. There’s really no be working exclusively with people suffering from scientific reason that we’ve chosen 18. That gives the cancer. The doctors, nurses, and pharmacists show a kids that are treated here access to studies that are dedication to patients I’ve never seen anywhere else. just not available in pediatric hospitals. KIM KRAMER EYTAN STEIN When it comes to developing great new therapies, With the CAR T cell program everyone’s been there really is a multidisciplinary team effort. My very excited about, that program was pioneered department, pediatric oncology, is just one part of in children and then moved to adults. That was this. It’s the nuclear medicine team, the medical primarily because the tumor that was being targeted physics team, the pharmacology team, the radiation is something that’s very common in kids with safety officers, and all the other departments that acute lymphoblastic leukemia. I think there’s a buy into putting forth the time and effort to make recognition that including kids doesn’t hamper something succeed. The dedication and loyalty your trial; it helps your trial. and effort and diligence and experience are phenomenal here. LAUREN KAPLANIS ALEXANDER DRILON Right. You always look at the patient as a whole, whether they’re 18 or 81. Of course there is a I agree. Another layer is that there’s so much uniqueness with the pediatric population because openness to new ways of thinking at MSK, even in general their understanding and expectation beyond having the best scientists. It’s really a is different. And then there is the family too, so culture. This includes some of the innovations we’ve you have an additional aspect of care that you’re talked about, like dropping the age limit on some providing to the family along with the patient. One clinical trials and focusing on rare cancers. It’s also of the great things about younger patients is their partnering with pharmaceutical companies to pay resilience, which is really cool. for travel and lodging for people with rare cancers to come here from places like Brazil and China. NAI-KONG CHEUNG That openness to new ways of doing research is I agree. They may be hurting one day with all the a beautiful thing. treatment, then the next day they act like they forgot LAUREN KAPLANIS what just happened. It’s amazing how kids can bounce back like that. I feel incredibly fortunate to work with talented doctors from around the world. But I can bounce off my opinions or my suggestions, and they’re open to hear that too. Everyone has that caring and compassion, which is unique. You can’t find that everywhere. I know from working on clinical trials with pediatric patients that it’s important to the family that what they tell a nurse carries weight with everyone on the team, including the doctors.
When I started working here, I realized that everyone at MSK, no matter what role they play, knows they’re at an institution dedicated to treating people with cancer. ... The doctors, nurses, and pharmacists show a dedication to patients I’ve never seen anywhere else.” – DAVID HYMAN
42 MEMORIAL SLOAN KETTERING CANCER CENTER ONE FOCUS ONE MSK
EYTAN STEIN PHASES OF CLINICAL TRIALS Building on what you’re saying, I think that in phase I drug development, everyone has a voice. If it’s the Clinical trials are grouped into phases depending on the purpose of the research. Each phase builds on the last. nurse or the research study assistant, all ideas are taken seriously to contribute to the benefit of that specific patient and the benefit of the study as a whole. Phase I trials focus on the safety PHASE I of the treatment and finding the DAVID HYMAN TRIALS appropriate dose. That same commitment to improving cancer care goes to the very top of the institution. It’s not just about wait times and how many patients you see in a clinic. It’s not just a business. It’s about creating PHASE II Phase II trials determine if the an environment that allows us to advance the field. TRIALS treatment is effective. When I go to other incredible institutions — great, wonderful institutions — they cannot believe the environment and the systems MSK has put in place Phase III trials compare the treatment to the to enable the type of work that we just take for standard of care and are often the final stage granted here. PHASE III before a drug is submitted to the FDA for TRIALS ALEXANDER DRILON approval, though sometimes trials enter phase IV if questions remain about their best use. I agree with that. I think there’s sort of an “if you build it, they will come” kind of theme here.
NAI-KONG CHEUNG This framework has become more flexible in recent years. With the advent of targeted therapies, the individual characteristics This brings us full circle to the question we began of a tumor can help determine if a person is likely to benefit from with, about why we stay in oncology. For me, I know a particular treatment, even before enrolling in a clinical trial. that I need to meet a standard. It’s almost as if you’re Research has shown that tumor profiling leads to significantly trying to improve on your own self. In fact, you try to better outcomes for people in clinical trials, even as early as phase surpass yourself. You want to be a better doctor. And I. Another departure from the past is that treatments are being as you get better, the institution gets better. And that approved by the FDA without going through all of the stages. is the goal.
2017 ANNUAL REPORT 43 FOCUS ON BASIC SCIENCE
If there’s one thing that unites the scientists in the Sloan Kettering Institute, it’s the drive to understand the roots of biological processes — the orderly expression of genes in a developing embryo, the constellation of atoms in a protein, a chain of metabolic reactions in a cell. Increasingly, with the tools of modern biology, scientists can home in on these molecular events with laserlike focus. Their discoveries are bringing clarity to some of the murkiest problems in cancer. Scientists are finding new ways to model disease in the lab, with the goal of determining the most effective treatments. ONE FOCUS SEARCHING WIDE, DIVING DEEP
46 MEMORIAL SLOAN KETTERING CANCER CENTER ONE FOCUS ONE MSK
The genome-editing tool CRISPR has had a sizable effect on science and medicine in recent years. With these powerful molecular scissors, scientists can snip out specific pieces of DNA or make changes at precise genetic addresses. MSK researchers used CRISPR in several inventive ways this year to push cancer science forward.
Left: Ted Kastenhuber, a member of Scott Lowe’s lab in the Sloan Kettering Institute, removes frozen cancer cells from liquid nitrogen. Above: Mr. Kastenhuber grows cancer cells in vitro. The cells are from mouse tumors that the team generated in the lab. Growing cancer cells outside the body could make it easier to test drug sensitivity more quickly and efficiently compared with studying the results in patients.
2017 ANNUAL REPORT 47 ONE FOCUS
NATURE’S SWISS ARMY KNIFE: THE MANY USES OF CRISPR
UNRAVELING THE CAUSE OF A DEADLY CANCER The rare liver cancer fibrolamellar hepatocellular carcinoma (FL-HCC) strikes fewer than 1,000 individuals a year worldwide, mostly children and young adults. There are few effective treatments besides surgery. FL-HCC is usually diagnosed late, so it is often fatal. Because FL-HCC is so uncommon, it’s hard for researchers to learn more about it, or even to conduct clinical trials of potential medicines. And without knowing more about the disease’s underlying biology, they can’t come up with solutions to stop it. But what if the disease could be recreated in the lab? Could scientists use a synthetic model to test new FL-HCC drugs? A team led by cancer biologist Scott Lowe creates genetically engineered mouse models to understand key cancer drivers. Scott Lowe, Chair of the Cancer Biology and Genetics Program in the Sloan Kettering Institute, decided to try just that. They used CRISPR to engineer mice with the same mutation that affects people with the disease. Models give us the freedom to fail and to explore a wide It worked beautifully. “We showed that if you can reproduce that genetic variety of approaches. This way, we can accelerate the event in mice, they will develop a discovery of treatments that are more likely to be effective cancer that looks very much like before exposing people to experimental medicines.” human FL-HCC,” Dr. Lowe says. – EDWARD KASTENHUBER “This demonstrates that the mutant gene causes FL-HCC.” The research came about through a collaboration between Dr. Lowe’s lab at MSK and Sanford Simon’s lab at The Rockefeller University. Several years CRISPR: A BACTERIAL CUT-AND-PASTE SYSTEM ago, Dr. Simon and colleagues discovered that nearly all people with FL-HCC share CRISPR stands for the same mutation in their tumors. It was a big advance — one made C R I S P R even more remarkable by the fact that Dr. Simon’s own daughter, Elana, Clustered Regularly Interspaced Short Palindromic Repeats suffered from FL-HCC and was centrally involved in the research effort. But still, it was only a correlation. These short sequences of repetitive DNA are found in bacteria and other microorganisms. To find out for sure whether this Microbes use these sequences as a type of immune system against viruses. mutation was responsible for driving the disease, Dr. Lowe’s team, including Key to the whole operation are stretches In 2012, scientists at the University of California, Edward Kastenhuber, a student at the of DNA in the CRISPR sequences that match Berkeley, and elsewhere realized they could Gerstner Sloan Kettering Graduate the genetic sequence of viral DNA. When turn this bacterial cut-and-paste system into a School of Biomedical Sciences, used these sequences are transcribed into RNA, powerful tool for genetic engineering. Researchers CRISPR to snip out the portion of the they bind to viral DNA and direct an enzyme can give the Cas9 enzyme a synthetic RNA as a chromosome that is lost in people — for example, one called Cas9 — to snip guide, one that matches a gene or DNA sequence with FL-HCC. The remaining bits of the DNA at the match site. This disarms of interest. They can then use the CRISPR-Cas9 chromosome then combined, fusing the the invader. Bacteria retain a record of past system to make very precise cuts and other two genes that are normally separated. viral infections, much like our own immune alterations in the DNA of cells. system does, stitched into their DNA.
48 MEMORIAL SLOAN KETTERING CANCER CENTER ONE FOCUS ONE MSK
The team plans to use the model to test a variety of drugs to see if they can slow or stop the cancer’s growth. FL-HCC Below: Activated T cells, shown under a microscope, are prepared and ready for gene editing. could be a good target for drugs called Bottom: Justin Eyquem (left) and Jorge Mansilla-Soto are postdoctoral fellows in Michel Sadelain’s lab in the Sloan Kettering Institute. kinase inhibitors, but scientists won’t know for sure until they test them. “Models give us the freedom to fail and to explore a wide variety of approaches,” Mr. Kastenhuber says. “This way, we can accelerate the discovery of treatments that are more likely to be effective before exposing people to experimental medicines.” The findings were published in the Proceedings of the National Academy of Sciences in November 2017.
BUILDING A BETTER CAR Chimeric antigen receptor (CAR) T cells are a powerful tool to treat certain blood cancers. (Read more about CAR T therapy on page 8.) But the way they are made is somewhat inefficient. The current process involves removing immune cells from patients and using modified viruses to deliver the CAR gene into those cells. But this method inserts the gene randomly at multiple spots in the genome. This scattershot approach isn’t as efficient as it could be, and could actually cause problems by disrupting the function of important genes. This past year, researchers in SKI used CRISPR to build a better CAR T model.
continued
2017 ANNUAL REPORT 49 ONE FOCUS
Postdoctoral fellows Justin Eyquem PLUGGING A HOLE IN METASTASIS and Jorge Mansilla-Soto, working in the lab of Michel Sadelain, showed that if they used CRISPR to place the CAR at STOPPING CANCER’S SPREAD One of the most challenging types of a very specific genome location called Cancer metastasis — which occurs when metastatic cancer attacks the fluid and the TRAC locus, the cells were not only cells break off from a tumor, spread tissues that surround the brain and spine. more homogeneous, they were also more through the bloodstream or lymph If people develop this condition, called effective. The approach paves the way vessels, and take root in another part leptomeningial metastasis (LM), they for more reliable CAR therapies and of the body — causes the overwhelming usually die within weeks or months. even off-the-shelf versions that would majority of cancer-related deaths. In MSK cancer biologist Joan Massagué, not need to be made from a person’s own fact, it’s widely estimated that 90 percent Director of SKI and Executive Director cells. They published their findings in of cancer deaths are due to metastatic of the Alan and Sandra Gerry Metastasis the journal Nature in February 2017. disease rather than the original tumor. and Tumor Ecosystems Center, has “The method we developed will Many primary tumors can be wiped been studying the intricacies of cancer likely transform a costly and variable out with surgery, chemotherapy, and metastasis for nearly two decades. Much T cell–manufacturing process into a other treatments. Once cancer migrates, of Dr. Massagué’s current work is focused more uniform, universal, and safer one,” however, it becomes much harder to stop. on latent metastasis, which happens Dr. Eyquem says. This is especially true when it spreads when cancerous cells left behind after Also remarkable is the speed at which to vital organs, such as the lungs, liver, treatment form new cancers years or they were able to accomplish this feat. or brain. even decades later. “We started to work on this project less than three years ago, and we expect to bring it to the clinic by early 2019,” Dr. Eyquem says.
KNOW THY GENOME As precise and powerful as CRISPR can be, it’s only as good as one’s knowledge of the genome being cut. CRISPR can aim for multiple targets. But if it does, then instead of making precise snips in the exact spot in the genome you’re aiming for, you might slice it too much. In May 2017, researchers at SKI presented a way to solve this problem. The team — which included postdoctoral fellows Joana Vidigal and Yuri Pritykin, graduate student Alexendar Perez, and SKI faculty members Christina Leslie and Andrea Ventura — built computer software to help scientists design more-effective guide RNAs. CRISPR uses guide RNAs to find specific regions of the genome, where it then makes a cut. The new software, called GuideScan, allows researchers to identify guide RNAs that have one or only a few possible matches in the genome, reducing the potential for Joan Massagué (center), with medical oncologist Karuna Ganesh (right) and research associate too many cuts. GuideScan is freely Harihar Basnet, has made groundbreaking discoveries about the genes that influence how tumors accessible to researchers everywhere, interact with their environment. to help enable even more skillful use of the CRISPR technology. “Pretty much anything you can imagine, you can do,” Dr. Vidigal says. “And now you can do it precisely.” It’s difficult for cancer cells to seed new tumors in other parts of the body. To get through all the barriers that are waiting for them when they leave the mother ship, the ones that survive have to be tougher than the average cancer cell.” –JOAN MASSAGUÉ
50 MEMORIAL SLOAN KETTERING CANCER CENTER ONE FOCUS ONE MSK
“It’s difficult for cancer cells to seed understood how that protein worked, new tumors in other parts of the body,” he Drs. Massagué and Boire looked for a way says. “To get through all the barriers that to block its function. The solution was are waiting for them when they leave the just as surprising as the initial discovery: In the past, LM was part mother ship, the ones that survive have to A compound targeting the protein — of the fatal end stage of be tougher than the average cancer cell. originally developed to treat asthma This explains why these cells tend to be but ultimately ineffective against that cancer. [But] now that more aggressive and harder to treat.” disease — suppressed LM and slowed its patients are living longer In March 2017, Dr. Massagué and progression in mice. Now the researchers and we’re able to treat physician-scientist Adrienne Boire are investigating the possibility of using other sites of metastasis, published a paper in the journal Cell on the compound to treat people with LM. this is becoming a clinical LM. To figure out how certain cancer “In the past, LM was part of the fatal cells grow in spinal fluid, the researchers end stage of cancer,” Dr. Boire says. By problem that we need to implanted several cell lines of breast and that point, people had so many other learn how to address.” lung cancer in mice and monitored them complications that not many efforts were –ADRIENNE BOIRE to see which ones resulted in LM. focused on LM. But “now that patients To their surprise, they discovered are living longer and we’re able to treat that all of the cell lines that colonized other sites of metastasis, this is becoming the spinal fluid had the same well- a clinical problem that we need to learn known protein in common. After they how to address.”
Adrienne Boire (right), with senior research technician Majdi Alghader, was inspired to study leptomeningial metastasis by a patient of hers who had the condition.
2017 ANNUAL REPORT 51 ONE FOCUS
TOR DE FORCE: CRYO-EM TECHNOLOGY
BRINGING A KEY PROTEIN Drug Administration for the treatment of assembled an impressively detailed view INTO FOCUS some types of kidney and breast cancer. of mTOR — the first ever — including what Scientists call it the master growth But overall, mTOR-targeted drugs it looks like in action. To do so, they used regulator: a protein complex in cells that have been disappointing. That may be an innovative technology called cryo- senses when they have enough nutrients because mTOR is a large and complicated electron microscopy (cryo-EM), a kind and cues them to grow and divide. piece of cellular equipment. There are of satellite imagery for the cell. When this complex, called mTOR, is many interacting parts, and it may be With this technique, scientists shoot triggered, cells begin making copies of key hard to take down the whole thing with beams of electrons at a purified sample ingredients, such as membranes, DNA, a single shot. Without a clear map of the of molecules that is flash frozen in chilled and organelles. They use these extra protein’s structure, it’s impossible to liquid ethane. The electrons bounce off materials when they split into daughter cells. know how it works — or how to stop it. the molecules in the sample, creating For years, scientists have sought to In December 2017, a team of scientists an image. Thousands of individual target abnormally active mTOR with led by Nikola Pavletich, Chair of the pictures are taken, and then a scientist drugs as a way to treat cancer. Two such Structural Biology Program, and Haijuan uses sophisticated algorithms and high- drugs are approved by the US Food and Yang, a senior research scientist in his lab, powered computers to assemble the
Once you solve a protein’s structure — in essence, creating a three-dimensional map showing where all its atoms are — you gain a much deeper understanding of how the protein works and how its function could be manipulated with drugs.” – NIKOLA PAVLETICH
Nikola Pavletich (left), with lab member Buren Li, a student at the Gerstner Sloan Kettering Graduate School of Biomedical Sciences, studies biological molecules at an atomic level, including the proteins that control cell growth and proliferation.
52 MEMORIAL SLOAN KETTERING CANCER CENTER ONE FOCUS ONE MSK
pictures into a crisp, three-dimensional image. MSK installed a cryo-electron microscope, the Titan Krios, in 2017. Below: Buren Li with Haijuan Yang and the cryo-electron microscope that arrived at MSK in 2017. Bottom: One of its first uses was to help scientists Structural biologist Stephen Long (right), with lab manager Jason Cruz, also utilizes cryo-EM technology. tackle the structure of mTOR. “Once you solve a protein’s structure — in essence, creating a three-dimensional map showing where all its atoms are — you gain a much deeper understanding of how the protein works and how its function could be manipulated with drugs,” Dr. Pavletich says. Previously, such detailed atom-by- atom pictures could only be produced with X-ray crystallography, a painstaking and time-consuming method that involves first making a crystal out of a protein and then X-raying it. But not all proteins will form crystals. That’s especially true of large proteins and protein complexes with multiple moving parts, like mTOR. Cryo-EM eliminates the crystallization step, which makes determining structures much easier and faster. The mTOR protein is actually part of a larger assembly of several interlocking protein pieces that operate together. The whole complex is called mTORC1. The structure newly obtained by cryo-EM shows how all the pieces fit together, including how mTOR is turned on. What once would have taken years to complete took just a few months. “Before cryo-EM, people could model bits of this protein and bits of that protein,” Dr. Yang says. “Now we can put it all together.”
Before cryo-EM, people could model bits of this protein and bits of that protein. Now we can put it all together.” – HAIJUAN YANG
2017 ANNUAL REPORT 53 FOCUS ON PATIENT CARE
Every advance at MSK is intended to achieve a singular goal: improving our patients’ well-being. In 2017, teams across the organization optimized surgeries, minimized unnecessary treatment, built new spaces for recovery, and made facilities feel a little bit more like home. Lyndell Kegerise (right) was among the first to stay in MSK’s 75th Street Patient Residence, an apartment-style facility for people recovering from bone marrow transplants. ONE FOCUS JUST LIKE HOME
56 MEMORIAL SLOAN KETTERING CANCER CENTER ONE FOCUS ONE MSK
A CONVERSATION WITH LYNDELL KEGERISE In January 2017, Dr. Hamlin said that we were running out of options. That hit me hard. He said that LYNDELL KEGERISE I would be a great candidate for a stem cell transplant MSK patient and he’d like me to meet Dr. Sauter, who would perform it. WESLEY KEGERISE CRAIG SAUTER Lyndell’s husband Lyndell had high-risk disease, so that dictated the transplant. When patients approach 70, we have a little more pause, but she didn’t have any major medical problems. Life at the Jersey Shore was good for Lyndell Kegerise. The WESLEY KEGERISE former real estate professional Our MSK team found a donor through the Be the Match program — this 25-year-old fellow who was a was diagnosed with non-Hodgkin wonderful match. We’re extremely grateful to him.
lymphoma in 2005, but under LYNDELL KEGERISE the care of MSK oncologist Paul I was afraid he was going to back out after I initially Hamlin, her disease went into didn’t achieve remission. I hope I get to meet this remission and stayed there for man one day because he stuck in there with me. He was ready when I was ready. eight years. But in 2014, when she was 66, her disease relapsed, A NEW PLACE TO HEAL and then relapsed again in 2015. When chemotherapy and Mr. and Mrs. Kegerise had looked into staying at a immunotherapy couldn’t keep New York City hotel while she recovered from her transplant, until a nurse at MSK Basking Ridge her in remission for longer than gave them another idea: MSK’s brand-new 75th a year, Mrs. Kegerise and her Street Patient Residence, an apartment-style facility for husband, Wesley, learned that bone marrow transplant patients and their caregivers that opened in 2017. The studio, one-, and two-bedroom her best option was a stem cell units are outfitted with full kitchens, bathrooms, transplant with hematologic laundry, cable TV, and Wi-Fi. For some patients, their oncologist Craig Sauter. stay may be covered by insurance. continued
Left: Wesley and Lyndell Kegerise at the 75th Street Patient Residence. Above: Mr. Kegerise and Noel Neylon. Right: Mrs. Kegerise’s doctor Craig Sauter.
2017 ANNUAL REPORT 57 ONE FOCUS
LYNDELL KEGERISE LYNDELL KEGERISE Eric, one of my chemo nurses at MSK Basking Ridge, They thought of things we didn’t even think about. said, “You know, the new facility might be open by Our air was filtered. Our water was filtered. the time of your transplant.” The next time I was back, he said, “Lyndell, it opened!” So I pursued it. WESLEY KEGERISE This is the remarkable thing about MSK. The CRAIG SAUTER 75th Street Patient Residence team was so easy I thought it was great because she lives in New Jersey. and wonderful to work with. I had to move our She didn’t need inpatient care, but we like to have our reservation about six times because we didn’t exactly patients close by for follow-ups. It’s a good resource know when Lyndell would be OK for the transplant, for patients who need to be here frequently. and nothing was a problem for them. Your room is ready when you’re ready. The people at MSK work WESLEY KEGERISE so well integrating with all the departments that the We said, “This is great — take our reservation now!” patient doesn’t have to worry about anything except When your loved one is going into a long hospital getting better. stay, what is the caregiver going to do? How are you going to go back and forth? All of these thoughts LYNDELL KEGERISE were going through my head. But MSK was sensitive Everything was coordinated for us. We just had to to the needs of the caregiver as well as the patient. show up. And it was wonderful being on the east side At a hotel, the room isn’t sanitized. They don’t near the hospital, so we didn’t have to go across town. understand your medical needs. But here the staff is trained to understand the needs of the patient. LIFE AFTER TRANSPLANT
Mrs. Kegerise had her transplant and stayed in Memorial Hospital to recover for 30 days. Mr. Kegerise stayed at the residence. Then Mrs. Kegerise joined him The people at MSK work so well at the residence a few blocks away, where they stayed for 40 more days. integrating with all the departments that the patient doesn't have to worry about LYNDELL KEGERISE anything except getting better.” Even when you get out of the hospital, you’re still –WESLEY KEGERISE going to see the transplant team every other day. The whole coordinating team at the 75th Street Patient Residence made it easy for us. They would call in the evening and say, “Your van will be here at 8 am” to go to the hospital. If for some reason it was late, they would call a driver.
WESLEY KEGERISE At the residence, you have your own little apartment. If Lyndell wanted to take a nap, she could go in the bedroom and I could be in the living room watching TV. That’s a real benefit. And the staff couldn’t be more accommodating. Lyndell loves Bigelow mint tea, and they even got it for her. The session assistant, Ritsuko, and door attendant, Terry, would call us and say, “Do you need a ride in tomorrow at a certain time?” Noel, the superintendent who changed the filters, was so nice.
LYNDELL KEGERISE He became like our family.
NOEL NEYLON (MAINTENANCE SUPERVISOR) I know the people who stay with us, like the Kegerises, need support from our entire staff. Doing everything I can to create a warm, friendly environment for patients and their families to come “We try to provide a warm and casual environment,” says Noel Neylon, seen home to is very important to me. I am proud to have here in one of the residence’s apartments. “Our patients have enough hard- been at MSK for more than 23 years, and I hope that ships to deal with. They shouldn't have to worry about having any problems we can continue to make a difference in our guests’ at their home away from home.” experiences by treating them like family.
58 MEMORIAL SLOAN KETTERING CANCER CENTER ONE FOCUS ONE MSK
The couple on their wedding day in 1968 (left), and Lyndell Kegerise in treatment at MSK (right).
A COMMON BOND LYNDELL KEGERISE That was very nice. Our Saudi Arabian family was LYNDELL KEGERISE able to join us for pizza in the common area. At the residence, you are with people who are going In October 2017, Mrs. Kegerise was cleared through the same thing as you. We met a gentleman to return home. who worked on 9/11 and got blood cancer. We befriended a family from Saudi Arabia, and the son LYNDELL KEGERISE took Wesley under his wing. He cooked for him. The I was nervous leaving, but it was very coordinated. night before we left, they said, “Come down to our I had a little setback at Christmas — I got an infection apartment and spend some time with us.” At the end so I was back in the hospital — but I’m doing great. of the evening, the father, who was also a transplant I feel great. I have energy, and I’m getting stronger. patient, gave me his prayer beads. Every December, I would have scans done, and the WESLEY KEGERISE cancer was always back. This was the first time in three years I didn’t hear the word “cancer” at Most days I would go with her to her appointments Christmas. It was unbelievable. and have lunch with her. Some days I would go to the art museum or the Museum of Natural History. The couple will celebrate their 50th wedding A couple days I would hit golf balls at Chelsea Piers. anniversary in September. I could go back for lunch, see her in the afternoon, and walk home in the evening. It was so convenient. LYNDELL KEGERISE
LYNDELL KEGERISE We want all the special people in our lives over the past 50 years to come celebrate with us. We are so I encouraged him to get out. I said, “I’m taken care of blessed. Every day is a gift. — it’s you I’m worried about! Go do something fun.”
WESLEY KEGERISE Our daughters came in from Delaware and Atlanta. They could stay with me at the residence while Lyndell was in the hospital. That was another beautiful thing: People could visit.
2017 ANNUAL REPORT 59 ONE FOCUS SEEING PROSTATE CANCER IN A NEW LIGHT
60 MEMORIAL SLOAN KETTERING CANCER CENTER ONE FOCUS ONE MSK
The whole ambience they created was just outstanding. I always felt that if I ever had a diagnosis of cancer, I would not walk but run to MSK. And that’s exactly what I did.” –GREGORY PAGE
DOCTOR BECOMES PATIENT As a dentist, Gregory Page knew the importance of staying on top of his health. He had prostate-specific antigen (PSA) tests, which measure for a protein in the blood that is elevated in men with prostate cancer, as part of his regular routine. When his PSA came back abnormally high in 2007, he made sure to see his doctor each year to more closely monitor his level. In April 2017, his doctor saw that Dr. Page’s PSA had risen high enough to warrant a biopsy. The test came back positive for cancer. The news was understandably difficult for Dr. Page to take in — even more so because it came on top of what had been a challenging year so far. His godmother, best friend, and brother had all recently died. New York City dentist Gregory Page came to MSK for a less-invasive “It was not a good year for me,” approach to prostate cancer treatment. After undergoing light-activated recalls the 68-year-old from New York therapy with Jonathan Coleman, Dr. Page was able to resume his normal City. “I said, ‘God, you’re giving me a lot activities within days, including lunch at the Renaissance Harlem, near to handle here.’ ” his office. Dr. Page was already under the care of a urologist, but hearing he had cancer made him reconsider where he wanted to go for treatment. He remembered the times he had escorted one of his good friends, a lung cancer survivor, to MSK’s Rockefeller Outpatient Pavilion.
continued
2017 ANNUAL REPORT 61 ONE FOCUS
“The whole ambience they created FINDING A LESS-INVASIVE receives a medicine called padeliporfin was just outstanding,” he says. “I always OPTION (Tookad®) through an IV. Then the doctor felt that if I ever had a diagnosis of cancer, In June, Dr. Page and his fiancée, places a thin laser fiber into the prostate I would not walk but run to MSK. And Cynthia, met Dr. Coleman and his nurse, gland, which activates the drug so it can kill that’s exactly what I did.” Connie Estes. Dr. Coleman remembers the cancer. Patients can go home the same day. Before calling MSK’s Patient how impressed he was with Dr. Page’s “There’s a need for new technology to Access Service, which schedules first knowledge of his circumstance. better destroy cancerous tissue without appointments for people coming to MSK, “He had definitely done his harming the surrounding tissue, and Dr. Page researched urologists online. homework,” Dr. Coleman says. “He that’s where this type of therapy comes When he saw a YouTube video of MSK was extremely intelligent and well into play,” Dr. Coleman says. urologic surgeon Jonathan Coleman, informed. He was thoughtful, inquisitive, Right now, vascular-targeted he knew he had found the doctor he and concerned about his cancer while photodynamic therapy is performed wanted to see. also being concerned about treating it only through clinical trials, and it’s not Dr. Page recalls, “Dr. Coleman too aggressively.” an option for every man with prostate discussed the various treatments for Ms. Estes was equally taken by the cancer. However, efforts are under way prostate cancer, and he also used the couple. “They are both the nicest people, to make it more widely available. word ‘cure,’ ” which is possible for many and every interaction we had was a At their next meeting, Dr. Coleman men with prostate cancer. “That’s a good delight,” she says. “It was obvious that told Dr. Page that he was recruiting men word to hear when you have cancer,” they had researched prostate cancer for a trial that would bring vascular- he adds. and treatment.” targeted photodynamic therapy closer Another point in the video that She told the duo that Dr. Coleman was to US Food and Drug Administration really resonated with Dr. Page was when doing promising research with vascular- approval. He had 30 out of the 50 men Dr. Coleman said that the procedures targeted photodynamic therapy, a form he would need. Dr. Page knew this was he does have minimal side effects. of prostate cancer treatment that uses his opportunity. “I had friends who had their prostates a light-activated drug to zap prostate “I looked at my fiancée, I looked at taken out, and it took them years to tumors with minimal side effects. Dr. Coleman, and I said, ‘Could I be recover,” Dr. Page says. “One of my Dr. Coleman has been offering number 31?’ ” he recalls. “He said yes, friends had incontinence problems for vascular-targeted photodynamic therapy and I hugged him like he was my long- a year. I have another friend who had since 2010. The procedure requires only lost brother. I knew I was getting to have a pump put in. I didn’t want all light sedation — the same type used for world-class treatment.” of that.” a colonoscopy. Once sedated, the patient
Above: Jonathan Coleman is hoping the drug becomes a mainstream option for men with this type of cancer. Right: Narrow optical fibers activate Tookad to destroy prostate cancer.
62 MEMORIAL SLOAN KETTERING CANCER CENTER ONE FOCUS ONE MSK
I remember I was so excited to make that call. As an office practice nurse, you really get to know patients and their families. When the biopsy came back benign, it was great news. It makes my day when I am able to call a patient with news like this.” –CONNIE ESTES
Connie Estes helped prepare Gregory Page for his treatment with Jonathan Coleman.
THE BIG DAY — AND A forms of prostate cancer treatment, Now, nearly a year postsurgery, QUICK RECOVERY he hasn’t had any serious issues with Dr. Page is doing great. He’s busy at Dr. Page had his procedure in October incontinence or erectile dysfunction. work and helping plan Cynthia and his 2017 at Memorial Hospital. He went At his three-month postsurgery checkup wedding. He says this year is shaping up home the same day. He had to stay in in January, Dr. Coleman didn’t find any to be much better than the last. shaded light conditions for the first two cancer. Ms. Estes relayed the good news “As a healthcare provider, it’s days he was home because Tookad is to Dr. Page. important for me to spread the word activated by light, but his fiancée helped “I remember I was so excited to about positive things that can enhance him pass the time. make that call,” she recalls. “As an office and prolong people’s lives,” he says. “When the 48 hours were up, I got up, practice nurse, you really get to know “I feel very fortunate that I was at the put on my clothes, and went to a baseball patients and their families. When the right place, at the right time, with the game. And I felt fine,” he remembers. biopsy came back benign, it was great right doctor and staff. How many people After the procedure, the only side news. It makes my day when I am able to can say they had a complete turnaround effect Dr. Page experienced was some call a patient with news like this.” in nine months?” minor soreness. And unlike other major
2017 ANNUAL REPORT 63 ONE FOCUS
Lisa DeAngelis (right) is searching for ways to improve outcomes for people with brain tumors and neurologic complications of cancer. Viviane Tabar studies the use of stem cells to model cancer and to repair brain tissue after injury. Dr. Tabar also leads the Multidisciplinary Pituitary and Skull Base Tumor Center at MSK.
INTERVIEW WITH THE UNIQUE CHALLENGES OF BRAIN CANCERS
VIVIANE TABAR LISA DEANGELIS LISA DEANGELIS Chair of the Department Chair of the Department of Neurosurgery of Neurology People have very different ideas about what makes life meaningful. It’s important that we know what that means to all of our patients, so we can not only treat their disease but also help guide them through difficult decisions and honor their wishes and their There are few diseases as feared — values, especially if they reach a point at which they or as challenging to treat — as cancers may not be able to articulate that. So you need to of the brain. But there are very few know that early on. doctors in the field of neuro-oncology VIVIANE TABAR with the expertise, experience, and I agree. I think it’s absolutely crucial to understand compassion of Lisa DeAngelis and what patients really want and to tailor our treatment to their expectations. I remember early in my career Viviane Tabar. Both have spent nearly someone who had a large, benign tumor, and we were all of their distinguished careers at very proud to have removed it completely. But the patient was not really satisfied because she turned MSK. Dr. DeAngelis has been Chair of out to be a wine connoisseur and she lost her ability the Department of Neurology since to smell. That impacted her quality of life far more 1997; Dr. Tabar was named Chair of the than we had anticipated. Department of Neurosurgery in 2017. Obviously, some people deal with much more challenging neurological and psychological problems related to a brain tumor diagnosis than that. That In addition to treating patients, both kind of experience is why I often tell my trainees doctors also conduct groundbreaking that your first ten years as a surgeon are focused on developing your skills and becoming a good surgeon. research. They sat down to talk about But what’s more challenging afterward is developing their approach to treating people with good judgment. neurologic cancers, what makes MSK special, and much more.
64 MEMORIAL SLOAN KETTERING CANCER CENTER ONE FOCUS ONE MSK
LISA DEANGELIS NEW DEVELOPMENTS IN It’s also really important to understand that treating THE FIELD the family is an integral part of treating the patient. It’s the family who bears the consequences if the LISA DEANGELIS person’s personality and identity are changed Having taken care of people with glioblastoma dramatically by their illness. In some ways, the and malignant brain tumors for more than 30 years, family struggles more than the patient. I’ve often I really have seen a noticeable improvement in the said to people, “This is going to be harder on you quality of life for people who live with these diseases. than it’s going to be on your spouse,” or father, or One reason is newer drugs, such as temozolomide whoever the patient is. I think that’s something [Temodar ®], which is much less toxic than prior that we in the neurology world confront much chemotherapies and better tolerated. Also, the more frequently than other doctors. addition of bevacizumab [Avastin®] has helped VIVIANE TABAR patients avoid corticosteroids for brain edema or swelling and the attendant side effects. That’s been Yes, that’s very insightful. The families do take on very gratifying and enabled patients and families to a large burden that sometimes leaves me in awe of make the best use of whatever time they have left. their generosity. Brain cancers are probably some of the most challenging diseases to deal with. The other thing that’s changed is that there are people who are living many years with this illness. LISA DEANGELIS That’s not something that we saw — or saw very rarely You sometimes ask yourself, “How do these people — in the ’80s and ’90s. It’s important to understand even get out of bed in the morning and face the day?” that the proportion of these people is very small. And the fact that we haven’t substantially prolonged life for more patients is the most important problem that we struggle with. But those people who live for six or seven years after treatment often do extraordinarily well. They are able to work and enjoy life. That’s a I think it’s absolutely critical to understand dramatic change. what patients really want and to tailor our continued treatment to their expectations.” – VIVIANE TABAR
It’s also really important to understand that treating the family is an integral part of treating the patient. It’s the family who bears the consequences if the person’s personality and identity are changed dramatically by their illness.” – LISA DEANGELIS
2017 ANNUAL REPORT 65 ONE FOCUS
VIVIANE TABAR THE IMPORTANCE OF TREATMENT In the neurosurgery department, we’ve evolved over the last ten years to put a greater focus on offering LISA DEANGELIS surgery while maximizing function. That’s in part We’ve seen in both of our disciplines, whether with because of technologies that I expect will continue primary or metastatic tumors, that there can be to evolve and allow us to offer people more options. recovery of function. Particularly with primary Take, for example, patients who suffer from brain tumors, I think there was a lot of therapeutic nihilism metastases, when cancer spreads from another part associated not only with the fact that these are of the body. Traditionally they were told that their life difficult cancers to treat but also with the long-held expectancy was a year or less, and I would admit that belief that people could not recover neurologically. they perhaps received less attention from surgeons If they were left severely compromised from a in the past. But today, we often focus our discussion functional point of view, what was the point? on what surgery can do to improve quality of life. If a patient suffers from a weak leg or a weak arm, we But in fact we have learned that with multiple means are more likely to offer them surgery if we think that of treatment — surgery, radiation, chemotherapy — it can help them overcome that deficit, even if we patients with very considerable deficits can make cannot impact life expectancy. substantial recoveries and have a very meaningful return of function. That’s been a paradigm shift and is very encouraging therapeutically.
VIVIANE TABAR Improving function also allows some people to be eligible for more-aggressive treatments, for In the neurosurgery department, we’ve clinical trials or new drugs. I think that’s where evolved over the last ten years to put a strides are going to be made. Gains at the individual greater focus on offering surgery while level and for a subset of patients are going to move maximizing function.” the field forward. – VIVIANE TABAR
66 MEMORIAL SLOAN KETTERING CANCER CENTER ONE FOCUS ONE MSK
WHAT SETS MSK APART VIVIANE TABAR Yes. It’s the norm for me if I get a thank-you note LISA DEANGELIS from a patient that also refers to my nurse. MSK is about the people. It’s about the team. We have LISA DEANGELIS a fantastic multidisciplinary, collaborative team — people with deep expertise in their respective fields, Absolutely. such as neurosurgery, radiation oncology, neural VIVIANE TABAR pathology and neural imaging, and so on. They are an invaluable component of what we do. We work incredibly well together, which doesn’t And I think the patients definitely appreciate it. mean that we always agree with each other. In Our nurses contribute to patients’ well-being fact, some of the most valuable exchanges are throughout their hospital stay and afterward. when we don’t agree. Somebody will bring another consideration to the table that makes you think The patients definitely appreciate the team effort about a problem or see a patient from a different among doctors too. It’s not uncommon for us to perspective, and you realize that perhaps you say to patients, “Well, let me discuss this with my haven’t considered every aspect of things. colleagues and we’ll get back to you.” I enjoy when the patient is a little incredulous that you get back I’m absolutely convinced that this is all to the to them the following day with an opinion from benefit of the patient. There is no question in my several experts that would have taken maybe a mind that what we bring to the table collectively few months to get individual appointments with. far exceeds the sum of the individual parts. That model works extremely well between our VIVIANE TABAR two departments. I agree. The depth of expertise and dedication of LISA DEANGELIS my colleagues at MSK is really what keeps me and Our global team approach is so different from other my patients afloat. There’s great comfort in being institutions that it does sometimes take patients able to discuss a challenging case with the group. and families a little bit of time to acclimate to it. To listen to the input of people with deep experience But I think they rapidly come to appreciate the as well as younger people who have a different benefit of it. perspective — people who have one foot in the lab and one foot in the clinic, or those who are willing to challenge the norm. It’s also very inspiring to be surrounded by not only clinical and scientific excellence but also people with genuine dedication to the patient. It’s no secret There is no question in my mind to all of us that this is a challenging job, particularly that what we bring to the table caring for people with brain tumors. We lose a lot of patients. It would be terrifying if you didn’t have collectively far exceeds the sum your colleagues next door. of the individual parts.” When we are facing a difficult surgery or a difficult – LISA DEANGELIS outcome from surgery, it’s very reassuring to us and to the patient to be able to reach out to our neuro-oncologists, who sort of pick up the person where he or she landed and move them to the next phase. That provides not only support to each other but also support to the patient, giving a different perspective and usually a positive outlook on what’s to come.
LISA DEANGELIS Our nurses and nurse practitioners are a critical component of this. They’re very much a part of our team. We are so fortunate to have an incredible nursing workforce here, including the floor nurses and the advanced practice nurses. Nurses are our front line to patients — we jointly share that focus on addressing patient and family needs.
2017 ANNUAL REPORT 67 ONE FOCUS
INTERVIEW WITH A BOLD NEW TAKE ON CARE
LEE ERICKSON ERICKSON LEE Implementing telemedicine is about a bigger Deputy Physician-in-Chief paradigm shift. We want to move the majority of for Clinical Operations cancer care out of the healthcare setting entirely. Instead of making you come to us, we’ll come to OTTO you. If we can turn this whole model inside out, CHRISTIAN it’d be amazing. Director of Teleoncology CHRISTIAN OTTO Telemedicine can have a significant impact on quality of life. When patients feel unwell and we’re Telemedicine uses electronic asking them to travel, that can be challenging. communications such as We’re also seeing data showing survival benefits. For video conferencing and example, take a study done by [MSK epidemiologist] Ethan Basch that was presented at the American secure email to provide care Society of Clinical Oncology annual meeting in without an in-person visit. June 2017. Here, Lee Erickson, Deputy LEE ERICKSON Physician-in-Chief for Clinical It showed five months of additional survival just Operations, speaks with from having patients report their symptoms to their physician. Christian Otto, Director of Teleoncology, about this burgeoning field at MSK. They both joined MSK in early 2017.
Lee Erickson (right) and Christian Otto are bringing new and existing technologies to MSK to allow patients to receive care virtually.
68 MEMORIAL SLOAN KETTERING CANCER CENTER ONE FOCUS ONE MSK
CHRISTIAN OTTO MAKING APPOINTMENTS EASIER And that’s only one component of symptom monitoring at home. We haven’t even added coaching, CHRISTIAN OTTO in which nurses educate patients on corrective I think we will get to a place where the majority of behaviors, or the collection of biomedical data. preoperative assessments, symptom management, What if we were able to identify an infection early oncology follow-ups, postoperative wound by following our patients’ temperatures, and then checks, and discussion of results could be done via start antibiotics several days earlier? telemedicine. And on the other side, there are Uber-like services that go to the patient’s home. LEE ERICKSON I’ve read about gadgets being worked on that do LEE ERICKSON simple lab tests through your smartphone. Prick your We had a patient who had his blood drawn at his finger and instead of putting the blood into a glucose kid’s Little League game. machine, it’s a little insert that goes into your phone. CHRISTIAN OTTO CHRISTIAN OTTO We’re not trying to do away with face-to-face These tools give a full picture of how the patient interaction. We really want to supplement the is doing. It’s being present almost 24-7 versus an times that we’re not with a patient, and perhaps oncologist receiving a call when the patient is having make some of their appointments easier by having a challenge. them stay home.
TELEMEDICINE IN ACTION LOOKING AHEAD
LEE ERICKSON CHRISTIAN OTTO Patients at the Josie Robertson Surgery Center use First, we’re expanding telemedicine across our a program within our patient portal to report how Manhattan sites. Then we’re moving into the they’re doing once they’re home, and they seem very regional sites. We have a number of pilots in services happy with it. Say we send you a message every day like genetics and psychiatry. Our third prong is asking how your pain is, and on day three you text going to the patient’s home. us and say, “Shouldn’t I be feeling better by now?” We’ve actually accumulated enough data to show you LEE ERICKSON a chart for pain that’s normal, and you can compare I think of it like smartphones. In the beginning, yourself against it. Patients like it. They feel safer and they were this really expensive thing for people with more connected. disposable income. But we hit a tipping point, and it changed the culture. A similar thing needs to happen CHRISTIAN OTTO in healthcare. When we hit another tipping point, I think there’s a level of comfort in it. At MSK, we I think we’re in for some major disruption. have implemented a falls prevention program that patients are asked if they’d like to participate in. CHRISTIAN OTTO It involves having a camera in the room that lets the We’ve been able to begin pilots in Manhattan, nursing staff monitor the patient. You can place a the regional care network, and patients’ homes. virtual border around the patients who are at high I think there’s so much momentum because of risk for falls so that an alarm sounds if they try to the can-do attitude here. get up unassisted. LEE ERICKSON LEE ERICKSON The can-do attitude around this place is Then the person watching the monitor can pretty amazing. say to the patient through the system, “I’ll come help you.”
CHRISTIAN OTTO In the first eight months of a pilot on the fourth floor of Memorial Hospital, patient falls decreased by 50 percent. It’s solving a real issue that poses a We’ve been able to begin pilots danger to patients. in Manhattan, the regional care network, and patients’ homes. I think there’s so much momentum because of the can-do attitude here.” –CHRISTIAN OTTO
2017 ANNUAL REPORT 69 ONE FOCUS DRIVING CANCER CARE
70 MEMORIAL SLOAN KETTERING CANCER CENTER ONE FOCUS ONE MSK
Going the extra mile Driving patients and families between with such passion, and when I looked in appointments means they often share the mirror, I saw tears streaming down for people affected by personal moments with their passengers. her face. She was happy. She had just cancer is what Ansar Some of those experiences, like enduring gotten good news, and it was a healing Mohammed and Luther a challenging treatment session or song. That’s what MSK is about — it’s a receiving a life-changing diagnosis, are healing place.” Nickelson do best. understandably tough. “I can’t shy away Both men are proud to be part of the They are part of a team from this part of my job,” Mr. Mohammed more than 17,000 scientists, doctors, of 36 shuttle drivers says. “I make sure my passengers know nurses, and support staff who make I will take care of them. Their doctors and up the MSK community. Whether it’s who, on any given day, nurses will take care of them. We are all offering words of encouragement during transport 750 patients, in this together.” a ride between appointments, making But there are many positive moments groundbreaking scientific discoveries, caregivers, and staff too. “When I first started three years or providing unmatched patient care, to MSK’s facilities ago, I was driving a woman who started the focus is clear, Mr. Mohammed says: throughout Manhattan. singing a song that came on the radio,” “We all come to work each day to help.” They also deliver critical Mr. Nickelson recalls. “She was singing medicines, supplies, and patient samples.
I make sure my passengers know I will take care of them. Their doctors and nurses will take care of them. We are all in this together.” –ANSAR MOHAMMED
Left: Ansar Mohammed (left) and Luther Nickelson in front of MSK’s 53rd Street patient shuttle. Above left: Mr. Mohammed, Mr. Nickelson, and manager Paul Adamec. Above right: Mr. Mohammed in the driver’s seat.
2017 ANNUAL REPORT 71 ONE FOCUS
STATISTICAL PROFILE
13 14 15 16 17
PATIENT CARE
Patient Admissions: Adults 20,773 20,640 21,064 21,708 21,953 Patient Admissions: Children 1,553 1,504 1,403 1,370 1,553 Total Admissions 22,326 22,144 22,467 23,078 23,506 Total Patient Days 144,345 146,855 151,827 160,072 161,661 Average Patient Stay (days) 6.5 6.6 6.8 6.9 6.9 Bed Occupancy Rate (1) 83.0% 84.3% 90.9% 92.5% 94.3%
Outpatient MD Visits: Manhattan 463,724 480,260 489,897 512,142 526,006 Outpatient MD Visits: Regional Network 108,198 113,699 136,506 153,451 196,232 Total Outpatient Visits 571,922 593,959 626,403 665,593 722,238 Screening Visits 12,826 10,282 22,403 23,497 31,683 Surgical Cases 20,465 20,420 21,368 23,066 25,330
New Radiation Oncology Patients Starting Treatment: Manhattan 4,031 4,268 4,408 4,831 5,283
New Radiation Oncology Patients Starting Treatment: Regional Network 2,653 2,714 3,017 3,399 4,510
Diagnostic and Interventional Radiology Procedures 416,360 435,501 466,848 498,372 543,322 Clinical Investigation Protocols (2) 735 776 879 1,072 1,133
(1) Based on adjusted bed count (2) Excludes studies closed to accrual
72 MEMORIAL SLOAN KETTERING CANCER CENTER ONE FOCUS ONE MSK
13 14 15 16 17
STAFF
Sloan Kettering Institute Members 143 140 140 131 133 Hospital Attending Staff 935 995 1,033 1,091 1,148 Registered Nurses 2,221 2,373 2,605 2,864 3,721 Administrative and Support Staff 9,707 10,223 10,965 11,638 12,325 Total Staff(1) 12,975 13,699 14,711 15,697 17,301 Volunteers 1,004 902 967 943 1,019
EDUCATION
Residents and Clinical Fellows: Positions 464 465 464 468 468 Residents and Clinical Fellows: Annual Total 1,691 1,674 1,723 1,734 1,749 Research Fellows 323 351 355 344 346 Research Scholars 133 110 98 92 120 Research Associates 91 95 110 112 115 Graduate Research Assistants 41 47 47 43 37 PhD Candidates 227 239 265 292 278 MD/PhD Candidates 19 18 20 26 24 Registrants in CME Programs 3,681 5,614 3,581 4,724 6,098 Medical Observers 630 579 574 563 511 Medical Students 392 505 548 569 577 Nursing Students 179 257 312 351 355 Social Work Students 7 7 4 8 7 Radiation Oncology Technology Students 15 15 15 12 12 Physical Therapy Students 2 6 5 5 6 Occupational Therapy Students 2 3 2 2 2 Laboratory Medicine Students 9 9 18 20 13
(1) In 2017, 26 staff members held appointments in both the institute and the hospital.
2017 ANNUAL REPORT 73 ONE FOCUS
FINANCIAL SUMMARY
2017 TOTAL 2017 TOTAL OPERATING OPERATING REVENUE EXPENSES (in thousands) (in thousands)
$4,452,793 $4,213,028
$2,335,132 Compensation and Fringe Benefits
$3,580,449 Patient Care Revenue
$1,491,154 Purchased Supplies and Services $296,493 Grants and Contracts
$278,643 $287,145 Contributions and Depreciation and Pledge Payments Amortizations
$297,208 $99,597 Royalty and Other Income Other Expenses
74 MEMORIAL SLOAN KETTERING CANCER CENTER ONE FOCUS ONE MSK
13 14 15 16 17
OPERATING REVENUE (in thousands) Patient Care Revenue $2,367,731 $2,560,457 $2,809,813 $3,094,461 $3,580,449 Grants and Contracts 202,061 229,562 234,402 257,893 296,493 Contributions 138,343 168,797 137,538 161,245 191,843 Net Assets Released from Restrictions — Pledge Payments 79,199 103,112 129,528 86,850 86,800 Royalty and Other Income 208,703 241,238 273,556 242,934 159,458 Unrestricted Investment Return Allocated to Operations 82,028 87,917 90,648 136,979 137,750
Total Operating Revenue $3,078,065 $3,391,083 $3,675,485 $3,980,362 $4,452,793
OPERATING EXPENSES Compensation and Fringe Benefits $1,689,501 $1,782,477 $1,987,388 $2,131,070 $2,335,132 Purchased Supplies and Services 924,691 1,062,603 1,172,467 1,311,764 1,491,154 Provision for Bad Debts and Assessments 19,969 35,859 64,194 35,003 54,254 Depreciation and Amortizations 210,373 217,342 232,866 263,964 287,145 Interest Expense 55,039 50,147 49,401 48,724 45,343
Total Operating Expenses $2,899,573 $3,148,428 $3,506,316 $3,790,525 $4,213,028
INCOME FROM OPERATIONS $178,492 $242,655 $169,169 $189,837 $239,765
PHILANTHROPIC REVENUE $380,500 $376,533 $276,747 $317,270 $318,386
CAPITAL SPENDING $315,282 $473,859 $710,873 $634,134 $737,965
BALANCE SHEET SUMMARY Assets $8,481,418 $8,963,268 $9,592,021 $9,891,492 $10,636,012 Liabilities 3,337,444 3,596,860 4,058,058 4,160,515 4,530,909
Net Assets $5,143,974 $5,366,408 $5,533,963 $5,730,977 $6,105,103
2017 ANNUAL REPORT 75 ONE FOCUS
BOARDS OF OVERSEERS AND MANAGERS
AS OF MARCH 31, 2018
DOUGLAS A. WARNER III JAMES D. ROBINSON III Chair Honorary Chair
MARIE-JOSÉE KRAVIS LOUIS V. GERSTNER, JR. Vice Chair of Boards and Honorary Chair of the Board, Chair, Board of Managers, Sloan Kettering Institute Sloan Kettering Institute
SCOTT M. STUART RICHARD I. BEATTIE Vice Chair of Boards and Honorary Chair of the Board, Chair, Board of Managers, Memorial Hospital Memorial Hospital
CLIFTON S. ROBBINS NORMAN C. SELBY CRAIG B. THOMPSON, MD Treasurer Secretary President and Chief Executive Officer
Dominic Barton Philip H. Geier, Jr. Bruce C. Ratner Lucy R. Waletzky, MD Richard I. Beattie Louis V. Gerstner, Jr. Clifton S. Robbins Douglas A. Warner III Aneel Bhusri Jonathan N. Grayer Alexander T. Robertson Peter A. Weinberg Mrs. John J. Byrne + Jamee Gregory James D. Robinson III Jon Winkelried Ian M. Cook Jane D. Hartley Virginia M. Rometty Deborah C. Wright Stanley F. Druckenmiller Benjamin W. Heineman, Jr. David M. Rubenstein Mortimer B. Zuckerman Anthony B. Evnin, PhD William Helman Lewis A. Sanders Roger W. Ferguson, Jr. David H. Koch Alan D. Schnitzer Henry A. Fernandez Marie-Josée Kravis Norman C. Selby Steve Forbes Donald B. Marron Stephen C. Sherrill William E. Ford Kathryn Martin Peter J. Solomon Richard N. Foster, PhD Jamie C. Nicholls John R. Strangfeld Stephen Friedman James G. Niven Scott M. Stuart Ellen V. Futter Hutham S. Olayan Craig B. Thompson, MD
+ ex officio
BOARD OF OVERSEERS EMERITI Peter O. Crisp Elizabeth J. McCormack, PhD Richard M. Furlaud Benjamin M. Rosen James W. Kinnear Fayez S. Sarofim Paul A. Marks, MD Mrs. Arnold Schwartz
BOARD OF SCIENTIFIC CONSULTANTS Frederick R. Applebaum, MD James R. Downing, MD Caryn Lerman, PhD James E. Rothman, PhD Richard Axel, MD Levi A. Garraway, MD, PhD Arthur Levinson, PhD William R. Sellers, MD Philip A. Cole, MD, PhD Maura L. Gillison, MD, PhD Richard Lifton, MD, PhD Gregory L. Verdine, PhD Nancy E. Davidson, MD Joseph L. Goldstein, MD Paul Nurse, PhD Ralph Weissleder, MD, PhD Titia de Lange, PhD Gregory Hannon, PhD Stanley R. Riddell, MD Irving L. Weissman, MD
76 MEMORIAL SLOAN KETTERING CANCER CENTER ONE FOCUS ONE MSK
LEADERSHIP MEMORIAL SLOAN KETTERING CANCER CENTER
AS OF MARCH 31, 2018
CRAIG B. THOMPSON, MD KATHRYN MARTIN President and Chief Operating Officer Chief Executive Officer
JOSÉ BASELGA, MD, PhD JOAN MASSAGUÉ, PhD Physician-in-Chief and Director, Sloan Kettering Institute Chief Medical Officer, Memorial Hospital
ELIZABETH N. MCCORMICK, MURRAY F. BRENNAN, MD PAUL SABBATINI, MD PETER STETSON, MD, MA MSN, RN, CENP Vice President, International Deputy Physician-in-Chief, Deputy Physician-in-Chief and Senior Vice President and Chief Programs and Director, Clinical Research Chief Health Informatics Officer Nursing Officer International Center
LARRY NORTON, MD LEE ERICKSON, MD KENT SEPKOWITZ, MD ROBERT BENEZRA, PhD Senior Vice President, Office of the Deputy Physician-in-Chief, Deputy Physician-in-Chief, Deputy Director, President and Medical Director, Clinical Operations Quality and Safety Sloan Kettering Institute Evelyn H. Lauder Breast Center Core Technologies
DEBRA BERNS MICHAEL P. GUTNICK JORGE LOPEZ, JR., ESQ. RICHARD K. NAUM Senior Vice President and Executive Vice President and Executive Vice President and Senior Vice President, Development Chief Risk Officer Chief Financial Officer Chief Legal Officer WENDY PERCHICK KERRY BESSEY JAMES T. HARDEN EDWARD J. MAHONEY Senior Vice President, Senior Vice President and Senior Vice President, Senior Vice President, Strategic Planning and Innovation Chief Human Resources Officer Strategic Partnerships Facilities Management and Construction PATRICIA C. SKARULIS MARGARET M. BURKE ELIZABETH A. HERBERT Senior Vice President and Senior Vice President, Senior Vice President, CYNTHIA MCCOLLUM Chief Information Officer Ambulatory Care and Hospital Hospital Administration Senior Vice President, Operations Hospital Administration CAROL A. SLATTERY JASON KLEIN Vice President, ERIC COTTINGTON, PhD Senior Vice President and ANNE MCSWEENEY Sloan Kettering Institute Senior Vice President, Research and Chief Investment Officer Special Advisor to the President, Administration Technology Management Development RUTH LANDE MARK SVENNINGSON NED GROVES Senior Vice President, AVICE A. MEEHAN Senior Vice President, Executive Vice President and Patient Revenues Senior Vice President and Finance and Controller Hospital Administrator Chief Communications Officer CAROLYN B. LEVINE, ESQ. Deputy General Counsel and Corporate Secretary
PAUL A. MARKS, MD President Emeritus
2017 ANNUAL REPORT 77 ONE FOCUS
LOUIS V. GERSTNER, JR. GRADUATE SCHOOL OF BIOMEDICAL SCIENCES MEMORIAL SLOAN KETTERING CANCER CENTER
AS OF MARCH 31, 2018
LOUIS V. GERSTNER, JR. CRAIG B. THOMPSON, MD Chairman of the Board President
JOAN MASSAGUÉ, PhD KENNETH J. MARIANS, PhD LINDA D. BURNLEY Provost Dean Associate Dean
KATHRYN MARTIN MARK SVENNINGSON CAROLYN B. LEVINE, ESQ. Treasurer Assistant Treasurer Secretary
TRUSTEES Richard I. Beattie Marie-Josée Kravis Ellen V. Futter Peter J. Solomon Louis V. Gerstner, Jr. Craig B. Thompson, MD David H. Koch Douglas A. Warner III
SLOAN KETTERING DIVISION WEILL CORNELL GRADUATE SCHOOL OF MEDICAL SCIENCES
AS OF MARCH 31, 2018
JOAN MASSAGUÉ, PhD USHMA NEILL, PhD Director Vice President, Scientific Education and Training
GRADUATE PROGRAM CO-CHAIRS
NIKOLA P. PAVLETICH, PhD MARILYN D. RESH, PhD ALEXANDER Y. RUDENSKY, Biochemistry and Cell and Developmental PhD Structural Biology Unit Biology Unit Immunology and Microbial Pathogenesis Unit ANDREW KOFF, PhD DAVID A. SCHEINBERG, Molecular Biology Unit MD, PhD Pharmacology Unit
78 MEMORIAL SLOAN KETTERING CANCER CENTER ONE FOCUS ONE MSK
MEMORIAL SLOAN KETTERING DEVELOPMENT: THE MOMENTUM CONTINUES
Clockwise from top left: Douglas A. Warner III, Louis V. Gerstner, Jr., Craig B. Thompson, and a Cycle for Survival event in Bethesda, Maryland. MSK’s fundraising operation maintained strong forward momentum during the course of 2017, building on the many achievements of the Campaign for Memorial Sloan Kettering. The Campaign, which officially concluded on December 31, 2016, compiled a record of historic success under the leadership of Co-Chairs Douglas A. Warner III and Louis V. Gerstner, Jr., along with MSK President and CEO Craig B. Thompson.
New gifts and pledges to MSK for 2017 • the Olayan Group’s commitment of internationally, in the process raising totaled $344.5 million, a 12.1 percent $10 million to establish a precision $35 million for rare cancer research. And increase over the year before. Of that pediatrics cancer medicine program in November, 875 runners participated amount, $330.3 million were cash gifts. in the TCS New York City Marathon as • a $10 million pledge from the Warren Dedicated benefactors at all levels members of Fred’s Team and raised more Alpert Foundation to create the contributed to this impressive success. than $5.3 million to fund research at MSK. Warren Alpert Center for Digital and Of the many gifts received, the following Continuing at the helm of the MSK Computational Pathology stand out for the impact they are having development team in 2017 were Anne on the institution: • $7 million from the estate of M. McSweeney, Special Advisor to the Mamdouha S. Bobst, which brings President for Development, and Senior • Alan and Sandra Gerry’s commitment the total received from Mrs. Bobst’s Vice President Richard K. Naum, of $15 million to create the Alan and estate to $29 million who over a span of years built MSK’s Sandra Gerry Metastasis and Tumor fundraising office into one of the best Ecosystems Center, which brings their As in past years, MSK also benefited in the country. The operation is well total support for this vital area of significantly from the energy and positioned to support the continued research to $25 million dedication of thousands of volunteers growth in strength and stature of all • a pledge of $12.5 million from Board who took part in athletic fundraisers. three aspects of the institution’s mission member Stephen Friedman and his wife, Cycle for Survival, which ranks as the as MSK leads the way into a new era in Barbara, through their foundation to fastest growing athletic fundraiser in the cancer medicine. create the Friedman Family Foundation country, attracted 31,000 participants Functional Genomics Initiative in 16 cities across the United States and
2017 ANNUAL REPORT 79 ONE FOCUS
DONORS TO MEMORIAL SLOAN KETTERING JANUARY 1, 2002–DECEMBER 31, 2017
$200,000,000 AND ABOVE $20,000,000–$24,999,999 $5,000,000–$9,999,999 Damon Runyon Cancer David H. Koch Anonymous Anonymous Research Foundation Allan H. Selig Estate of Eleanor Backer Lewis A. Sanders The Society of MSK Band of Parents Foundation Estate of Joseph J. Santry The Thompson Family Robert and John Bendheim Nassef Sawiris $100,000,000–$199,999,999 Foundation The Leon Black Family Richard Serra and Clara The Estate of Geoffrey Beene Foundation, Inc. Weyergraf-Serra Mr. and Mrs. William H. The Carson Family Charitable The Peter Jay Sharp Foundation Goodwin, Jr., and the Trust Mr. and Mrs. Richard Siegal Commonwealth Foundation $10,000,000–$19,999,999 The Steven A. and Alexandra M. Estate of Margaret McCormack for Cancer Research Anonymous Cohen Foundation, Inc. Sokol Henry and Marie-Josée Kravis Trust of Burton Abrams Ian and Patricia Cook The William and Lynda Steere The Starr Foundation The Warren Alpert Foundation Trust of Richard J. Eisemann Foundation Mortimer B. Zuckerman Bristol-Myers Squibb Company Anthony B. and Judith W. Evnin Scott M. and Lisa G. Stuart The Kristen Ann Carr Fund Goldman Sachs & Company Swim Across America, Inc. Mr. and Mrs. Raymond T. Dalio Mr. and Mrs. Philip H. Geier, Jr. The Three Little Pigs Foundation Shelby Cullom Davis Charitable Family of Charles Hallac UBS $50,000,000–$99,999,999 Fund Estate of Sherlock Hibbs John L. Vogelstein Stanley F. and Fiona The Stephen and Barbara ICAP Sue and Edgar Wachenheim III Druckenmiller Friedman Foundation The Jewish Communal Fund The Weinberg Family The Leonard and Evelyn Lauder The Arnold and Arlene Dr. and Mrs. Min-Hwan Kao Foundations Foundation Goldstein Family Foundation F. M. Kirby Foundation, Inc. Michael A. and Zena Wiener Virginia and D. K. Ludwig Fund The Donald B. and Catherine C. The Robert J. Kleberg, Jr., and for Cancer Research Marron Foundation Helen C. Kleberg Foundation Robertson Foundation The Robert and Kate Niehaus Trust of L. H. P. Klotz Foundation John W. Kluge $2,500,000–$4,999,999 The Olayan Group Trust of Evelyn Lauder Anonymous Mr. and Mrs. Milton Petrie The Lebensfeld Foundation Mr. and Mrs. Bruce Adam $25,000,000–$49,999,999 Laurance S. Rockefeller Estate of Tse Kyung Lee AKTIV Against Cancer The Atlantic Philanthropies Laurance S. Rockefeller Fund The Leon Lowenstein Alex’s Lemonade Stand Foundation The Elmer and Mamdouha Donna and Benjamin Rosen Foundation, Inc., and Robert The Allbritton Foundation Bobst Foundation Robert F. X. Sillerman and Laura and John Bendheim Bethany Allen The Breast Cancer Research Baudo Sillerman through their The Lustgarten Foundation for Stephen and Madeline Anbinder Foundation Tomorrow Foundation Pancreatic Research John M. Angelo and Judy Hart Jack and Dorothy Byrne The Simons Foundation Trust of Estelle A. Manning Angelo Foundation The Society Boutique — MSK Martin S. and Sheila Major and The Laura and John Arnold Alan and Sandra Gerry Thrift Shop Family Foundation The Louis V. Gerstner, Jr. The Society of MSK Special Melanoma Research Alliance The Arthur & Rochelle Belfer Foundation, Inc. Projects Committee Estate of Samuel U. Mitchell Foundation Steven A. Greenberg Charitable Stop & Shop Supermarket The Naddisy Foundation Estate of Mary Ann Benjamin Trust Company, Inc. Jamie Nicholls and Fran Biondi Estate of Lillian R. Berkman The Sidney Kimmel Foundation Mr. and Mrs. Douglas A. Charitable Trust Mr. and Mrs. Melvin R. Berlin Parker Institute for Cancer Warner III Peserga International Family Immunotherapy Estate of Kathryn D. Wriston Foundation The James E. and Diane W. Prostate Cancer Foundation Dirk and Natasha Ziff Frederick Henry Prince Burke Foundation, Inc. David M. Rubenstein Memorial Fund Burroughs Wellcome Fund Stand Up To Cancer Bruce C. Ratner Estate of Nizza Burstyn The Tow Foundation Mr. and Mrs. John S. Reed Mrs. D. Wayne Calloway The Robbins Family Foundation Iris and B. Gerald Cantor Dorothy Rose and Foundation Dr. Milton Rose Estate of Marion B. Carstairs
80 MEMORIAL SLOAN KETTERING CANCER CENTER ONE FOCUS ONE MSK
DONORS TO MEMORIAL SLOAN KETTERING JANUARY 1, 2002–DECEMBER 31, 2017
James D. Carter Estate of Charles J. Mauro $1,000,000–$2,499,999 Trust of James J. Corbalis, Jr. Estate of Anne M. Cassidy The Abby R. Mauzé Charitable Anonymous Cordeiro Family Foundation Estate of Franklin Chenenky Trust Estate of Marguerite Abrams Sharon Levine Corzine Pei-Yuan Chia and the Chia Estate of Florence Miner Mr. and Mrs. Andrew B. Trust of Caroline S. Coulton Family Foundation Gloria Miner Abramson The Countess Moira Foundation Charles Payson Coleman The New York Community Trust Mr. and Mrs. Frederick R. Adler Creative Bath Products, Inc. Estate of Gloria S. Confort The Samuel I. Newhouse Mr. and Mrs. Fred M. Alger III Mr. and Mrs. Peter O. Crisp Crimson Lion/Lavine Family Foundation Estate of Billie H. Allen CureSearch for Children’s Foundation Stavros S. Niarchos Foundation Elisabeth and Philip Allen Cancer The Irma L. and Abram S. Croll Nonna’s Garden Foundation The Rita Allen Foundation Estate of Helen M. Curry Charitable Trust Ronald O. Perelman Allen & Company Trust of Margaret E. Dahm Cure Breast Cancer Foundation, The Pershing Square Alliance for Cancer Gene John and Georgia DallePezze Inc. Foundation Therapy Dennis D. Dammerman The D10 Myrna and Bernard Posner Estate of Roone P. Arledge The Dana Foundation The Doris Duke Charitable Estate of Catherine R. Price Arms Wide Open Childhood Mr. and Mrs. Marvin H. Foundation Laura and Christopher A. Cancer Foundation Davidson The Mitzi and Warren Eisenberg Pucillo The Award of Courage Trust of Myra Davis Foundation/The Susan and Mrs. Katharine J. Rayner Corporation Estate of Bernard S. Davison Leonard Feinstein Foundation Trust of Allan J. Riley Roger and Lori Bahnik Christina and Emmanuel Farmer Family Foundation The Jim and Linda Robinson Estate of Eileen W. Bamberger Di Donna Trust of Harold Farrington Foundation The Batishwa Fellowship Estate of Charles E. Dillman Estate of Elizabeth M. Jack Rudin Trust of Edgar D. Baumgartner James and Judith K. Dimon Frelinghuysen The Louis & Rachel Rudin Estate of Leola E. Bell Gloria DiPietro-Cooper Trust of Mary Frohsinn Foundation Mr. and Mrs. Daniel C. Benton Trust of James Douglas Estate of Jeanette R. Fulham The May & Samuel Rudin Family Estate of Irma Berg Michael Douglas and Catherine Estate of Francis Gonzalez Foundation Allen and Joan Bildner Zeta-Jones The Gray Foundation–Basser Estate of Marilyn L. Schaefer The Anita and Leonard Boxer Trust of Nancy K. Dunn Initiative Estate of Grace A. Shapro Family Foundation Trust of Phyllis K. Dunn Jonathan N. Grayer Dr. David E. and Beth Kobliner Breast Cancer Alliance, Inc. Gail and Richard Elden Hazen Polsky Foundation, Inc. Shaw Mr. and Mrs. Viatcheslav I. The Ellison Medical Foundation William Randolph Hearst Mr. and Mrs. H. Virgil Sherrill Brecht The Emerald Foundation Foundations The Joachim Silbermann Family Peter and Linda Bren Mr. and Mrs. Israel Englander Mr. and Mrs. Benjamin W. Paul E. Singer The Andrea and Charles Entertainment Industry Heineman, Jr. Joan and Joel Smilow Bronfman Philanthropies, Inc. Foundation The Charles and Marjorie The Sohn Conference Estate of Helen Brown Mr. and Mrs. David Epstein Holloway Foundation, Inc. Foundation Trust of Emil A. Buelens Equinox Holdings, Inc. Trust of John S. Holmes Susan and Peter Solomon Family Tory Burch Estate of Selma Ettenberg Estate of Irma A. Howard Foundation Estate of Diane B. Burkhart The Eunice Foundation William Lawrence & Blanche The Sontag Foundation The Burnett Foundation Edward P. Evans Foundation Hughes Foundation Sportsmen for Charity Mr. and Mrs. Donald G. Calder Estate of Harry Fagen Humans of New York Trust of Marie Stephenson Cancer Research Institute Fayez Sarofim & Co. W. M. Keck Foundation George Strawbridge, Jr. Robert B. Catell The John K. Figge Family Estate of Martin C. Kessler The Margaret Dorrance John and Michael Chandris Estate of Barbara D. Finberg Kids Walk for Kids with Cancer Strawbridge Foundation of The Laura Chang and Arnold First Quality Enterprises, Inc. Susan G. Komen Foundation Pennsylvania I Chavkin Charitable Fund The Jerome and Anne C. Fisher Trust of Grace Fay Lamb The Joseph and Arlene Taub Trust of Paul H. Chook Charitable Foundation Myra Nelson Larrison Foundation Trust of Charles P. Ciaffone Flight Attendant Medical Livestrong Foundation Margaretta J. Taylor Trust of George Clegg Research Institute The Lymphoma Foundation Estate of Richmond E. James L. Coleman The Stephanie and Lawrence Trust of Philip R. Mallory Thompson Simon & Eve Colin Foundation, Flinn, Jr. Charitable Trust The Maloris Foundation Trust of Jane Toplitt Inc. The Raymond and Maria Floyd The T. J. Martell Foundation for TOSA Foundation The Comer Science and Family Foundation Leukemia, Cancer, and AIDS The V Foundation for Cancer Education Foundation Estate of Harry N. Forman Research Research The Connecticut Cancer Terry Fox Run for Cancer The G. Harold & Leila Mathers Trust of Bessie Weintraub Foundation Research (NYC) Foundation Cookies for Kids’ Cancer Lorraine Friedman
2017 ANNUAL REPORT 81 ONE FOCUS
DONORS TO MEMORIAL SLOAN KETTERING JANUARY 1, 2002–DECEMBER 31, 2017
Trust of Oscar H. Friedman The Y. C. Ho/Helen and Michael The Lois H. Mann Charitable Trust of Elizabeth L. Perkins Friezo Family Foundation Chiang Foundation Foundation Perry Capital LLC Fund for Ophthalmic Estate of Brian W. Holman Margaux’s Miracle Foundation Pfizer Inc. Knowledge Estate of Harriet Huber Mrs. Joseph L. Martino Estate of Jean D. Pitcher Estate of Frank H. Gabriel The Howard Hughes Medical Mrs. William L. Matheson Estate of Jeanne Poli Gabrielle’s Angel Foundation Institute Nancy and Paul McCartney Mrs. Jenice Pulver Sara Gadd Estate of Dorris J. Hutchison Mr. and Mrs. Thomas E. Sara and Iser Rabinovitz Estate of Thomas Gardiner Leslie Hutchison and McInerney RBC Capital Markets Trust of Virginia L. Garrison Virginia Shaw Estate of Donald G. McKeon Lynne & Andrew Redleaf The Gateway for Cancer Hyundai Hope on Wheels Estate of Myra L. McKolic Foundation Research IBM Corporation Merrill Lynch & Co. Foundation, Revlon Trust of Florence K. Geffen Inspire 2 Live Foundation Inc. Charles H. Revson Foundation The Lawrence M. Gelb Barbara and Tom Israel Fred and Marie-Noelle Meyer RJR Oncodermatology Fund Foundation, Inc. Trust of Harry C. Jaecker, Jr. Estate of Wilma S. Mills Estate of Edith Roberts Genentech The Rona Jaffe Foundation Jim and Mary Jane Milton Estate of Josephine T. General Electric Company JHSF NY, Inc./GEMA Julie and Edward J. Minskoff Robertson Eileen Genet Fund for Ovarian Investments/Instituto Estate of Robert C. Mitchell Estate of Anne Morales Rodgers Cancer Research and Jose Auriemo Sami Mnaymneh Mary Jo and Brian Rogers Prevention Estate of Clarence W. Johnson Trust of Douglas C. Mohl The Felix and Elizabeth Trust of Josephine A. Gilmore Estate of Wilda Johnson The Ambrose Monell Rohatyn Foundation Estate of Thelma Gish J. P. Morgan Chase Foundation The Laura Rosenberg GIST Cancer Research Fund The JPB Foundation Tom and Janet Montag Foundation, Inc. Estate of Anna H. Gleason Trust of Marion Kahn Estate of Warren A. Montel Estate of Lillian E. Rosenmerkel Miriam and Alan Goldberg Estate of Pearl M. Kamer- Morgan Stanley Juliet Rosenthal Foundation Gary Goldbloom Bloomfield The William T. Morris The Peter M. Sacerdote The Joyce & Irving Goldman Katzman Family Foundation Foundation Foundation Family Foundation Brian & Joelle Kelly Family Mr. and Mrs. Charles H. Mott The Raymond & Beverly Sackler The Horace W. Goldsmith Foundation Trust of Anna V. Muller Fund for the Arts and Sciences Foundation The Brian Kennedy Trust Estate of Elaine Muller Wendy and Neil Sandler Golfers Against Cancer Estate of Mary B. Ketcham Multiple Myeloma Research Estate of Margaret W. Schafer Foundation Layla and Ed Khalily Foundation The Richard H. Schneider The Gordon Fund Estate of John W. Knox Mushett Family Foundation, Family — Tami, Brady and Estate of Andrew S. Gordon Mr. and Mrs. Matania Kochavi Inc. Casey Schneider Trust of Jane H. Gordon Estate of Rosemarie Krulish Trust of Saul Nathonsohn Estate of Catherine M. Schooley Grass Family Foundation The Thomas G. Labrecque The National Brain Tumor The Beatrice & Samuel A. Seaver The Marion and Louis Foundation Society Foundation Grossman Foundation Estate of Emma Landau Needles’ Family Charitable Mr. and Mrs. Norman C. Selby Mr. and Mrs. Robert Grossman Philippe Laub Lead Trust The Shen Family Foundation Trust of Helen Guerin Lebara Foundation The New York Yankees Trust of Henry H. Shepard Kate Medina Guthart and Leo A. Gerald Leigh Charitable Trust Foundation Trust of William and Isabelle Guthart Estate of Wilhelmina LeJeune George L. Ohrstrom, Jr. Sherlock The Marc Haas Foundation The Lerner Foundation Foundation Mr. and Mrs. Stephen C. Sherrill Hackers for Hope Estate of Ada Leventhal William C. and Joyce C. O’Neil Alfred J. and Stephanie Shuman Mr. and Mrs. James J. Hagan Estate of Harold F. Levinson Charitable Trust through the Windmill Lane Estate of Joseph M. Hand Leon Levy Foundation Estate of Abby O’Neill Foundation Mr. and Mrs. John J. Hannan The LisaBeth Foundation The Ovarian Cancer Research Mr. and Mrs. Herbert J. Siegel Estate of Margaret H. Hanson The Litwin Foundation Fund M. Steven and S. David Stephen P. Hanson Harry J. Lloyd Charitable Trust Pancreatic Cancer Action Silbermann Jamie and Jeffrey Harris Carol and Michael Lowenstein Network The Rosanne H. Silbermann Gladys and Roland Harriman Robert S. Ludwig and Estate of Jimmie Christine Foundation Foundation Gwenyth E. Rankin Parker Mary Ann and Arthur M. Hassenfeld Family Lymphoma Research Francine Parnes Siskind through the Siskind The Heckscher Foundation for Foundation Party City Corporation Family Sarcoma Fund Children Mr. and Mrs. J. Randall Pediatric Cancer Foundation The Skirball Foundation Trust of Gilbert Helman MacDonald Estate of Frederick Pelda Estate of Ann Smith Estate of Marie B. Hilliard Mr. and Mrs. Joel Mallah John and Francie Pepper Trust of William Kirkland Smith
82 MEMORIAL SLOAN KETTERING CANCER CENTER ONE FOCUS ONE MSK
DONORS TO MEMORIAL SLOAN KETTERING JANUARY 1, 2002–DECEMBER 31, 2017
Trust of Emily V. Smyth $500,000–$999,999 The Richard E. Capri The Fibrolamellar Cancer Trust of Clemance and Edwin Anonymous Foundation on behalf of the Foundation Snyder Agilent Technologies, Inc. Wolf Family Estate of Alice H. Ficht St. Baldrick’s Foundation American Brain Tumor Estate of Richard B. Carman Trust of Alice D. Fiedler John R. & Inge P. Stafford Association Mr. and Mrs. Kenneth Carmel Trust of Marie Finch Foundation The American Italian Cancer Estate of Wesley S. Carnrick The Grace J. Fippinger Mrs. Kay Stafford and the late Foundation The Tina and Richard V. Foundation, Inc. Senator Ronald B. Stafford American Skin Association Carolan Foundation First Eagle Investment Bonnie and Steven E. Stern Estate of Hugo Andriesse James & Patricia Cayne Management Estate of Stanley R. Stones Roland Arthur Charitable Trust Estate of Susan L. Fischer Mr. and Mrs. David K. Storrs Aventis Pharmaceuticals, Inc. Trust of Betty R. Ciaffone The Michael J. Fox Foundation Mr. and Mrs. Paul A. Street Gail L. Baird Family Foundation Citigroup Trust of Ira S. French The Sussman Family Fund Mr. and Mrs. Robert C. Baker The Julie and Frank Cohen Trust of Dr. Benjamin T. Trust of M. Allen Swift Family Foundation Foundation Friedman Tang Family Foundation The Bank of America Charitable Estate of Harry J. Colish Trust of Edith West Friedmann Tarnopol Family Foundation Gift Fund The Julien Collot Foundation, The Anna Fuller Fund Trust of Irving Tirkfield Trust of Barbara G. Bargar Inc. Estate of Maud Gallagher Estate of Lillian Tomek Estate of Doris A. Baumann Constant Convocation Center Estate of Joseph G. Gaumont The Beth C. Tortolani Richard I. Beattie The Elaine Terner Cooper Estate of Selma Geller Foundation The Arnold and Mabel Beckman Foundation Joe Gellert Dom and Tia Tran Foundation Trust of Faye Copeland Estate of Lillian B. George Anthony and Carole Trapani Trust of William T. Benitt Estate of Howard Corlies The Gerber Foundation The Trump Group The Besen Family Estate of Leonard Corso The Aaron and Betty Gilman Tudor Investment Corporation The Bie Family Foundation Frederic R. Coudert Foundation Family Foundation Daniel P. and Grace I. Tully Estate of Dan Biele Chandler Cox Foundation Estate of William J. Glasgow Foundation Jane and Bill Bird Estate of Helen M. Cramer Estate of Robert E. Gleason Mr. and Mrs. Thomas Tuttle Estate of Philip Bisaccio CURE Childhood Cancer Mr. and Mrs. Robert S. Goldberg Uniting Against Lung Cancer Trust of Susan E. Black Mr. and Mrs. Rafic Dahan Alfred G. & Hope P. Goldstein Universal Network Television Mr. and Mrs. John N. Estate of Thomas R. Daly Fund Trust of Virginia and Edward Blackman, Jr. Davis Charitable Foundation Estate of Helen M. Golen Van Dalson Betty, James, and Thomas Estate of Sandra Newman Mr. and Mrs. Sidney Goodfriend Vanguard Charitable Blake (The Thomas Blake, Sr. Dawson David J. Grais and Lisa A. Cutler Endowment Fund Memorial Fund) The Thompson Dean Family Mr. and Mrs. Peter G. Grayson Estate of William N. Vaughan The Blue Dot Foundation Foundation Mr. and Mrs. Alan I. Greene Trust of Edward W. Vollintine Antoinette E. & Herman Boehm Estate of Carol T. Decker Trust of Phyllis A. Greene Trust of Paul H. Volpe Foundation The DeGroot Family Trust of Richard M. Greifer Lucy R. Waletzky, MD Trust of Ethelvida Boehme Foundation Estate of Edythe Griffinger Joan and Sanford I. Weill Estate of William Boehme Annette and Oscar de la Renta Peter M. Guggenheimer Louis and Jane Weinstock Mr. and Mrs. David Boies Frederick A. DeLuca Foundation Mr. and Mrs. William W. The Lillian S. Wells Foundation, Estate of Marcel S. Bollag Dempster Charitable Trust Haerther, Jr. Inc. Trust of Frederick W. Bonacker, Deutsche Bank Securities Inc. Estate of Ethel V. Haldeman The Honorable Hilary M. Jr. Elizabeth K. Dollard Charitable Evelyn A. J. Hall Charitable Weston The Bondi Foundation Trust Trust Mr. and Mrs. Clay T. Whitehead Estate of Adele Bozio Estate of Ruth Drazen Mr. and Mrs. Stephen L. Judy and Fred Wilpon Family Trust of Nancy J. Bradford The Walter S. and Lucienne B. Hammerman Foundation, Inc. Terri Brodeur Breast Cancer Driskill Foundation Estate of Olga V. Hargis Estate of Carolyn H. Wilson Foundation Estate of Louis Duenweg Susanne and Shelley Harrison Winterburn Foundation Trust of Dorothy Fielder Brown Mr. and Mrs. Barclay Ehrler Mr. and Mrs. William B. Diana S. Wister The Honorable Tina Brozman Mr. and Mrs. Richard S. Emmet Harrison, Jr. Meryl and Charles H. Witmer Foundation Esophageal Cancer Education Jane Hope Hastings The Wolfensohn Family Mrs. Edwin M. Burke Foundation Philanthropic Trust Foundation Janet Burros Memorial Trust of Virginia J. Faber Estate of Judith B. Helfant Mr. and Mrs. Robert Wright Foundation Arthur Falcone Trust of Richard V. Henry, Jr. Zev’s Fund Inc. Hilary and Joseph A. Califano, Jr. Estate of Katie Fasal Estate of Ruth H. Hewlett Ziff Brothers Investment, LLC The Cancer Research Estate of Beatrice Feinstein Richard Hogan and Carron Ronald Zung Foundation of America Paul Felzen Sherry
2017 ANNUAL REPORT 83 ONE FOCUS
DONORS TO MEMORIAL SLOAN KETTERING JANUARY 1, 2002–DECEMBER 31, 2017
Trust of Milan M. Holdorf Trust of Martin C. and Margaret Trust of Jo Anne H. Olmsted Estate of Alana M. Schuster Trust of H. Thomas V. Lohsen E. Stanley O’Neal The Seraph Foundation Hollingsworth Trust of Louis J. Lombardi Estate of Beatrice P. K. Palestin Trust of Leonard & Ruth Trust of Benjamin Holmes Mr. and Mrs. Edward Lundy Elsa U. Pardee Foundation Silverman Trust of Karla Homburger Lung Cancer Research The PaulieStrong Foundation Evelyn R. Simmers Charitable Hope Funds for Cancer Foundation Estate of James T. Perch Trust Research LUNGevity Foundation The Perelman Family Suzanne Cohn Simon Estate of Claire Hughes- Estate of Evelyn P. Lyon Foundation SIR Foundation Glasgow Earle I. Mack Foundation The Perkin Fund Trust of Barbara K. Snader Estate of Jane Hunter Manhasset Women’s Coalition Estate of Philip W. Pfeifer Estate of William E. Snee The Patricia M. Hynes and Roy Against Breast Cancer Estate of Lucie Picard Beatrice Snyder Foundation L. Reardon Foundation Estate of Lucille Knowles Estate of Marion M. Pincus Lavinia Branca Snyder Deanne and Arthur Indursky Freedman Mann Alicia and Corey Pinkston The Society of MSK Associates Invest for Children, a March of Dimes Foundation Plastic Surgery Foundation Committee Foundation of Investindustrial Estate of Dana Marin Josephine K. Poling Society of New York Workers’ Mrs. H. Anthony Ittleson Estate of Anne Markowitz Polo Ralph Lauren Corporation Compensation Bar Association Trust of Clyde H. Jacobs Trust of Anthony J. Masard Ruth Porat and Anthony Estate of Katherine R. Johnson & Johnson Max Cure Foundation Paduano Sonneman The Robert Wood Johnson Mr. and Mrs. Louis V. Mazzella Estate of Gerald E. Proctor Trust of Shirley J. Sontag Foundation Estate of William J. McCann Project A.L.S. Roy M. Speer Foundation Trust of William C. Johnston Trust of John C. McCormick Margot Rosenberg Pulitzer Spin4Survival Estate of Al Jolson Mr. and Mrs. Thomas R. Foundation Trust of Barbara A. Stapleton Estate of Horace A. Jones McCullough PVH Corp. Estate of Helen E. Steadman Stephanie and Ken Karl The James S. McDonnell The Mitchell P. Rales Family Mr. and Mrs. Howard Stern Trust of Norman Katz Foundation Foundation Trust of Charles M. Stevenson Fritz and Adelaide Kauffmann Estate of Ralph Melson Recanati Foundation The Mel Stottlemyre Myeloma Foundation The Mesothelioma Applied John Bradbury Reed Foundation Mr. and Mrs. Robert B. Kay Research Foundation Trust of Irene Dorothy Reel Trust of James Strobridge Pamela and Dwaine Kimmet Metlife Foundation Estate of Muriel G. Reich Trust of Gail M. Suchocki Kinetics Foundation The Merck Company James N. Rentas 5K Run/Walk Mrs. Laure Sudreau-Rippe Estate of Joan E. Kinley Foundation Estate of Agnes Rezler The Michael Sweig Foundation Kavlifondet Estate of Ruth Vitow Messias Trust of Argyll C. Rice J. T. Tai & Co. Foundation Estate of Hazel V. Knapp Trust of Russell A. Meyer Estate of Richard A. Riecker Ping Y. Tai Foundation Estate of Ruth Koch Peter Michael Foundation Louise and Frank Ring James R. Tanenbaum and The Koodish Family Charitable The Milbank Foundation for The Andréa Rizzo Dance Elizabeth M. Scofield Trust Rehabilitation Therapy Fund The Edward N. & Della L. Trust of Robert W. Kreger Francois Wallace Monahan Rock Out for the Cure Thome Memorial Foundation, Mr. Kenneth J. Kret The Norman M. Morris Drs. Helena and David Rodbard Bank of America, N.A. Trustee The Kronthal Family Foundation Alexander J. Roepers The Craig D. Tifford Foundation, The Lakeside Foundation Trust of Paula Moss Shafi Roepers Inc. The Jacob & Valeria Langeloth Muscular Dystrophy Trust of William C. Rogers TripAdvisor Charitable Foundation Association Mr. and Mrs. Stephen J. Foundation Trust of Charles T. Larus Mustaches for Kids Rosenthal Barbara Davies Troisi Trust of Ethel T. Larus National Childhood Cancer The Arthur Ross Foundation, Foundation Estate of Owen Laster Foundation Inc. Thomas N. Tryforos Eugene and Elizabeth Lavin Carole and Raymond Neag Helena Rubinstein Foundation Estate of Stanley F. Tucker Lazard Capital Markets S. Arthur and Dorothy Neufeld Amanda and David Russekoff Turner Construction Company Estate of Anne Leventon Foundation Trust of Edward G. Ryder Twenty-First Century Fox, Inc. Mr. and Mrs. Allan L. Levey Neuroendocrine Tumor Moise Safra Family The Tyler Foundation Dr. Nancy Alpern Levin Research Foundation Dr. Nathan E. Saint-Amand United Hospital Fund of Fran and Ralph Levine News Corporation Sarcoma Foundation of America New York Life Raft Group Occidental Petroleum Henry Schein Cares Foundation United Way of Tri-State Estate of Lillian Light Corporation Estate of George W. Schneider Trust of Ward M. Vanderpool Trust of Catherine M. Lincoln Trust of Melba M. O’Connell III The Vanneck-Bailey Foundation Estate of Leah W. Linn The Sylvan and Ann Oestreicher Ira Schneider Memorial Cancer Variety–The Children’s Charity Live4Life Foundation Foundation Foundation Richard C. Vergobbi
84 MEMORIAL SLOAN KETTERING CANCER CENTER ONE FOCUS ONE MSK
DONORS TO MEMORIAL SLOAN KETTERING JANUARY 1, 2002–DECEMBER 31, 2017
Estate of Christine Villano Estate of Anita S. Appel David A. and Merle L. Brown Estate of Rosetta Damilano Vital Projects Fund, Inc. Mr. and Mrs. Frank W. Brownstein Hyatt Farber Trust of DeWitt S. Davidson Walk the Walk America, Inc. Appleton, Jr. Schreck Guy and Sally Davidson The Warner Foundation, Inc. Estate of Bente Arquin Mr. and Mrs. Norman Trust of Richard L. Davies The Wasily Family Foundation Joyce Ashley Brownstein The Arthur Vining Davis Estate of Ingeborg K. Watson Estate of Rose Ashton-Irvine Estate of Madalyn B. Bryant Foundations Trust of Thomas J. Watson, Jr. The David R. and Patricia D. The Bugas Fund Estate of Frederick W. Davis Estate of Ruth C. Weismann Atkinson Foundation Estate of Lillian Burg Estate of Leonard Davis Mr. and Mrs. Harold S. Avon Foundation Estate of Edith R. Burger Trust of Marion E. Dean Wertheimer B*Cured Gilbert and Ildiko Butler Family Deborah A. DeCotis WestRock Foundation Estate of William C. Bahn, Jr. Foundation, Inc. Estate of Lorraine J. Dehoog Trust of Reamer W. Wigle Ariela and Mendel Balk Estate of Marian Butler The Delaney Family Jacqueline and Robert Willens The Banbury Fund The Cancer Couch Foundation Trust of Carolyn B. Denney The David and Ellen Williams Estate of Iris Baranof Cancer Support Services, Inc. The De Rosa Foundation for Foundation Trust of Margaret D. Barber The Paul Robert Carey Colon Cancer Research and Trust of Maria Wolter Estate of Florence Barrack Foundation Prevention Mary and Bob Yellowlees Estate of Marcia Batten Mr. and Mrs. Michael Carr The Desmoid Tumor Research Trust of Richard A. Yudkin Betsy L. Battle Mark A. Castellano Foundation Estate of Anna M. Zavatt Trust of Gertrude E. Beck Estate of Georgia M. Catrini Hester Diamond Foundation Larry and Anne Zimmerman Estate of Grace Becker Trust of Ruth C. Celarek Mr. and Mrs. Lyman B. Cheryl K. Beebe and James A. Estate of Burdette G. Dickerson Grimm Chamberlin The Dickson Foundation Estate of Ethel A. Bell Trust of Cicely J. Chandler Estate of Evelyn Z. Diehl Trust of Virginia Poole Chanel, Inc. The DiMenna Foundation, Inc. $250,000–$499,999 Benjamin Charina Endowment Fund Alcides & Rosaura Diniz Anonymous Corinne Berezuk and Michael Mr. and Mrs. Bernard T. Chauss Foundation Trust of George Aaron Stieber Joan Chorney The Andree Wildenstein AbbVie Foundation Bergstein Family Foundation Florence Chu, MD Dormeuil & Roger Dormeuil The Louis & Anne Abrons Estate of Gertrude G. Bernstein Chris4Life Colon Cancer Foundation Foundation, Inc. The Lisa E. Bilotti Foundation Foundation William C. Dowling, Jr. Accelerate Brain Cancer Cure The Blackstone Charitable CIBC World Markets Foundation Foundation Foundation Corporation Dresner Foundation Estate of John D. Adams, Jr. James Blake Foundation A. James & Alice B. Clark Dr. Scholl Foundation Dr. Miriam and Sheldon G. The Nancy and Robert S. Blank Foundation Trust of Margaret Due Adelson Medical Research Foundation Estate of Gerald Clements Trust of Harriet C. Duker Foundation Trust of Ronald M. Blau Estate of Dorothy L. Cobb Mr. and Mrs. Adam Dunn Adenoid Cystic Carcinoma Madeline and Alan S. Blinder Trust of Joan F. Cobb Trust of Francis C. Dykeman Research Foundation Estate of Ida Bloom Estate of Frances B. Cohen Marie E. Dykeman The Louis & Bessie Adler Edith C. Blum Foundation, Inc. Coins for Alzheimer’s Research Estate of Laura D. Eastman Foundation Albert and Betty Bodian Trust The Eberstadt-Kuffner Fund The Aetna Foundation Estate of Marthe Bonneau Paul Jackson Coleman Inc. Trust of Sebastian & Helen Trust of Lillian Borchardt Mr. and Mrs. John K. Colgate, Jr. ECD Global Alliance Albrecht The Louis L. Borick Foundation Terry Collins Mr. and Mrs. Thomas J. The Alliance Against ASPS The Albert C. Bostwick The Community Foundation for Edelman Foundation Foundation Northern Virginia–Hanlon The Edelman Family Trust of Eileen Alpert Mr. and Mrs. Kevin A. Family Fund Eli Lilly & Co. Alzheimer’s Association Bousquette Estate of Robert I. Conley Estate of Rita H. Schaefer Elliott American Asthma Foundation Trust of Alice M. Branch Cooley’s Anemia Foundation Empire Blue Cross & Blue Shield American Health Assistance The Braver Foundation Estate of Lillian Copperman The Charles Engelhard Foundation Bridgemill Foundation Estate of Leonard Cossack Foundation American Heart Association Estate of Paul P. Brieloff The Cowles Charitable Trust Trust of June K. Evans The American Ireland Fund Bright Focus Estate of Mary O. Craft Trust of Lillian Evans The Ametek Foundation, Inc. The Brightwater Fund, Gloria Cure Alzheimer’s Fund Lord Evans of Watford Dorothy A. Anderson Jarecki Estate of Edna W. Curl Trust of Sarah W. Ewing Estate of Margaret B. Anderson Trust of Marie H. Brock Filomen M. D’Agostino Mr. and Mrs. Barton Faber Estate of Mark J. Anton Trust of Constantine Brown Foundation Corp. Estate of Giuliana Fantini
2017 ANNUAL REPORT 85 ONE FOCUS
DONORS TO MEMORIAL SLOAN KETTERING JANUARY 1, 2002–DECEMBER 31, 2017
Trust of Mary E. Farrell Mr. and Mrs. Bradley Goldberg Estate of Dorothy M. Holder The Gwen L. Kosinski Estate of Ralph R. Feigelson Leslie H. Goldberg Estate of Martha Holloway Foundation The Feinstein Family Trust of Marc S. Goldberg Mr. and Mrs. D. Gregory Mr. and Mrs. Marvin H. Koslow Foundation Corinne and Daniel Goldman Horrigan The Fred W. Kramer Charitable The Isabel, Harold, and Gerry Susan Wallack Goldstein Estate of Chester S. Howard Trust Feld Fund for Bereavement Arthur A. Gosnell Dina Hubell and the Labkon Mr. and Mrs. Robert A. Kramer Trust of Robert I. Fendrich Estate of Barbara Grace Family Cheryl Gordon Krongard Hilary Carla Feshbach Estate of Felice M. Grad Estate of Karen L. Hudson Trust of Walter C. Kronke Mrs. Frederick Fialkow Laurence Graff Estate of Samuel Hughes Estate of Samuel Kuflik Estate of Selma Fine Graff Diamonds Hunter Douglas Estate of Ann Kuhlmann Jeanne Donovan Fisher Graham Holdings Company Syde Hurdus Foundation, Inc. Estate of Harriette H. Kussin The Jodi Spiegel Fisher Cancer Granary Associates IBM International Foundation Estate of Sidney J. Lacher Foundation The Grateful Foundation, Inc. The Interpublic Group of Mr. and Mrs. Joseph M. La Aaron Fleischman and Lin Susan Zises Green Companies Motta Lougheed Foundation The Greenberg Breast Cancer Bruce H. Jacobs Estate of Harriet L. Lampert The Floren Family Foundation Research Foundation Trust of Clyde H. Jacobs The Matthew Larson Fondazione Italiana Estate of Eldridge A. Greenlee Harry A. Jacobs, Jr. Foundation for Pediatric For the Love of Life Grinberg Family Foundation Janssen Pharmaceutical Brain Tumors Steve Forbes Virginia and Howard Products LP Trust of Ella B. Larsson Trust of William Forbes Groombridge Estate of Mira Jelin Vivian F. Laube Foundation 14 Mr. and Mrs. Martin D. Gross Robert Charles Jenkins Lavelle Fund for the Blind, Inc. The Evan Frankel Foundation Trust of William Gross The JMB Hope Foundation Betty Reid Lawson Mr. and Mrs. Lewis Frankfort Shoshanna Gruss Estate of Robert L. Jones Mrs. Lois H. Lazaro Trust of Jill and Jayne Franklin Gurwitch Products Max Kade Foundation, Inc. The Iris and Junming Le Mark and Mary-Anne Franklin Robert C. Halboth Eugene S. and Constance Kahn Foundation Estate of Mr. Edward W. Frantel Mrs. Melville W. Hall The Kahn Charitable Lead Annuity Trust Frazier Foundation Trust of Kenneth L. Hallam Foundation Trust of Joseph Lebednik The Edna R. Fredel Charitable Jeanne G. Hamilton and Lawson The Leonard B. Kahn The Richard S. and Karen Lead Annuity Trust W. Hamilton, Jr. Family Foundation LeFrak Charitable Foundation Estate of Frank O. Fredericks Foundation, Inc. Kaleidoscope of Hope Mr. and Mrs. Thomas V. Leeds Free to Breathe Trust of Florence M. Hammer Foundation In memory of Stacey Leondis The Fribourg Foundation Trust of Robert Hanson Estate of William Kanter Estate of Donald LeRoy Estate of Gerard M. Friedman Mr. and Mrs. Jose Kuri Harfush Trust of Henry & Miriam Leukemia Research Foundation Estate of Eugenie Fromer Harrington Discovery Institute Kaplan Estate of Barbara Grande LeVine The Anna Fuller Fund Mr. and Mrs. Robert L. Edward M. Kaufmann Trust of Leona Levy Richard M. Furlaud Harteveldt Linda and Ilan Kaufthal Bertha and Isaac Liberman Estate of Leonard Galasso Trust of Abraham Hases Estate of Helen Keena Foundation, Inc. Estate of Regina M. Gallichio Estate of Katherine Hawrylow Trust of Fenton O. Keister The Anne Boyd Lichtenstein Estate of Norman D. Galloway Estate of Irma Hayes Robert J. Keller Foundation Mr. and Mrs. Robert M. Haymakers for Hope J. C. Kellogg Foundation Estate of Helen Lieber Gardiner Austin D. Hearst The John R. Kennedy Estate of John E. Liebmann Trust of Esther B. Garnsey Hecht and Company Foundation Mr. and Mrs. Richard Lightburn Trust of Frances L. Gatterdam Philanthropic Fund Kern Family Fund Young Ae Lim and Joonsikk Estate of Mildred B. Gehrke Mr. and Mrs. Charles Heimbold, Estate of Patricia A. Kerrigan Moon General Atlantic Foundation Jr. The Kettering Family Pauline H. Lin The Patrick A. Gerschel Cherie Henderson and David Foundation Linda Lipay Foundation Poppe Estate of Ursula A. Kildea Estate of Marian J. Looser Leonardo Giambrone Hendrickson Family Trust of Estelle Knapp Lostritto Family The Albert and Pearl Ginsberg Foundation Trust of Paul and Fran Knight Dr. Christine A. Loveland Foundation Heyman-Merrin Family The Kohlberg Foundation Milton Lowenstein Liane Ginsberg Foundation The Greater New York City MacDonald-Peterson GIST Cancer Awareness Brian J. Higgins Affiliate of Susan G. Komen for Foundation Foundation The Hillcrest Foundation the Cure MacMillan Family Foundation The Glades Foundation James and Angela Ho The Kors Le Pere Foundation John Magnier Mr. and Mrs. Eugene J. Glaser The Catie Hoch Foundation Joel Koschitzky, Ramat Gan Estate of Julian Malkiel Trust of Ruby A. Godfrey Estate of Laverne Hodges Israel Estate of Albert Manning
86 MEMORIAL SLOAN KETTERING CANCER CENTER ONE FOCUS ONE MSK
DONORS TO MEMORIAL SLOAN KETTERING JANUARY 1, 2002–DECEMBER 31, 2017
Trust of Jack & Ruth Marcus Trust of Edmund L. Murray Stewart Rahr Estate of Bertha Schulman Estate of Marvin Margolies Edith L. Nathanson Trust of Harriet C. Rath The Schultz Foundation Mrs. John L. Marion Trust of Louise F. Neely Bonnie Reiss and Family Mr. and Mrs. John W. Scully Susan and Morris Mark Craig H. Neilsen Foundation Estate of Helen H. Reiss Searle Scholars Program Trust of Sarah H. Marks Estate of Gwendolyn L. Trust of Ruben & Helga Resnik The Selander Foundation The Marmot Foundation Nekrewich Trust of Anne Ressner The Select Equity Group Estate of Edith Lipphardt Estate of Ann M. Nelson Trust of Barbara C. Rex Foundation Martens Jerome and Elaine Nerenberg Estate of Walter E. Rex III The Nina and Ivan Selin Family Estate of Elizabeth Martin Foundation The Rice Family Foundation Foundation Trust of Richard and Betty Muriel Neumann Anne S. Richardson Fund Estate of Sam Seltzer Martin The Newport Foundation The Ritter Family Foundation Mr. Frank Senior Estate of Ann L. Martinez Trust of Irene Newton Irene Ritter Foundation Seventh District Association, Dorothy Marx The New York Stem Cell Trust of Lillian Robbins Inc. The Lucille and Paul Maslin Foundation Mr. and Mrs. Stephen Robert Estate of Gladys N. Severud Foundation Estate of Jane M. Nicholson Robin Hood Foundation The Shanken Family Trust of Cecelia Matarazzo Trust of Florence S. Nilsson Estate of Sandra Sheppard Foundation Estate of Michael Matchen James G. Niven Rodgers Estate of Elizabeth L. Shanley Mr. and Mrs. Howard A. Matlin Fred and Gilda Nobel Estate of Ellen S. Rogoff Estate of Odette Sharow Estate of Harry H. Maus The Lyla Nsouli Foundation Kenneth C. Rohan Trust of Minnie M. Shaw Paul S. May for Children’s Brain Cancer Ginni Rometty Hope Sheridan Foundation The Mayday Fund Research Estate of Judith Rosenbaum Shiseido Americas Corporation The Helen & William Mazer The Oceanic Heritage Foundation Estate of Nathan Rothstein Renee and Irwin Shishko Foundation Trust of Robert M. Ochs Estate of Wilhelmina T. Rouget Estate of Lillian M. Siemionko MBNA America Bank Trust of Dorothy B. O’Connor Trust of Cecile N. Ruben The Grace, George, and Judith The MBNA Education Mr. and Mrs. Wm. Montague Trust of Maurice Ruben Silverburgh Foundation Foundation Oeste, Jr. The Selma and Lawrence Ruben Leonard and Donna Simon Mr. Brian McCarthy The Okonite Company Foundation Trust of Angie S. Skinner Mary Jane McCarthy Grace Oughton Cancer Andrew Sabin Family Foundation The Alan B. Slifka Foundation The Michael W. McCarthy Foundation Mrs. Orhan I. Sadik-Khan Gordon Smith Foundation The William & Jane Overman Mrs. Edmond J. Safra The Gordon H. and Norma Mr. and Mrs. Thomas R. Foundation Mr. and Mrs. Herbert E. Saks Smith Family Foundation McCullough Eileen and James A. Paduano Mara and Ricky Sandler Estate of Robert A. Smith Estate of John C. McDaniels Parfums de Coeur Ltd. Foundation Estate of Roberta A. Smith Mr. and Mrs. Jay H. McDowell Rosalind and Kenneth Pearlman Isabella Santos Foundation Ms. Beryl Snyder Estate of Charles McGreevy Richard S. Pechter Trust of Erika Saphier Society for Immunotherapy of Estate of Mary T. McKibbin PepsiCo Foundation, Inc. The Sass Foundation for Cancer Estate of Alan McMaster Trust of Jerry Perenchio Medical Research Solving Kids’ Cancer Laura Mercier Ovarian Cancer Estate of Ann Perkins The Saw Island Foundation JMCMRJ Sorrell Foundation Fund Estate of Claude E. Petruzzi Trust of Paul C. Sawyer The Seth Sprague Educational The Reuven Merker Charitable The Pew Charitable Trusts Trust of Edwin & Grace Sayers and Charitable Foundation Foundation, Inc. Mr. Donald Pfanz Mr. Thomas Scalera and Dr. Trust of James L. Stackhouse Estate of Despina Messinesi Pin Down Bladder Cancer Rebecca Timlin-Scalera Arthur A. Stamm Mr. Robert A. Metzler Mr. and Mrs. Jeroen Henk L. Pit Estate of Christine C. Scanlan The Robert Steel Foundation for Trust of Russell H. Michel Jerry W. Pittman Trusts of Anabel M. Scarborough Pediatric Cancer Research Elizabeth R. Miller and James Estate of Ronald A. Poeter and Walter L. Scarborough Trust of Frederick T. Steinberg G. Dinan and the Dinan Estate of Elizabeth Polotaye The Milton Schamach The Jeffrey Steiner Family Family Foundation Precision Medicine Research Foundation, Inc. Foundation Mr. and Mrs. Richard A. Miller Associates Mr. and Mrs. Stephen Scherr The Guy M. Stewart Cancer Mrs. Minot K. Milliken Trust of Helen M. Price Trust of Edward and Irene Fund Melissa and Robert Mittman Estate of Seymour Price Schlosser Estate of Sonia Stolin-Moresco Estate of Dorothea K. Money Prudential Financial, Inc. Trust of Jennie C. Schneider Trust of May Strang Trust of Anny S. Moore Trust of Raymond F. Prussing Rob and Karen Schneider Estate of Erik Straub Diana M. Moore Robert Pufahl Mrs. Silvia A. Schnur The Daniel P. Sullivan Clinical Yvonne and Arthur Moretti Purdue Pharma LP Mr. and Mrs. Paul C. Schorr IV Fellowship Fund Ronald and Brenda Morey Patricia A. Quick Charitable Estate of Evelyn Schrank Timothy P. Sullivan Charitable The Owen Moscone Foundation Trust Trust of Crystal Schull Lead Trust
2017 ANNUAL REPORT 87 ONE FOCUS
DONORS TO MEMORIAL SLOAN KETTERING JANUARY 1, 2002–DECEMBER 31, 2017
Susquehanna Foundation Estate of Ruth Whitfield The Amaturo Foundation, Inc. Trust of James R. Barber Trust of Hazel L. Sutton William F. and Barbara K. American Express Foundation Estate of Lucille H. Barbour The Taft Foundation Whitman American Federation for Aging Barish Family Foundation The Paula Takacs Foundation The Helen Hay Whitney Research Trust of Grace M. Barry for Sarcoma Research Foundation American Lung Association Estate of Kaethe F. Barry Target MarkeTeam, Inc. Mr. and Mrs. Frank C. American Society of Colon and Estate of Patricia A. Barry Frank N. Tedesco Whittelsey III Rectal Surgeons Estate of Robert B. Bartow Estate of Ida Tepper The Jesse R. Wike Charitable Trust American Urological Mario Batali Foundation Trust of Annette M. Terdina Estate of Sylvia C. Williams Association Trust of Eileen L. Batten Estate of Stella R. Thater Kendrick R. Wilson III Amgen, Inc. Trust of Joyce A. Battle Think Pink Rocks Mr. and Mrs. Jon Winkelried Estate of Maurice Amzalak The Modestus Bauer Foundation Thrasher Research Fund Elizabeth Winterbottom Anderman Foundation Trust of Ruth M. Baughman Mr. and Mrs. Carl W. The Winters Family Fund Mr. and Mrs. Harold F. Lynn B. Bayard Timpson, Jr. Wooden Nickel Foundation Anderson Estate of Thelma Beatty Mr. and Mrs. Alexander Tisch Worldwide Cancer Research Richard and Peggy Anderson Trust of John A. Beaty Estate of Michael Z. Toman Trust of Vincent J. Zappolo Warren and Lillian Anderson Mr. and Mrs. Edmund Becker The Robert Mize & Isa White The Zickler Family Foundation Mr. and Mrs. Jerome V. Ansel Lisa J. Becker and Anthony M. Trimble Family Foundation Estate of Robert E. Ziegler Anthony Brands Pesco Mr. Steven Trost Nicholas B. Zoullas The Antonacci Family Estate of Charles R. Beechler Walter and Elaine Ullrich Mr. and Mrs. Jeffrey A. Zucker Foundation Trust of Kathe Begeest Trust of Irwin C. Unger Aon Foundation Laurence D. Belfer United Leukemia Fund Inc. Estate of Marilyn Apelson The Robert & Renee Belfer United Way of New York City Maite Aquino Memorial Fund Family Foundation The Lucy & Eleanor S. Upton $100,000–$249,999 Mr. and Mrs. Rand V. Araskog Estate of Robert D. Bennett Charitable Foundation Anonymous Trust of Theodocia D. Arkus Trust of Isidore Bergner Estate of Monique Uzielli 44Love Project Mr. and Mrs. William J. Mr. Bernard S. Berkowitz Nancy and Nicholas Valeriani A & P Foundation Armfield IV Joan and James Berkowitz Fund The Vasey Foundation Catherine and Paul Aaron Paul Armin Family Foundation Berkowitz II Foundation Veejay Foundation Mr. and Mrs. Ghazi Abbar Nicole Sinek Arnaboldi and Leo Gary and Carol Berman Family Estate of Eleanor B. Vogel Abbott Laboratories Arnaboldi Foundation, Inc. Voices Against Brain Cancer Jean Ackerman Kym S. Arnone Estate of Tony P. Bernabich Foundation Estate of Michael Ackerman The Aronson Family The Bill Bernbach Foundation Douglas Walker Acorn Foundation Foundation Steffi and Robert Berne Estate of Muriel F. Wall Mr. and Mrs. William R. Trust of Richard Aronson Mrs. Louis Bernstein The Bert & Sandra Wasserman Acquavella Mary Kay Ash Charitable Luciano and Giancarla Berti Foundation Mr. and Mrs. Laszlo Adam Foundation Be the Difference Foundation Marla J. Wasserman The Francis X. Ahearn, Sr. The Isaac and Carol Auerbach Jacqueline Bikoff Clyde Watson and Denis Devlin Foundation Family Foundation Estate of Margaret L. Bingman Samuel Waxman Cancer Roger and Elizabeth Ailes Autism Speaks Biomet Research Foundation Mr. and Mrs. Lee S. Ainslie, III AVIESAN Trust of C. June Bisplinghoff Trust of Geraldine W. Webber Ms. Kay Alchu The Ayres Baechle Foundation BJ’s Charitable Foundation The Sue Ann and John L. Trust of Eileen I. Alessandrini Mr. and Mrs. Charles Ayres Bladder Cancer Advocacy Weinberg Foundation Daniel G. Alexander Trust of Maureen E. Bacchi Network Stephen L. Weiner Lee A. Alexander Dr. Joseph J. Bailey Trust of Raymond Blake The Scott Weingard Memorial The Shana Alexander Charitable Elliot A. Baines Blaker Family Fund Fund Foundation The Baird Family Fund Hector Payares Blanco Mr. and Mrs. Boaz Weinstein Alexandria Real Estate Equities, Mrs. Judy K. and Mr. Jack W. Bill Blass Licensing Company, Inc. Estate of Elias Weiss Inc. Baker Mr. and Mrs. Jeff T. Blau In memory of Marie T. Weiss Mr. and Mrs. John P. Allen The Solomon R. and Rebecca D. Ambassador and Mrs. Alan J. John A. Weissenbach and Ann Robert and Elaine Allen Baker Foundation Blinken Southworth AllianceBernstein David M. and Barbara Baldwin Mr. and Mrs. James A. Block Effie Wells-Lonning Alliance for Life Sciences & Foundation Inc. Estate of Vivian K. Blonder Trust of Ida Wharton Health Estate of David B. Ballard Trust of George Bloostein Estate of Ann White Estate of Lori S. Alper Estate of Harold P. Bannister The Walter & Adi Blum Whitehall Foundation Mr. and Mrs. Robert I. Alpern Mr. and Mrs. Robert L. Foundation, Inc. John C. Whitehead Sheikha Noura Alsheikh Barbanell Trust of Eli Blumenfeld
88 MEMORIAL SLOAN KETTERING CANCER CENTER ONE FOCUS ONE MSK
DONORS TO MEMORIAL SLOAN KETTERING JANUARY 1, 2002–DECEMBER 31, 2017
Harold and Adele Blumenkrantz Trust of Dorothy A. Burkert Childhood Brain Tumor Dudley P. Cook Estate of Simon P. Blustone Estate of Louise V. Burnett Foundation Mr. and Mrs. Errol M. Cook D. Dixon Boardman Mr. and Mrs. Harold Busch The Children’s Brain Tumor Trust of Kristen H. Cook Bruce Bocina Mr. and Mrs. Jonathan J. Bush Foundation Estate of Phyllis Cook Estate of Marti A. Boden Estate of John D. Bush Children’s Neuroblastoma Mrs. William B. Cook Peter Bodok The Paul Nabil Bustany Cancer Foundation Mr. and Mrs. E. Gerald Cooper Estate of Alan A. Bohlinger Foundation The Francis and Miranda Estate of Ruth L. Cooper Estate of Marjorie R. Boselly Estate of Ruth J. Butterworth Childress Foundation Estate of Morris Coppersmith The Boston Foundation Estate of Lillian A. Byman The Jane Coffin Childs Estate of G. R. Couch Estate of Lydia Botfeld Dr. and Mrs. Robert A. Caine Memorial Fund for Medical Mr. and Mrs. Paul Coulson Alan F. Bovee Mr. and Mrs. Bruce L. Calhoun Research Courtesy Associates, Inc. Trust of William R. Boyle Mr. and Mrs. Jeremiah M. Chordoma Foundation The Cowboy Fund Estate of Mary C. Brabson Callaghan Estate of Selma Chyatt Anne Cox Chambers Foundation Estate of Elsie L. Bradford Trust of Douglas M. & Dorothy William Joseph Ciliberti Estate of Edith C. Cox The Bradshaw Family M. Calligar The Cindy Foundation for Trust of Burton L. Craig, Jr. Neal C. Bradsher and Elizabeth Trust of Marilyn Campbell Ovarian Cancer Research Trust of Franklin C. Craig M. Johnson Cancer Research & Treatment Judith Ann Cion Revocable W. Michael and Lois Craig Brahman Capital Fund Trust Estate of John A. Crampton Brain Tumor Funders’ Leah Rush Cann Estate of Piera Circiello Credit Suisse Group Collaborative James A. Cannon Amanda Styles Cirelli Trust of Louise Crites Anna M. and Mark R. Brann Estate of Edward A. Cantor Foundation for Pediatric Crohn’s & Colitis Foundation of Mr. and Mrs. Henry R. Breck Paul T. Cappuccio Cancer Research America Milton Brenner Michael and Carol Carey Mr. and Mrs. Robert Citrone The Crown Family Mr. and Mrs. Fred J. Carlsberg Foundation The Anne L. and George H. Bruce Crystal Brettschneider Trust of Jacqueline Carnrick Clapp Trust Trust of Leroy & Barbara Estate of Mae Bridewell Mr. and Mrs. Edmund M. Estate of Lyman W. Clardy Cubicciotti The Broder Family Foundation, Carpenter Mr. and Mrs. Neil A. Clark The Cure Starts Now Inc. Mr. and Mrs. Warren E. Estate of Ina Clarke Mr. and Mrs. James F. Curtis III Estate of Edna Brodie Carpenter III Estate of Mary M. Cleary Cusa Realty, LLC Estate of Eleanor V. Brogdon Estate of Eugene Carrara Cleveland Clinic Health System Custom Design Tom and Meredith Brokaw Estate of Irene A. Carson CLL Global Research Communications, Inc. Randall Brooks Estate of William K. Carson Foundation William J. Cwenn Carl and Nickey Brown Mr. and Mrs. William M. Carson Estate of Albert Cohen Mark and Elizabeth Czarnecki Trust of Fern G. Brown Estate of Colon B. Carter Trust of David Cohen Mrs. Charles A. Dana, Jr. Ms. Betsy Levine-Brown and Trust of Winifred T. Carter Mr. and Mrs. Laurence W. Estate of Richard Daniels Mr. Marc Brown Estate of Elsie Cartotto Cohen The Gloria and Sidney Danziger Trust of Ruth Ann Brown Joan (Perkowski) Cashin Clarence L. Coleman Jr. and Foundation, Inc. Estate of William A. Brown, Sr. Foundation Lillian S. Coleman Foundation Estate of Hannah Danziger Brown Helicopter, Inc. Casual Male Corp. James J. Coleman, Jr. The E. S. P. Das Foundation Brown Performance Group Catch 25 Foundation, Inc. Estate of Gertrude T. Coles Barbara A. Dauphin Trust of Blanche A. Browne Catwalk 4 Cancer Karen Collias and Geoffrey The Davee Foundation The Brownington Foundation The Cayuga Foundation Levitt Estate of Paul D’Aversa Estate of Vernon Brunelle Estate of Charlotte A. Celian Robert and Maryann Collin Estate of Hazel Davidson Estate of Sheri-Ann Bryan Mr. and Mrs. E. Val Cerutti Estate of Arthur R. Collins Mr. and Mrs. Scott E. Davidson Elizabeth Bucher Trust of George F. Chagnot Estate of Edna E. Collins The Ellen and Gary Davis Trust of William R. Buchner Trust of Henry D. Chaikin Estate of Lila V. Collins Foundation The Peter & Carmen Lucia Buck Dr. Kalpana Chakraburtty The Colon Cancer Foundation Trust of Jane Davies Foundation Ray and Patti Chambers James J. Colt Foundation, Inc. Trust of Hermine S. Dawson Estate of Edwin Buckingham Margaret Anne Chappell Comerica Charitable Trust Roxana V. Dawson Melva Bucksbaum and the Tribhuwan N. and Sadhna Community Foundation for Estate of Sara De Castro Robert I. Goldman Foundation Chaturvedi Greater Atlanta Estate of Karin D. de Chellis Janna Bullock Trust of Mea Chee Condé Nast Publications Estate of Jean Decker Mr. and Mrs. Roy R. Bumsted III Michael and Pamela Chepiga Estate of John Confort, Jr. Estate of Libiro DeFilippis Trust of Florence Bunn Estate of Camille Chericone Mr. and Mrs. Alexius Conroy The Lawrence and Florence Mr. and Mrs. Franz H. Burda Chesed 24/7 Consolidated Edison Company DeGeorge Charitable Trust Mrs. Coleman P. Burke Child Neurology Foundation of New York Lynn DeGregorio
2017 ANNUAL REPORT 89 ONE FOCUS
DONORS TO MEMORIAL SLOAN KETTERING JANUARY 1, 2002–DECEMBER 31, 2017
The DeGregorio Family Mr. and Mrs. Frederick Four Seasons Hotel–New York Mr. and Mrs. William H. Girvan Foundation Elghanayan The Fan Fox and Leslie R. The Harvey S. Gitlin Family Mr. and Mrs. Roberto de Martin Elk League for Cancer Samuels Foundation, Inc. Foundation Guardiola Research Amy K. Foy and Nicholas J. Gail C. Gittleson Estate of Katherine C. DeHaan Trust of Arnold B. and Joan S. DeFlora Estate of Grace E. Glenn Goff Elkind Estate of Thomas R. Foy Glenwood Management Mr. and Mrs. Morgan A.G. Dejoux Andrew J. Entwistle Maria Frangella Foundation for Corporation Anthony Del Bove EOS Products, LLC Colon Cancer Research Victoria and Justin Gmelich Estate of Helen Demitriades Estate of Lillian Epps Claire and Meyer W. Frank Trust of Carmen Gobbi Mr. and Mrs. Steven Denning Mr. and Mrs. Christopher Errico and Leann Frank Charitable Trust of Glenn R. Gobble The Derfner Foundation Rafael Etzion Foundation Christina and Peter Gold Mr. and Mrs. Francois de Saint The Charles Evans Foundation Trust of Irene R. Frank The Goldhirsh Foundation Phalle Estate of Eugene M. Evans, Jr. Mr. and Mrs. Joel M. Frank Goldhirsh-Yellin Foundation Ernst and Paula Deutsch The Evslin Family Foundation Nicole and Steve Frankel Estate of Elizabeth B. Golding Foundation Expect Miracles Foundation Helen Frankenthaler Ms. Miriam Goldman Thomas and Margaret DeVita Trust of James D. Ezzell Foundation The Barbara L. Goldsmith The DeWitt Wallace Fund Gloria B. Falkson Mr. and Mrs. David Lee Foundation Mr. and Mrs. Anthony Diaco Family Reach Foundation Frankfurt Shelley and Graham Goldsmith The Miriam & Arthur Diamond Fanconi Anemia Research Fund Trust of James and Mary Lawrence Goldstone, MD Charitable Trust Mr. and Mrs. Alfonso Fanjul, Jr. Frankhouser Herman B. Golub Charitable The Ernest & Jeanette Dicker Mr. and Mrs. James T. Fantaci Doreen Frasca and Tom Mead Trust Foundation Joyce Fefferman Estate of Gloria Freed Trust of Manuel and Anne Estate of Margaret DiDonato Estate of Marion E. Feigenbaum The Freed Foundation Goodman Estate of Richard I. Diennor The Alfred & Harriet Feinman Estate of Katherine Freeman Google Trust of Mary L. Dillon Foundation Mr. and Mrs. Sanford Freiman Trust of Steve Gorczyca Discavage Family Foundation Gretchen V. and Samuel M. Frey Family Foundation, Inc. Christy and Sheldon Gordon Mr. and Mrs. Daniel L. Doctoroff Feldman Zoltan Fried Jeff Gordon Children’s Oliver S. & Jennie R. Donaldson The Corinne Feller Memorial Susan and Fred Friedman Foundation Charitable Trust Fund Charles A. Frueauff Foundation The Gordon Family Foundation, Estate of Maurice A. Donovan Roger W. Ferguson, Jr. Estate of Bella Frutkin Inc. John R. Doss Trust of Thelma F. Fernandez Estate of Roger M. Furiness Trust of Louise S. Gosse Percy S. Douglas Fetzer Institute Estate of Joseph F. Fursa, Jr. Marietta A. Goulandris Estate of Susie M. Downing Trust of Lydia K. Fiedler Mr. and Mrs. Thomas J. Gahan Eileen F. Gould and Robert J. Mr. and Mrs. Frank P. Doyle Michael Fieldstone and Maya Trust of Ralph W. Gaines Dwyer Trust of Max Drechsler Hartman Estate of Anne Gallagher Julie Gould Fund for Medical Dreyer’s Grand Ice Cream, Inc. Debra Fine and Martin Schneider Anita C. Garoppolo Research Estate of Donald E. Drinkwine Estate of Gloria Fine Mr. and Mrs. Julius R. Gaudio Estate of Richard P. Gould Jane Clausen Drorbaugh Randee and Howard Fischer GC for a Cure 5K Run/Walk Go With Courage, Inc. Dr. Jeffrey Duban Estate of James K. Fisher Bruce G. Geary Foundation Grantham Mayo Van Otterloo Trust of Anne Duerden Estate of Nellie G. Fishman Trust of Louis C. Geiger & Co. Trust of Patricia P. Duffy Estate of William and Frederica Trust of William G. Genner, Sr. Estate of Harvey R. Graveline Estate of Doris M. Dunham Fissell Kara and Peter Georgiopoulos Stephen and Myrna Greenberg Margaret H. Dunwiddie Trust of Loretta B. Fitzgerald Estate of Jacques A. Gerard Brigadier General and Mrs. The Durst Organization, Inc. Mr. and Mrs. Thomas M. Robert and Sylvia Gergen William S. Greenberg Estate of Evelyn J. Dyba Fitzgerald III Estate of Charles J. Gerhart Estate of Helen S. Greenwood Thomas Edelman James B. Flaws and Marcia D. Panayotis Gerolymatos Mr. and Mrs. Peter S. Gregory Doris M. Edwards Weber Trust of Alda Getti Trust of Maurice Griffel E. E. Cruz Company Fleisher Family Foundation Estate of Theresa A. Ghiringhello Trust of Dorothy G. Griffin Mr. and Mrs. Blair W. Effron The Francis Florio Fund of the Judith Gibbons and Francesco John and Amy Griffin Trust of Bertram Ehrlich New York Community Trust Scattone Foundation Trust of Raymond Ehrlich Trust of Robert B. Fordham The Ryan Gibson Foundation Mr. and Mrs. Melvin W. Griffin Estate of Elinor Ehrman The Mary Alice Fortin Marlene and Alan Gilbert Trust of William C. Griffith, Jr. Estate of Greta Einhorn Foundation Gilead Sciences Trust of Vernon H. Grigg Albert Eisenberg Foundation Richard N. Foster Estate of Rosemarie M. Gilman Grodetsky Family Foundation Trust Trust of Aida A. Foti Mrs. Bruce A. Gimbel Estate of Evelyn Gross Estate of Estelle Eisenstat Foundation for Women’s Cancer Trust of Adele Ginsburg Estate of J. Stanley Gross
90 MEMORIAL SLOAN KETTERING CANCER CENTER ONE FOCUS ONE MSK
DONORS TO MEMORIAL SLOAN KETTERING JANUARY 1, 2002–DECEMBER 31, 2017
Trust of Lambert J. Gross The Per and Astrid Heidenreich James B. Hunter George Karnoutsos Estate of Anthony Grosso Family Foundation The Dr. Maxwell Hurston Kat’s Ribbon of Hope Trust of Bernice I. Grossteiner Trust of Shirley S. Heiligman Family Foundation, Inc. Trust of Jerry Katz Allen J. Grubman Mr. and Mrs. Robert M. I Back Jack Foundation, Inc. Trust of Toby Katz Kenneth and Ginny Grunley Hendrickson IBM Employee Services Center The Katzin Foundation Audrey and Martin Gruss Mr. and Mrs. John Hennessy Zapfel Fund Trust of John Kaufmann, Jr. Foundation The Maxine R. and Richard L. Mr. and Mrs. David W. Ichel Trust of Ralph W. Kaufmann Estate of Wanda Grzymala Henry Trust Estate of Priscilla T. Iden Mr. and Mrs. Robert M. Kavner Guardsmark, LLC Estate of Robert Hensel, Jr. Inamed Corporation Carl Michael Kawaja and Marilyn B. Gula Mountains of Estate of Antje Hensen Incyte Corporation Gwendolyn N. Holcombe Hope Foundation The John & Rose Herman Ingersoll Rand Company Thomas F. Kearns Estate of Pauline R. Gulau Foundation Mr. and Mrs. William H. Ingram Charles L. Keith & Clara Miller Trust of Elizabeth Guon Carolina Herrera, Ltd. International Myeloma Foundation Drs. Satyendra and Manjula Trust of Leon Hershaft Foundation Trust of Harry M. Kelly Gupta Estate of Rita Hertzig Irish Society of Medical Trust of Jacquelin J. Kelly Estate of Gloria E. Gurney Ms. Marlene Hess and Mr. Jim Oncology Estate of Ruth C. Kelly Gurney Foundation Zirin It Figures LLC Mrs. Ann Kelman and the late Mimi and Peter Haas Fund Trust of Marie Hesselbach Jacobus-Iacobucci Foundation Dr. Charles D. Kelman Helen and Samuel Haber Hewlett-Packard Company Estate of Harold F. Jaeger Kemmerer Family Foundation Hachette Filipacchi Media U.S. Heymann-Wolf Foundation Mr. and Mrs. Stanley R. Jaffe Estate of Barbara B. Kemp Jayma Meyer Hack and Bruce Trust of Gerald R. Hiering Thomas Jaffe Eleanora and Michael Kennedy L. Hack Estate of Manny Hilfman James Family Foundation Peter Kenner Family Fund The Hagedorn Fund Hillenbrand Family Foundation JDRF J. Kevin Kenny The Laverna Hahn Trust Mrs. John S. Hilson Trust of Ann E. Jennings Kensico Capital Management Estate of Margaret S. Hahn The Mark Hindy Charitable Richard H. Jenrette John A. Kent Hairy Cell Leukemia Foundation The Jewish Communal Fund Estate of Herman Kerner Foundation Trust of Myfanwy Hinkle Jewish Federation of Cleveland Estate of Charles L. Kerstein Martin and Deborah Hale The Hippodrome Dry Cleaning Mr. and Mrs. Peter James The Glenn D. Kesselhaut Estate of Elizabeth W. Hall Histiocytosis Association Johnson, Jr. Children’s Joy Fund Estate of Mazie J. Hall Estate of Vladimir Hladik The Samuel C. Johnson Trust Estate of Mary F. Kessler Trust of Lawrence E. Halvorsen Estate of Edward B. Hodge Mr. and Mrs. Roy J. Johnston Mr. and Mrs. Peter A. Kessler Estate of Helen Sue Hameetman Estate of Agnes S. V. Hoffman Trust of Vivyan Jordan Coyla E. Ketchy Milton and Miriam Handler Estate of Marion Hoffman Robyn and Ken Joseph Estate of Henri Khouri Foundation Estate of Ruth M. Hoffman Dr. Anil and Mrs. Anju Joshi Mr. and Mrs. Charles Khoury Estate of Stanley E. Handman Trust of Steward B. Hoffman, Sr. J.P. Wish Fund The Kibel Foundation Trust of Elaine A. Hansen Hoffman-La Roche Inc. Judges and Lawyers Breast Kids’ Cancer Research Estate of Marion K. Hardwicke Deborah H. and Sigmar K. Cancer Alert Foundation Estate of Mary Jane Harrington Hofmann Trust of Frank J. Kahn Doris and Floyd Kimble The Mary W. Harriman Hope V. Hofmann Trust of Nina M. Kaiser Foundation Foundation Mrs. Carolyn T. Holden Jane Kalmus The King Family Charitable Trust of Eugene R. Harris Trust of Burt Holtzman Harry P. Kamen Family Lead Trust Leonard B. Hart Howard and Carol Holtzmann Foundation Mr. James W. Kinnear II Laura Hartenbaum Breast Estate of Margaret Hooghuis Mr. and Mrs. Daniel B. Kamensky Patricia A. Kirby Cancer Foundation Estate of Herman L. Hoops Trust of Mildred Kaminsky Mr. and Mrs. James M. Trust of William Hartman Trust of Anita S. Horbacz Estate of Julie Kammerer Klausmann Mr. and Mrs. William R. Hartong Alfred Samson Hou Kanarek Family Foundation David L. Klein, Jr. Foundation The Abbe & Lloyd Hascoe Robert Howard Family Estate of Lee L. Kanarian Jeffrey Klein and John Goldwyn Foundation Foundation Estate of Eleanor Kane Kleinfeld Bridal Corp. Have a Chance, Inc. Ted and Laura Hromadka Mr. and Mrs. William Kane Robert D. Klemme Trust of Peter J. Hayes Estate of Frank Huber Estate of Bernard Kantor The Esther and Joseph Morris A. Hazan Family Nancy Hughes Steve and Meghan Kanzer Klingenstein Fund Foundation Humanscale Corporation Estate of Irvin L. Kaplan Mr. and Mrs. Steven B. Klinsky HCCF Foundation Estate of Edna Hunt The Lawrence Kaplan and Fernand Koch Mr. and Mrs. Andrew P. Heaney Carol Hunter Marilyn Kaplan Foundation Estate of Gale K. Kokubu Trust of Lonie G. Hearn Constance D. Hunter Marie H. Karger Estate of Elizabeth Koller Gillian Hearst Estate of Edith M. Hunter The Karma Foundation Mrs. Mitzi Koo
2017 ANNUAL REPORT 91 ONE FOCUS
DONORS TO MEMORIAL SLOAN KETTERING JANUARY 1, 2002–DECEMBER 31, 2017
Nancy Koodish The Marvin and Kay Lichtman Karen G. Mandelbaum Mr. and Mrs. David B. McQueary The Koppelman Family Foundation Estate of Harry Marder The Meckler Foundation Foundation Light of Life Foundation Estate of Ida Mae Margolis Mr. and Mrs. Keith A. Meister Robert A. Kotick Trust of Wilhelmina I. Lipfert Trust of Carlton G. Marie Melanoma Research Foundation Kovler Family Foundation Mr. and Mrs. Ira A. Lipman Edward J. Marino The Melville Foundation Mr. and Mrs. Bruce S. Kovner Lisa’s Heart Kids’ Cancer Jerome S. and Maria Markowitz Mr. and Mrs. Prakash Melwani Oliver Kramer Research Fund Zvi and Linda Markowitz Estate of Dorris M. Mendelsohn Trust of Clara R. Kraut The Harold I. & Faye B. Liss Estate of Benjamin Marmer Estate of Irving M. Mendelson George R. Kravis Foundation Karen Marshon Richard and Ronay Menschel Raymond & Bessie Kravis Mr. and Mrs. Martin Liss The Christina & Paul Martin Estate of Lorraine Mensing Foundation The Lucius N. Littauer Foundation Trust of Richard C. Merklen Enid and Richard Kreindler Foundation Estate of Emilie Martin Julia and Gilbert Merrill Mr. and Mrs. Jerome I. Kroll The Litterman Family Trust of Richard W. Martin Foundation Trust of Grace E. Kruse Foundation Mr. and Mrs. Roman Martinez IV Estate of Amy Joan Meskin Mr. and Mrs. David Kuhns Estate of Seymour Litwack Jo-Ann Marx, MD Trust of Ruth W. Metcalfe Lee and Murray Kushner Shaojun Liu Estate of Johanna Marx Mr. and Mrs. Frank A. Metz, Jr. KVFF Fund Live, Love, Laugh Foundation Estate of Rita B. Masse Estate of Abby E. Meyer Mrs. Thomas G. Labrecque Estate of Santina Livolsi Mary Jane Massie, MD, and Mr. Margaret L. Meyer Estate of Schubert L. Lamb Demarest Lloyd, Jr. Foundation William E. Pelton Estate of Ursula Meyer Deborah and Peter Lamm Lloyds Banking Group James Mathos The Emanuel N. Micallef Estate of Marvadene B. Jeanette and Peter Loeb Estate of Alice Matonic Foundation LaMonica Stephanie and James Loeffler The Hale Matthews Foundation Mrs. Sidney Michael The Edward & Kinga Lampert Long Island League to Abolish Trust of Walter J. Matthews Trust of William M. Michaelson Foundation Cancer The Matt’s Promise Foundation Trust of Florence B. Mickels Mr. and Mrs. Barry Lang Estate of Margaret S. Longwell Reuben and Rose Mattus and Cristine Meredith Miele Estate of Annie Langen Estate of Elizabeth Loos Doris and Kevin Hurley Foundation Estate of Anne Lanigan Estate of Anthony Lopez Family Foundation The Mike and Steve Foundation J. Clair and Pamela Lanning Mr. and Mrs. José Luis Los Arcos Sir Deryck and Lady Va Maughan Elaine P. Miles Mr. and Mrs. Mark Laracy James J. and Marianne B. Maverick Capital Charities Eleanor F. Miley Estate of Peter J. Laraia Lowrey Max Mara USA, Inc. Romeo Milio Lynch Syndrome The Forrest & Frances Lattner The Lucerne Foundation Mr. and Mrs. Hamish Maxwell Foundation Foundation Cynthia and Dan Lufkin Maynard Childhood Cancer Carolyn Rosen Miller Family Dr. Gerald D. Laubach Eric and Susan Luse Foundation Foundation The Lavin Family Foundation Ronald S. Lux Mr. Michael Mazzucca Mr. and Mrs. Donald K. Miller The M. J. & Caral G. Lebworth Mr. and Mrs. Alexander P. Lynch Amory and Sean McAndrew Mr. and Mrs. Larry J. Miller Foundation Trust of John F. Lynch Estate of Ralph L. McBean Mr. and Mrs. Matthew Miller Trust of Edwin S. Lee, Jr. Estate of Kathleen E. Lynch Estate of Ann C. McBride Mrs. Mary E. S. Milligan Gary Leet Estate of Charles S. Lyons Estate of Donald J. McCarraher Monroe & Judith Milstein The Lefkofsky Family Estate of Melvin E. Lyons Estate of Joe B. McCawley Philanthropic Fund Foundation Josiah Macy, Jr. Foundation Mr. and Mrs. Jeffrey A. Estate of Dorothy B. Minard Lehman Brothers Inc. Arthur & Holly Magill McDermott Allen Minsky Karen and James Lehrburger Foundation Lee McDonald Surendra Nath Misra Mr. and Mrs. Lewis E. Lehrman The Maguy Foundation McDonald Financial Group Leslie M. Modell Ernest E. & Marian E. Lehto The Arthur I. and Susan Maier Ralph McDonough Trust of Nettie Moffenson Joint Trust Foundation The Dextra Baldwin McGonagle Estate of Catherine Mohan Trust of Martha B. Leigh Estate of Margaret E. Maihl Foundation Estate of Irene Mokrzycki Estate of Helen Lesniewski Estate of Margaret H. Mairs McGraw-Hill Companies Trust of Celestine Elizabeth The Leukemia & Lymphoma Trust of Helen E. Major McKeen Fund Moloney Society Estate of Mariette P. C. Major Mr. and Mrs. Edward B. Estate of William Monaghan Charles and Margaret Levin Estate of Morris Major McKeough Pauline M. Monteleone Family Foundation, Inc. Estate of Walter Malen The McKnight Endowment Arthur R. Montgomery Laurence W. Levine Foundation Herbert J. Maletz Fund for Neuroscience John and Hee-Jung Moon Estate of Dina Levinsky Estate of Irving and Harriet Estate of Geoffrey McLoughlin Estate of Pauline Moor Elvire Levy Malitson Peter F. McManus Charitable Mr. and Mrs. Charles V. Moore Estate of Erna T. Lewine Peter L. Malkin Trust The Gordon and Betty Moore Mr. and Mrs. Robert Liberman Elissa Caterfino Mandel Estate of Mary E. McMaster Foundation
92 MEMORIAL SLOAN KETTERING CANCER CENTER ONE FOCUS ONE MSK
DONORS TO MEMORIAL SLOAN KETTERING JANUARY 1, 2002–DECEMBER 31, 2017
Estate of Percy W. Moore Mr. and Mrs. Jeremiah Mr. and Mrs. Gerard Pompilio Mr. and Mrs. Ira L. Rennert Tom & Judy Moore Foundation O’Connor The Ponagansett Foundation, Inc. Olivier and Yosun Reza The Garrett and Mary Moran The Drew O’Donoghue Fund Janis Z. Porch The Audrey Rheinstrom and Trust Trust of Emily C. O’Grady Cynthia and Gary Porter Anne Blevins Fund Estate of Barbara B. Morgan Dara and Tim O’Hara Trust of Ann C. Porterfield Estate of Roland S. Rhode Melissa and Chappy Morris Estate of Lynn O’Hara Dennis B. Poster Judy Rhulen and Family Alfred L. and Annette S. Morse Estate of Grace O’Hare Estate of Edna G. Potter Martin Rich Foundation Wendy O’Neill Estate of John A. Powers Trust of A. Leslie Richardson Ken and Linda Mortenson Oki Data Americas, Inc. John and Jane Powers Dr. and Mrs. Peter C. Estate of Lisa F. Morton Harold N. Openshaw, Jr. Foundation Richardson Mr. and Mrs. George K. Moss Mr. and Mrs. John D. Opie Trust of Ruth S. Prall Dee Dee Ricks Moss Foundation The Katie Oppo Research Prevent Cancer Foundation John and Emma Riconda Manuel and Mercedes Mosteiro Foundation Rita Price Trust of Margaret L. Rigby Lisa and Marcelo Mottesi Optiscan The Procter & Gamble Company Estate of Evelyn J. Rimosukas Trust of Helen J. Mueller Estate of Elaine Orbach Estate of Ardys M. and Harold I. Estate of Harry Rinehimer Virginia M. Mueller The Orchard Farm Foundation Proctor Estate of Elizabeth M. Ringo Estate of Irving Mulde Julie and Doug Ostrover Project Ladybug, Inc. Trust of Victoria Rinius Mrs. Sandy Mulligan Otis Elevator Company The William H. Prusoff The Fannie E. Rippel Foundation Estate of Earl Muroff Mr. and Mrs. Gunnar S. Foundation Estate of Norma Risman Mr. and Mrs. Thomas W. Overstrom III Dr. and Mrs. Mark Ptashne Abigail Rittmeyer Murphy II William and Ella Owens Estate of Richard I. Purnell The RMF Family Fund, Inc. Ernest Muth Medical Research Foundation Richard I. Purnell Fund The Caitlin Robb Foundation Sir and Mrs. Arthur D. Myers Mr. and Mrs. Neil Padron Bambi Lyman Putnam Bernard and Elaine Roberts Estate of Elaine Nachamis Daniel P. and Nancy C. Paduano Trust of Anna Marie Putti Estate of Floyd B. Roberts The National Genetics Family Foundation The Quain Family Trust of Irene M. Roberts Foundation, Inc. Mr. and Mrs. Gregory K. Palm Roselyn Flaum Radcliffe Vivien Rock NBC Universal Pam’s Pals Inc. Trust of Samuel J. Radcliffe, Jr. Robert and Ardath Rodale Trust of Joshua Needelman Mr. and Mrs. Jordan M. Pantzer Trust of Betty Raiff Family Foundation Estate of Leslie A. Nelkin Estate of Thomas Parissidi Richard E. Rainwater Rodale, Inc. Jane R. Nessen The Parnassus Foundation Estate of John T. Rakowski Estate of Maria Rolfe New York City District Council Rosalie Pataro Norman R. and Ruth Rales Michael Romanes of Carpenters Relief and Trust of Edith Pattison Foundation Sheldon Rose Charity Fund Estate of Herman L. Paul, Jr. Rally Foundation Estate of Sylvia Rosenberg New York State Bowling Pediatric Brain Tumor Mary L. Ralph Philanthropic Trust of Ilsa Rosenblum Association Foundation Fund Trust of Evelyn Rosenstein New York State Fraternal Order Pells-Mayton Foundation Mr. and Mrs. Edward A. Rankin Jeffrey Rosenzweig Foundation of Police Foundation Trust of James A. Pemberton Theodore A. Rapp Foundation for Pancreatic Cancer New York State Health Mrs. Richard T. Perkin Theodore S. Rappaport, PE, Research Foundation Mort Perlroth PhD, NYU Wireless, NYU Leo Rosner Foundation Gerald L. Nichols and The Dina Perry Charitable Fund Langone Medical Center Estate of Barbara Ross Jacqueline W. Nichols Lisa and Richard Perry John H. Rassweiler Mrs. Howard L. Ross Foundation Sandy and Norman Pessin Estate of Frank Rea, Jr. Estate of Sylvia Ross The Gertrude B. Nielsen Estate of Ruth Peterson Abigail T. Reardon Estate of Eva L. Rothberg Charitable Trust Estate of Frederick D. Petrie Estate of Phyllis E. Redmerski Philip and Marcia Rothblum Joseph P. Noonan Samantha and Ernst Pfenninger Elenore Reed Foundation The Northrop Family/Linda Trust of Peter H. Pflugk Estate of John Bradbury Reed Mr. and Mrs. Eric A. Rothfeld Northrop Fund for Ovarian Phelps Family Foundation Estate of Martha Cuneo Reed Estate of Eleanor S. Rothstein Cancer Research Phoebe’s Phriends, Inc. Estate of Samuel P. Reed Estate of Geraldine E. Rove Trust of Robert F. Novak Estate of Edmund Piasecki Compton Rees, Jr. Denise Rover The Nussbaum/Kuhn Trust of Charles V. Pickup Odette Regine Foundation Kylie Rowand Foundation Foundation Estate of Irene Pickup Christine and Mark Fran and Jeff Rowbottom The Michael A. O’Bannon Mr. Alessandro Pinto Reichenbaum Mr. and Mrs. Charles Royce Foundation Mr. and Mrs. Roy R. Plum Renaissance Charitable Estate of Pearl Rubin Trust of Anita Ober Estate of Beatrice Pockrass Foundation Rose G. Rubenstein Estate of James O’Brien Estate of John E. Polek The Beatrice Renfield Mr. and Mrs. Mitchell E. Rudin Estate of Ernestine A. O’Connell Abigail Pollak Foundation Jane and Mal Rudner
2017 ANNUAL REPORT 93 ONE FOCUS
DONORS TO MEMORIAL SLOAN KETTERING JANUARY 1, 2002–DECEMBER 31, 2017
Estate of Maria Stella Ruggirello Estate of Harold B. Schwartz Estate of Donna Simon Mr. and Mrs. Robert A. Staub Estate of Katherine L. Rummler Theodore G. Schwartz Family The Seymour Simon Charitable Esta Eiger Stecher The Russell Family Foundation Trust Mr. and Mrs. Edward C. Steele Estate of Roberta Russo Estate of Rosalind Marilyn M. Simpson Charitable Estate of Sanford L. Steelman Estate of Eileen B. Ruthrauff Schwartzbach Trust Marie C. Stefanos The Derald H. Ruttenberg Trust of Paul J. Schwarz Simpson Thacher & Bartlett The St. Giles Foundation Foundation Mrs. Arline Schwarzman Trust Estate of Dennis Stein Alexia Hamm Ryan and Baird Mr. and Mrs. Stephen A. Trust of Marie A. Sinclair The Fred & Sharon Stein Ryan Schwarzman Trust of Otto K. & Harriet J. Foundation Trust of Anne I. Ryan Mr. and Mrs. Jeffrey E. Singer Mr. and Mrs. Ernest F. Steiner Martin Sabowitz and Muriel Schwendeman Estate of Shirley Singer Mrs. Nancy Steinfeld Goldrich Trust of Robert E. Schwenk Estate of Madeline Sisia The Ernest E. Stempel Mrs. Joan H. Sadoff Trust of Fred J. Scollay Estate of Evelyn M. Skolnick Foundation The Saibel Foundation Estate of Jewel C. Seab Sky Zone Franchise Group The Aaron and Betty Lee Stern Estate of V. Edward Salamon Secunda Family Foundation SL 2005 Family Trust Foundation Mr. and Mrs. Eugene L. Salem The Jean & Charles Segal Estate of Alvin F. Sloan Estate of Irene Stern Salesforce.Org Foundation Foundation Dr. and Mrs. Bernard E. Small Derek Stevens Mr. and Mrs. William R. Janet Prindle Seidler Suse Smetana Estate of Winona H. Stevens Salomon Foundation Louis and Dora Smith J. McLain Stewart Trust of Rose K. Salzwas Mr. David Sekiguchi Foundation, Inc. Estate of Rebecca Stohl Samourkas Foundation of New Rena Selden Estate of Mary M. Smith Mr. and Mrs. Stuart P. Stoller York The Maryam and Hervey Seley Mr. and Mrs. Michael S. Smith Mr. and Mrs. Norman L. Stone Trust of Sidney Samuels Foundation The Randall and Kathryn Smith Stony Wold-Herbert Foundation Estate of Henry Sanborn Rosemary Selky Foundation Estate of Martha W. Stouffer Estate of Andrew D. Sanders R. B. Sellars Foundation Mr. Robert J. Smith Estate of Clair B. Stough The Sandler Family Dominique Senequier Estate of Woodrow Q. Smith Estate of Gene K. Strange Nina and Julian Sandler Sephardic Hospital Fund — Estate of Dorothy Smolen Mr. and Mrs. John R. Strangfeld Charitable Fund Medstar Catherine M. Smolich Estate of Alice K. Straschil Lt. Colonel (Ret.) Joseph Santa The Jacqueline Seroussi Trust of Robert J. Smutny Martha Washington Straus and Barbara Memorial Foundation Mr. and Mrs. Jay T. Snyder Harry H. Straus Foundation, Mrs. Barbara Santangelo L. J. Sevin Society of Interventional Inc. Estate of Ida M. Scagliarini Harold Shames Oncology Estate of Herta Strauss Scalamandré Silks Estate of Reuben Shane Valerie L. Sodano Lauri Strauss Leukemia Didi and Oscar S. Schafer Trust of Robert A. Shanley The Harry & Estelle Soicher Foundation Peter L. Schaffer Regina and Sam Shapiro Foundation Geraldine Stutz Trust Inc. Mr. and Mrs. Charles W. Scharf Estate of Saul Shapiro Trust of Robert Solnick Trust of Mary R. Suchanski Estate of Richard Scharff The Sharma Foundation Therese and Marshall Mr. and Mrs. Robert J. Sullivan Estate of Lee D. Schanbam Trust of Margaret S. Sharp Sonenshine Trust of George O. Summers Estate of Sylvia Schatzman Mrs. Patricia C. Shaw Professor and Mrs. C. Alan Susquehanna Foundation The LeRoy Schecter Foundation Estate of Bernice Baruch Shawl Soons David W. Sussman Trust of John F. Scheich Estate of Alice Sherwin Estate of Sharon Sorok Phyllis and Bernard Sussman Bill Scherman and Holly Joyner The Shevell Family Soros Fund Charitable Coco Swartchild Pasco L. Schiavo Estate of Leo A. Shifrin, MD Foundation Estate of Sandra Syms The Sarah I. Schieffelin Mr. and Mrs. Stanley B. Shopkorn Sotheby’s The Sy Syms Foundation Residuary Trust Mr. and Mrs. William Shulevitz The Honorable Joyce L. Sparrow Dorothy D. Taggart Trust Estate of Josephine L. Schiff Estate of Grace R. Shulman Estate of Manette H. Speas Mr. and Mrs. Jackson P. Tai Trust of Marina C. Schloesser Trust of Rose L. Shure Adam R. Spector Foundation Trust of Andrew Taras Mr. and Mrs. David L. Mr. and Mrs. Steven J. Sidewater Mr. and Mrs. Richard A. Spelke Trust of Joyce A. Taras Schlossberg Muriel F. Siebert Foundation Trust of Henry Spenadel Edward Tarby Estate of Billie Schneider Michael and Susan Siegel Estate of Regina W. Spence Estate of Ruth N. Taub The Schneider-Kaufmann Estate of Ruth Siegmann Alvira R. Spencer Mr. and Mrs. Brook Taube Foundation, Inc. Estate of Mary Siekert Estate of DeAnne Spencer Andrew and Susan Taussig Trust of Edward K. Schnepf Trust of Walter Silberfarb Estate of Agnes Spillmer Taryn Rose International Adolph & Ruth Schnurmacher Mr. and Mrs. Robert H. Silver Trust of Ruth M. Stafford Tay-bandz, Inc. Foundation The Slomo & Cindy Silvian Walter Stamm Estate of Florence G. Taylor Trust of Lola Schug Foundation Staten Island Yacht Sales, Inc. Estate of Gertrude S. Taylor
94 MEMORIAL SLOAN KETTERING CANCER CENTER ONE FOCUS ONE MSK
DONORS TO MEMORIAL SLOAN KETTERING JANUARY 1, 2002–DECEMBER 31, 2017
Trust of James M. Taylor Estate of June A. Vanderpool Charles and Elyse Weisenfeld Team Connor Cancer Foundation Jonathan and Sarah Vanica Andrew and Ronnie Weiss Team Luke vs. Neuroblastoma (GS Gives) Estate of Gertrude Weiss The Sidney and Loretta Teich Steven Vanover Foundation Jill and Jeffrey Weiss Foundation Varhegyi Foundation Trust of Gertrude Wellisch Telethon Italy–US Foundation The Varnum DeRose Trust The Nina W. Werblow Estate of Walter G. Terwedow Dr. Terry G. Vavra and Linda F. Charitable Trust The T. F. Trust Vavra Estate of Robert L. Werner Thank Heaven Foundation In memory of Madeline C. Virginia A. Werner Estate of Theresa M. Verducci Estate of E. Olga Wesner Thingelstad Estate of Andrea M. Vernick Mrs. Elizabeth G. Weymouth Mr. and Mrs. Andrew S. Thomas Victor’s Three D When Everyone Survives Estate of Robert P. Thome The Victoria’s Smile Foundation Whip Pediatric Cancer Trust of Robert W. and Pauline Trust of Eva Vida John C. Whitaker Z. Thompson Maria von Bothmer Villalba Estate of Frank A. Widenski Trust of Vernon Thompson The Family of Maria Elena Nancy P. Widmer The Vernon F. & Mae E. Villanueva Mr. and Mrs. Gene Wilder Thompson Charitable Estate of Dorothy Voelker Mr. Daniel Wilderman and Ms. Foundation Trust of Anna L. Vogel Barbara Rockenbach Thrill Hill Productions Estate of Gertrude Vogel Wilderness Point Foundation Trust of Bridget Tiedman Ralph W. Voit The Wilf Family Foundation Tiffany & Co. Mr. and Mrs. John Vollaro Lise & Jeffrey Wilks Family The Laurie M. Tisch Trust of Beverly Wachtel Foundation Illumination Fund Wachtell, Lipton, Rosen & Katz Andrea J. Will Memorial Estate of Margaret R. Tomas The Paul E. and Mary Wagner Foundation Trust of Bertha Tomaska Trust Trust of Kyle Will Estate of Milton Topolsky Estate of Lillie M. Waldon Barbara F. Williams Estate of John J. Tormey Wallace Special Projects Fund Mr. and Mrs. Eugene F. The Tortuga Foundation Mr. and Mrs. Scott S. Wallach Williams III Estate of Virginia M. Toth Mr. and Mrs. Paul D. Walsh Estate of Phyllis E. Williams Trust of Angelina Ann Tovar James M. and Marianne Walter Williams Trading LLC Toys ‘R’ Us Children’s Fund Estate of Frances M. Wanek Trust of Helen A. Wilson Mr. and Mrs. David C. Tracey Mr. and Mrs. Desmond Wang Helen and Stanley Wissak Jill Tracey The Warburg Pincus Foundation Michel C. Witmer Estate of Rita L. Tracey Estate of Shirley I. Warner Estate of James B. Wittrock Trust of Helen A. Trahin Warren/Soden/Hopkins Family The Henry Wolf Foundation Trust of Dorothy B. Traufield Foundation Trust of Toby Wolfberg Beatrice Travis-Cole Mr. and Mrs. Bruce Wasserstein Alice Aeschliman Wolfe The Bud Traynor Memorial Elizabeth T. Wassmundt Mrs. Barbara Wolfson Fund, Inc. Estate of Shirley F. Watkins Estate of Gordon Wootton Estate of Ruth Tropp Jesse O. and Doris R. Weaver Deborah C. Wright The W. James & Jane K. Fund Trust of Twylia H. Wright Truettner Foundation Mr. and Mrs. Peter Webster Estate of Bernadette Wyrough Scott and Margy Trumbull Mr. and Mrs. Bradford G. Ofer J. Yardeni Estate of Ina Tuckman Weekes III Estate of Arthur P. Young Estate of R. Read Tull Mr. and Mrs. John G. Weiger Estate of Ellen Youngelson Lucien L. and Shirley Turk Trust of Gertrude H. Weiler Alfred D. Youngwood John J. Twomey Mrs. John L. Weinberg Zegar Family Foundation Ahavas Tzedek Foundation Marc S. Weinberger The Patricia J. and Edward W. David V. Uihlein, Sr. Danny M. Weinheim Zeh Charitable Foundation Mr. and Mrs. Mark D. Unger The Isak & Rose Weinman The Isaac Ziegler Charitable The Unger Family Foundation, Foundation, Inc. Trust Inc. The Irving Weinstein Stanley Shalom Zielony The Valley Foundation Foundation Foundation Valley of the Sun United Way Estate of Louis Weinstock Martha E. Zimmer The van Ameringen Foundation Mr. and Mrs. Michael Weisberg Trust of Marie R. Zingg
2017 ANNUAL REPORT 95 ONE FOCUS
THE SOCIETY OF MEMORIAL SLOAN KETTERING CANCER CENTER
SUPPORTING RESEARCH The Society’s Campaign focused on SUPPORTING EDUCATION The Society of Memorial Sloan precision cancer prevention. Launched Established in 2016 and first awarded Kettering’s Special Projects grants by Luis Diaz, Head of the Division of in 2017, The Society Scholars Prize is fund innovative research at the Solid Tumor Oncology, the Precision intended to honor postdocs performing Sloan Kettering Institute that is Interception and Prevention initiative at the highest levels who are also often too nascent to receive support is developing ways to tailor cancer managing additional familial obligations from conventional sources. This prevention and early detection based and adjusting to being new parents. year, the grants were awarded to five on an individual’s genetic, lifestyle, and This merit-based prize is awarded scientists conducting research in environmental risk factors. The goal is annually to at least ten full-time postdoc developmental biology, immunology, to prevent cancer from ever occurring researchers who complete a brief and computational biology. or to intercept it at its earliest stages, application and personal statement. Each spring, The Society also awards maximizing the chance of a cure. They are reviewed by a selection panel research grants that specifically focus The Society Prize is awarded at the made up of MSK faculty parents, on providing crucial funding to MSK’s annual MSK Academic Convocation with final approval from The Society promising young investigators. In to a researcher, doctor, or team leader president in consultation with its 2017, the grants were awarded to eight who has made a positive and lasting executive committee. The prize provides projects, including a study involving diet impact in the fight against pediatric a cash award for up to four years and and obesity and their effect on breast cancer. The 2017 recipient of this prize is open to postdocs at MSK who have a cancer risk, a project exploring the was James Downing, President and dependent child under four years of age. mysteries of cancer metastasis, and a CEO of St. Jude Children’s Research type of radiation therapy for advanced Hospital in Memphis. Among his malignant pleural mesothelioma. many accomplishments, he has had The Society’s Associates Initiative a major influence on defining the focused on the effort to establish a genetics and genomics of pediatric new standard of care for pediatric cancers. Dr. Downing was instrumental cancer survivors. The number of in launching the Pediatric Cancer The Society is a group of children surviving cancer is increasing, Genome Project, which has compared dedicated, caring women. but the treatments that help these the complete genomes from the It is absolutely necessary that children survive their cancer can have cancerous and normal cells of more we continue to support the a lasting negative impact, leading to than 800 young patients. incredible strides Memorial learning disabilities as well as social- emotional and behavioral difficulties. SUPPORTING PATIENT CARE Sloan Kettering Cancer Center Some children, free of cancer, then Some of the most cherished traditions has made through its research face challenges with attention and and events at MSK — including the and patient care initiatives.” festive holiday parties held throughout concentration, processing speed, –JAMEE GREGORY memory, and social isolation — leading the year, complete with overflowing gift to lowered overall quality of life. bags for patients — are sponsored by MSK’s researchers are seeking ways The Society. This year was no different, to identify specific groups of pediatric with more than 200 of our youngest cancer patients at diagnosis that are patients and their families and friends at at an increased risk for these issues Pediatric Prom in May. and are implementing home-based computerized cognitive training programs immediately after finishing treatment to minimize ill effects.
96 MEMORIAL SLOAN KETTERING CANCER CENTER ONE FOCUS ONE MSK
1. Society President Jamee Gregory and Madison Avenue Business Improvement District President Matthew Bauer at the 31st Miracle on Madison Avenue shopping event benefiting The Society of MSK on December 2. 2. P ediatric oncologist Farid Boulad, Medical Director of the Pediatric Day Hospital, with a young friend at Pedatric Prom. 3. From left: Physician-in-Chief José Baselga, Silvia Garriga, Board Chair Douglas Warner, former Society President Lavinia Branca Snyder, Roser Salavert, Sloan Kettering Institute Director Joan Massagué, Tullia Lindsten, and MSK President and CEO Craig Thompson at The Society’s Spring Ball. 4. From left: Kristin Allen, Walter S. Tomenson III, Deborah DeCotis, Kirk Henckels, Jamee Gregory, Eugenie Niven Goodman, Mindy Webster, Benjamin Stokes, and Samuel Goldworm at The 1 Society’s Special Projects Dinner.
2 3
4
2017 ANNUAL REPORT 97
ONE FOCUS
THE SOCIETY OF MEMORIAL SLOAN KETTERING CANCER CENTER ADMINISTRATIVE BOARD
EXECUTIVE COMMITTEE
JAMEE GREGORY MRS. MICHAEL CARR ALEXIA HAMM RYAN MRS. RICHARD A. MILLER President Vice President Vice President Vice President
MRS. SCOTT C. JOHNSTON MRS. LARS FORSBERG Treasurer Assistant Treasurer
KATE ALLEN MRS. TIMOTHY P. O'HARA MARTHA VIETOR GLASS Secretary Assistant Secretary Past President
MEMBERS-AT-LARGE
Muffie Potter Aston Gretchen Gunlocke Fenton Mrs. Michael Kennedy Mrs. Louis Rose Mrs. James Halsey Bell Ruth G. Fleischmann Martha O’Brien Lamphere Mrs. Paul C. Schorr IV Mrs. Alan J. Blinken Elizabeth Kirby Fuller Patricia Herrera Lansing* Martha Sharp* Tory Burch Mrs. Robert M. Gardiner Kamie Lightburn Mrs. Stephen C. Sherrill Mrs. Bryan J. Carey Mrs. Mark V. Giordano Stephanie Loeffler Hope Geier Smith* Mrs. Kevin C. Coleman Mrs. Thomas S. Glover Mrs. Roman Martinez IV Mrs. Sean P. Smith Mrs. Peter G. Cordeiro Eugenie Niven Goodman Joyce L. Moss Amanda Taylor Mrs. Archibald Cox, Jr. Mrs. Roger P. Griswold, Jr. Jennifer Gaffney Oken Mrs. Andrew S. Thomas Jennifer Creel Shoshanna Gruss Palmer Jones O’Sullivan* Maria von Bothmer Villalba Mrs. Michael J.A. Darling Leslie Heaney Mrs. Gunnar S Overstrom, III Victoria Vought Mrs. Marvin H. Davidson Shabnam Henry Marcie Pantzer Naomi Waletzky Mrs. Hilary Dick Melanie Seymour Holland Mrs. Richard T. Perkin Mrs. Martha Webster Webb Egerton Robyn Lane Joseph Debra Pipines Eleanor Ylvisaker Mrs. Christopher Errico Victoria Greenleaf Kempner Shafi Roepers Mrs. Caryn Zucker
SUSTAINING BOARD
Courtney Arnot Mrs. Thomas M. Fitzgerald III Mrs. George F. Moss Mrs. Richard J. Sterne Mrs. Andres Bausili Mrs. Roberto de Guardiola Mrs. Charles H. Mott Leith Rutherfurd Talamo Mrs. Andrew M. Blum Mrs. John S. Hilson Nancy Coffey Nagler Mrs. Michael L. Tarnopol Dianne G. Crary Mrs. Ann F. Jeffery Mrs. Samuel F. Pryor IV Alexis Robinson Waller Mrs. James F. Curtis III Suzie Kovner Mrs. Bambi Putnam Patricia G. Warner Mrs. James H. Dean Mrs. Brian A. McCarthy Mrs. Benjamin M. Rosen Mrs. Thomas E. Zacharias Antonia Paepcke DuBrul Mrs. S. Christopher Meigher III Evelyn Angevine Silla Mrs. Thomas J. Fahey, Jr. Mrs. Minot K. Milliken Mrs. Paul Soros
PRESIDENT’S COUNCIL
Mrs. Rand V. Araskog Nina Garcia Conrod Julie Geier Mrs. Donald B. Marron D. Dixon Boardman Mrs. Charles A. Dana, Jr. Mrs. Richard S. LeFrak Linda Gosden Robinson
PAST PRESIDENTS
Mrs. Coleman P. Burke Mrs. Bruce A. Gimbel Mrs. Thomas V. Leeds Dr. Annette U. Rickel Mrs. Edwin M. Burke Alison Barr Howard Mrs. Derek L. Limbocker Mrs. Bijan Safai Mrs. William M. Carson Mrs. Peter D. Jones Jean Remmel Little Lavinia Branca Snyder Mrs. Walter B. Delafield Mrs. Kerryn King Mrs. M. Anthony May Mrs. Charles H. Dyson Mrs. Arie L. Kopelman Mrs. Frank A. Metz, Jr.
FOUNDER
Mrs. Edward C. Delafield *indicates new member
98 MEMORIAL SLOAN KETTERING CANCER CENTER
ONE FOCUS ONE MSK
PRODUCED BY Avice A. Meehan PHOTOGRAPHY Department of Communications Senior Vice President and Karsten Moran Memorial Sloan Kettering Cancer Center Chief Communications Officer 1275 York Avenue ADDITIONAL PHOTOGRAPHY New York, NY 10065 Ami Schmitz Rick DeWitt Vice President, Editorial Kreg Holt t 212-639-3573 and Content Strategy Michael Prince f 212-639-3576 MANAGING EDITOR DESIGN Jennifer Castoro Ideas On Purpose, New York www.ideasonpurpose.com CREATIVE DIRECTOR Randi Press PRINTING Allied Printing Services WRITERS Meredith Begley Jennifer Castoro Julie Grisham Bill Piersol Jim Stallard Matthew Tontonoz
PRODUCTION MANAGER Emily Kastl
CONTRIBUTORS Donna DePaolis © Copyright 2018 Kristin Glick Memorial Sloan Kettering Cancer Center Larissa Regala
2017 ANNUAL REPORT 99 GENERAL INFORMATION 212-639-2000
MAKE AN APPOINTMENT 800-525-2225
VISIT US ONLINE WWW.MSKCC.ORG
FACEBOOK.COM/SLOANKETTERING
TWITTER.COM/SLOAN_KETTERING
YOUTUBE.COM/MSKCC
INSTAGRAM.COM/SLOANKETTERING 1275 YORK AVENUE NEW YORK, NY 10065 WWW.MSKCC.ORG/ANNUALREPORT